

# 9th European Congress on Epileptology

June 27<sup>th</sup> - July 1<sup>st</sup>, 2010

*RHODES, GREECE*



**9th** European  
Congress  
on **Epileptology**  
in **2010**

June 27<sup>th</sup> - July 1<sup>st</sup> 2010, Rhodes

**Final Programme**

[www.epilepsyrhodes2010.org](http://www.epilepsyrhodes2010.org)

**ILAE-CEA**  
COMMISSION ON EUROPEAN AFFAIRS

# 29th International Epilepsy Congress

28th August - 1st September

# ROME 2011



29th International  
Epilepsy Congress



# ROME 2011



28th August - 1st September



## CONTENTS

<b>1. Welcome Messages and Committees</b>	<b>2</b>
<b>2. General Congress Information</b>	<b>7</b>
<b>3. Congress Venue Plan</b>	<b>11</b>
<b>4. Scientific Programme Information</b>	<b>12</b>
<b>5. Full Week Timetable</b>	<b>16</b>
<b>6. Scientific Programme</b>	
Sunday 27 <sup>th</sup> June	<b>18</b>
Monday 28 <sup>th</sup> June	<b>22</b>
Tuesday 29 <sup>th</sup> June	<b>38</b>
Wednesday 30 <sup>th</sup> June	<b>54</b>
Thursday 1 <sup>st</sup> July	<b>72</b>
<b>7. Poster Sessions</b>	
Monday 28 <sup>th</sup> June	<b>78</b>
Tuesday 29 <sup>th</sup> June	<b>100</b>
Wednesday 30 <sup>th</sup> June	<b>124</b>
<b>8. Poster Presentations</b>	
Monday 28 <sup>th</sup> June – Wednesday 30 <sup>th</sup> June	<b>142</b>
<b>9. Speaker List</b>	<b>144</b>
<b>10. List of Exhibitors and Floor Plan</b>	<b>152</b>



## WELCOME MESSAGES AND COMMITTEES

### A MESSAGE FROM THE PRESIDENT OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY (ILAE)

Dear Colleagues,

On behalf of the International League Against Epilepsy (ILAE), it gives me great pleasure to welcome you all to the 9th European Congress in Epileptology (ECE) in Rhodes.

The European Congress on Epileptology brings together people from around Europe and the world to share their experience as part of the congress programme, as well as networking with colleagues from near and far. The ILAE's mission is to ensure that health professionals, patients and their care providers, governments, and the public worldwide have the educational and research resources that are essential in understanding, diagnosing and treating persons with epilepsy. The European Congress on Epileptology enables the communication of the latest research findings, especially by supporting young researchers in attending the meeting.

The ILAE celebrated the centenary of its foundation last year in Budapest, where the organisation was established in 1909, and now has over 100 chapters throughout the world. The ILAE Commission on European Affairs continues to stimulate and coordinate all aspects of epileptology across Europe and aims to provide in-depth understanding of epilepsy for both basic scientists and clinicians by maximising the scientific quality of the ECE.

The island of Rhodes is rich in culture and history and the Medieval Town is designated as a UNESCO World Heritage City. It is located at the crossroads of two major sea routes of the Mediterranean. As the meeting point of three continents, it has known many civilizations. Throughout its long history the different people who settled on Rhodes left their mark and its strategic position made the city of Rhodes one of the leading cities of the ancient Greek world. On the occasion of the 9th ECE, the island will once again become a strategic meeting point for people from many countries, with the common goal of improving the care of persons with epilepsy in Europe and beyond.

I look forward to meeting you over the coming days and trust that you will have a productive and enjoyable experience at the 9th European Congress on Epileptology and in Rhodes.

With best wishes,



**Solomon L. Moshé**  
President

International League Against Epilepsy (ILAE)





## WELCOME MESSAGES AND COMMITTEES

### A MESSAGE FROM THE CHAIR OF THE ILAE COMMISSION ON EUROPEAN AFFAIRS (CEA)

Dear Colleagues,

It is with great pleasure that I welcome you to the 9<sup>th</sup> European Congress on Epileptology (ECE) in Rhodes, Greece, an interesting city and island with a rich history, for a congress that promises to offer outstanding scientific information as well as a perfect international podium for exchange of ideas.

The 9<sup>th</sup> European Congress on Epileptology has been organized by the Greek chapter of the ILAE in collaboration with the CEA and the congress organizing and scientific advisory committees. The scientific programme was structured to highlight issues which are currently at the frontier of epileptology.

In addition the congress programme was planned with Discussion Groups, Workshops and Teaching Sessions as well as the "How to Do" Courses to provide comprehensive information on epileptology in countries with limited resources. The ILAE-CEA will continue to focus on education, the improvement of care, research and communication in Europe and globally, together with other ILAE regional commissions.

At the opening ceremony of the congress the CEA will present the European Epileptology Award 2010 to Professor Martin Brodie and Professor Yehezkel Ben-Ari, in recognition of their outstanding contribution to epileptology.

I look forward to meeting you in Rhodes and to exchanging ideas about the CEA-sponsored future activities. I hope that the 9<sup>th</sup> ECE here in Rhodes will be a rewarding experience to all of you who have been working in this ever progressing field of epilepsy.

With best regards and Shalom,



**Meir Bialer**

Chair

ILAE Commission on European Affairs (CEA)



## WELCOME MESSAGES AND COMMITTEES

### INTERNATIONAL ORGANISING COMMITTEE (IOC)



**Michel Baulac**  
(France)  
Co-chair



**George Kostopoulos**  
(Greece)  
Co-chair




**Giuliano Avanzini**  
(Italy)



**Martin Brodie**  
(United Kingdom)



**Thanos Covanis**  
(Greece)



**Alla Guekht**  
(Russia)



**Svein Johannessen**  
(Norway)



**Nebojsa Jovic**  
(Serbia)



**Rüdiger Köhling**  
(Germany)



**Miri Neufeld**  
(Israel)



**Çigdem Özkara**  
(Turkey)



**Philip Smith**  
(United Kingdom)



## WELCOME MESSAGES AND COMMITTEES

### SCIENTIFIC ADVISORY COMMITTEE (SAC)



**Thanos Covanis**  
(Greece)  
Chair



**Giuliano Avanzini**  
(Italy)



**Michel Baulac**  
(France)



**Meir Bialer**  
(Israel)



**Martin Brodie**  
(United Kingdom)



**Marco de Curtis**  
(Italy)



**Christian Elger**  
(Germany)



**Stelios Giannakodimos**  
(Greece)



**Alla Guekht**  
(Russia)



**Svein Johannessen**  
(Norway)



**Vassilis Kimiskidis**  
(Greece)



**Michalis Koutroumanidis**  
(United Kingdom)



**Çigdem Özkara**  
(Turkey)



**Andreas Schulze-Bonhage**  
(Germany)



**Simon Shorvon**  
(United Kingdom)



**Torbjörn Tomson**  
(Sweden)



## WELCOME MESSAGES AND COMMITTEES

### A MESSAGE FROM THE CHAIRS OF THE INTERNATIONAL ORGANISING COMMITTEE (IOC)

Dear Colleagues,

It is with great pleasure that we welcome the delegates of the 9th European Congress on Epileptology to the beautiful island of Rhodes for what is certain to be a meeting of excellent quality. Under the auspices of the International League Against Epilepsy (ILAE) and the Commission for European Affairs (CEA) this meeting hosted by the Greek Chapter of ILAE aims to promote effective communication between clinical as well as experimental epileptologists towards the common goal, to improve the quality of life for people with epilepsy

Epileptology has undoubtedly been one of the first and most effective mentors of neuroscience. Localization of several brain functions and neuronal mechanisms of excitability and synchronization are some among many examples of the lessons taught to science by the study of epileptic patients. Will this great debt ever be repaid? The 9th ECE has been organized with the belief that the time is ripe for this repayment, for advancing new more effective treatments based on solid experimental evidence and in depth understanding of the pathophysiology of disease. The exploitation of several animal models of epileptogenesis as well as of seizures, advanced methodology like molecular neurobiology and non invasive brain imaging and recent recruitment of genetics and immunology have created a well founded momentum and hope that the goal of curing not just treating epilepsy is finally reachable. The 9th ECE reflects this momentum and it is a happy coincidence that it takes place in the very area where epilepsy was first demystified and studied as a brain disease by Hippocrates.

Leading topics of the Congress relate to the new frontiers in diagnostic and research methodology, AED development and predicting epileptogenesis, as well as the concept of idiopathic epilepsies and the challenges it is facing today. The main topics are linked with either a discussion group or a workshop. Further sessions will focus on specific types of epilepsy, their dependence on genetics, age and arousal level and recent advances in their treatment and in understanding their underlying mechanisms. The Chairs' Symposium, "The paradoxes of the paroxysms: seizure precipitating factors and underlying mechanisms", will be one of the highlights of the programme, for which we hope you can join us. Guided tours through posters and the selection of platform presentations will increase the effectiveness of primary findings presentations. The programme is completed with the traditionally effective teaching sessions by experts in their field.

We strongly encourage the exchange of ideas between clinical and experimental epileptologists, keeping in mind that our patients suffer both from their seizures and from the awe seizures cause to themselves and to others. Therefore it is part of our duty to convince patients and society that modern neuroscience has proven and substantiated the Hippocratic dictum that epilepsy is not sacred but a disease of the brain, whose mechanisms we increasingly understand.

Although there are plenty of sessions and activities to keep you occupied during the congress, we do hope that you find some time to explore Rhodes, the beautiful "island of Roses" and the largest island in the Dodecanese. The city of Rhodes was one of the leading cities of the ancient Greek world and the Medieval Town is today designated a UNESCO World Heritage City.

We would like to again extend a very warm and cordial welcome to all of you.

With best regards,



**Michel Baulac**

Co-chair

International Organising Committee



**George Kostopoulos**

Co-chair

International Organising Committee



## GENERAL CONGRESS INFORMATION

### Registration

The Registration Area is located in Capsis Convention Centre, beside the Capsis Hotel.

Congress Bags should be collected on-site in this area upon exchange of a voucher.

Please note that name badges must be worn at all times.

### Speakers Room

The Speakers Room is located in the Rodos Palace Convention Centre, adjacent to the session rooms. Opening times for the Speakers Room are listed on the Facilities Timetable Overview. Services to review and amend presentations will be available to all speakers. Technical assistance will be provided in this room.

Please note that all speakers should submit their finalised PowerPoint presentations at the main desk in the Speakers Room no less than 3 hours in advance of their session. Speakers at early morning sessions are required to submit their material no later than 17:00 on the evening before their session is scheduled.

### Exhibition

The Exhibition Area is located in the Capsis Convention Centre, adjacent to the registration area. Exhibition opening times are listed on the Facilities Timetable Overview. Exhibitor badges (pre-registered exhibitors only) will be available for collection at the exhibition desk situated in the Registration Area.

### Lunches and Coffee Breaks

Lunches and coffee breaks will be served in the Exhibition Area of the Capsis Convention Centre.

### Facilities Timetable Overview

	Sunday	Monday	Tuesday	Wednesday	Thursday
Registration	08:00 - 19:00	07:00 - 18:00	07:00 - 18:00	07:00 - 17:30	07:00 - 13:30
Speakers Room	08:00 - 19:00	07:00 - 18:00	07:00 - 18:00	07:00 - 17:30	07:00 - 12:00
Posters	-	09:00 - 18:00	09:00 - 18:00	09:00 - 18:00	-
Exhibition	-	09:00 - 17:00	09:00 - 17:00	09:00 - 17:00	09:00 - 12:00
Coffee Breaks	-	11:00 - 11:30 16:00 - 16:30	11:00 - 11:30 16:00 - 16:30	11:00 - 11:30 16:00 - 16:30	11:00 - 11:30
Lunch	-	13:00 - 14:30	13:00 - 14:30	13:00 - 14:30	-







## GENERAL CONGRESS INFORMATION

### Language

The official language of the congress is English; please note that translation facilities will not be provided.

### Replacement Badges

Please note that replacement badges will be charged at a fee of €50. Delegates should ensure that badges are worn at all times.

### Certificates of Attendance

Certificates can be collected from the pre-registration counter from Tuesday onwards during registration opening hours.

### Congress Secretariat

Members of the Congress Secretariat may be contacted at anytime at the Registration Area. For queries arising after the congress, please contact :

9th European Congress on Epileptology  
ILAE Congress Secretariat  
7 Priory Hall  
Stillorgan  
Dublin 18  
Ireland

Tel : +353 1 2056720  
Fax : +353 1 2056156  
Email : [info@epilepsycongress.org](mailto:info@epilepsycongress.org)

### Congress Venues

Capsis Hotel & Convention Centre  
Ixia, 85100 Rhodes  
Tel : +30 22410 25015  
Fax : +30 22410 20900

Rodos Palace Hotel & Convention Centre  
Trianton Ave. Ixia P.O. Box 121  
85100 Rhodes, Greece  
Tel : +30 22410 25222  
Fax : +30 22410 25350

### On-site Information

Smoking Policy	The congress has a strict no smoking policy.
Cloakroom (coats & luggage)	The cloakroom will operate on Sunday, 08:30 to 20:30, on Monday, Tuesday and Wednesday, 08:30 to 17:00 and on Thursday, 08:30 to 12:30. The charge will be €2 per item.
Wheelchair Accessibility	All parts of the Capsis Convention Centre and the Rodos Palace Convention Centre are wheelchair accessible.
Speakers Room	The Speakers Room is located in the Rodos Palace Convention Centre, adjacent to the session rooms.
Internet Centre	The Internet Centre is located beside the Poster Area.

### Liability and Insurance

The congress organisers will not accept liability for personal injury or loss/damage to property/ belongings of participants or accompanying persons, either before, during or following the

congress, tours or their stay in Rhodes. It is therefore recommended that participants arrange their own personal health, accident and travel insurance.



## GENERAL CONGRESS INFORMATION

### SPONSORS

The congress would like to thank the following companies for their support:



THE EPILEPSY COMPANY™

### SOCIAL EVENTS

#### Opening Ceremony and Welcome Reception

The Opening Ceremony will take place on Sunday 27<sup>th</sup> June at 18:30 in Hall 1 (Jupiter). The Ceremony will open with welcome addresses from representatives of ILAE as well as the congress committees. This will be followed by the Awards Ceremony, which this year will consist of the European Epileptology Award.

All delegates are welcome to join a Cocktail Reception which will be held after the Opening Ceremony at the Capsis Hotel Garden.

### Cultural Evening

A dynamic evening, reflecting the wealth of Greek culture, will be held at the unique "Dome" located at the congress venue, Rodos Palace Hotel on the evening of Wednesday 30<sup>th</sup> June. Participants will have the unique opportunity to learn more about local products offered by traditional kiosks designed especially for this event.

A flavoursome barbecue (seated buffet) will follow, while a folklore dancing group will set the tone of a traditional "Greek night out", accompanied by the sounds of an entertaining Greek music band.

Dinner : seated barbecue buffet  
including local wines  
Dress code : smart casual  
Cost per ticket : €85

Tickets may be purchased at the Tours Desk in the Registration Area.

### Tours

A range of full and half-day excursions are available daily throughout the congress and can be booked at the Tours Desk in the Registration Area.

## RHODES PRACTICAL INFORMATION

### Business Hours

Banks are open from 08:00 to 14:00 Monday to Thursday, and from 08:00 to 13:00 on Friday. Some banks are open between 15:30 to 16:30 on weekdays and 08:00 to 13:30 on Saturday.

Shops are open from 08:00 to 13:30 and from 17:30 to 20:30 on Tuesday, Thursday and Friday, and from 08:00 to 14:30 on Monday, Wednesday and Saturday. Department stores and supermarkets are open from 08:00 to 20:00 Monday to Friday, from 08:00 to at least 15:00 on Saturday and are closed on Sunday.

Periptera (street kiosks) are open from early morning until late at night. They sell everything from bus tickets to basic products.

### Currency

The currency in Greece is the Euro (€).



## GENERAL CONGRESS INFORMATION

### Credit Cards

All of the most popular credit, debit and charge cards (AMEX, Diners Club, Cirrus, Euro/Mastercard and VISA) can be used in banks and in ATM's to withdraw money, and also in hotels, restaurants and shops for purchases (signs are displayed at the entrance of the shops and restaurants showing which cards are acceptable). There is an ATM located within the Capsis Hotel.

### Electricity

The voltage in Greece is 220V (50Hz) and plugs are the two-pin continental European type.

### Communications

Internet access is readily available in hotels and internet centres and cafes located throughout Rhodes. An internet centre is located beside the Poster Area in the congress venue the Capsis Convention Centre. Delegates may also buy internet cards at the hotel reception, which can be used in the public areas for Wi-Fi.

The international telephone code for Greece is 30. Public telephone boxes, which are blue and found all over the island can be used either for local or for long distance calls. They all use phone cards, which can be purchased at just about every tourist shop. Telephone rates are reduced by 30% between 20:00 – 07:00 for long distance calls.

### Time Difference

Rhodes is in the Central European Time Zone (Greenwich Mean Time + 2 hours / U.S. Eastern Standard Time + 7 hours)

### Local Transport

The location of the congress venue is 4km from the Medieval Town of Rhodes, 11km from the Diagoras Rhodes International Airport, 50m from the Main Highway and 3km from the National Highway.

### Bus

There is a bus stop in front of the congress venue for local public transport. These local buses travelling around the city charge a flat €1 fee and they depart from a stand on Mandraki Harbour. Rhodes Town has two island bus terminals, which service one half of the island each. The east side bus terminal (Plateia Rimini) and the west side bus terminal, located next to the New Market. Unlimited travel tickets are available for one/two/three days (€10/€15/€25).

### Taxi


There are two zones on the island for taxi fares: Zone One is Rhodes Town and Zone Two (slightly higher) is everywhere else. Rates are a little higher between midnight to 06:00. Taxis tend not to use meters but prefer to use set fare rates. All drivers carry a booklet stating the current approved set fares. Request to see it if in doubt. Sample fares: airport – to Convention Centre €18 approx (11km).






CONGRESS VENUE PLAN

UPPER LEVEL



- REGISTRATION AREA
- SESSION ROOMS
- POSTER AREA
- SPEAKERS ROOM
- BUSINESS MEETING ROOMS
- EXHIBITION AREA
- INTERNET CENTRE
- LUNCH & COFFEE BREAKS
- ESCALATOR

GROUND LEVEL





## INTRODUCTION TO SCIENTIFIC INFORMATION

### A MESSAGE FROM THE CHAIR OF THE SCIENTIFIC ADVISORY COMMITTEE (SAC)

Dear Colleagues,

On behalf of the Scientific Advisory Committee, it is my pleasure to welcome you to Rhodes for the 9th European Congress on Epileptology (ECE). The SAC has worked extensively over the past two years in order to create a programme which encompasses recent scientific developments and enables the exchange of ideas and information between basic scientists, researchers and clinicians working in the field of epilepsy throughout the region.

The scientific structure of the programme makes every effort to highlight issues which are currently at the frontier of science. It comprises of four main topics: "AED development, selection and use relevant to gender and age", "Advances in techniques to delineate the epileptogenic zone", "Challenging the concept of idiopathic epilepsies" and "Predicting epileptogenesis: How far are we from reaching the goal?".

A whole range of teaching sessions will be taking place every morning between 07:30 and 09:00 and video sessions will also be organised on Sunday afternoon and Thursday morning to discuss particular cases relevant to both paediatricians and clinicians. The Chairs Symposium entitled "The paradoxes of the paroxysms - Seizure precipitating factors and underlying mechanisms" will take place on Monday between 09:00 and 11:00.

The ILAE Commission on European Affairs (CEA) will present the European Epileptology Award 2010 to Prof Martin J Brodie (UK) and Prof Yehezkel Ben-Ari (France), in recognition of their outstanding contribution to European epileptology. They will present on a topic of their choice during the Symposium for Excellence in Epileptology on Thursday 1<sup>st</sup> July. Also in this symposium, Prof Yao-Chung Chuang (Taiwan), winner of the Morris-Coole Prize 2009 (best paper in Epilepsia in 2009), will present his work, which was considered, by a jury of experts, as the most significant advance in knowledge in the field of epilepsy in 2009.

The standard of abstracts submitted by young researchers continues to rise; these are being presented every day in platform sessions and as posters.

The ILAE CEA has awarded 50 travel bursaries to authors who submitted abstracts of particularly high quality. The selected top authors will present their work at the Bursary Award Symposium which will take place on Wednesday 30<sup>th</sup> June between 14:30 and 16:00.

Many eminent speakers from around the world will be presenting over the coming days and I would like to thank them all for their valuable contribution.

Yours sincerely,



**Thanos Covanis**  
Chair

Scientific Advisory Committee





## GENERAL SCIENTIFIC INFORMATION

### AWARDS



#### European Epileptology Award 2010

The Commission on European Affairs will present the European Epileptology Award 2010 during the Opening Ceremony on Sunday 27<sup>th</sup> June at 18:30 in Hall 1 (Jupiter). The prize will be awarded to European epileptologists whose achievements are considered to have contributed significantly to the development of epileptology in Europe.

The European Epileptology Award 2010 has been awarded jointly to Martin J Brodie (UK) and Yehezkel Ben-Ari (France). Both award recipients will get an opportunity to present on a topic of their choice at the Symposium of Excellence in Epilepsy on Thursday 1<sup>st</sup> July in Hall 1 (Jupiter), 09:00 – 11:00. (Please note that Alfonso Represa (France) will make the presentation on behalf of Yehezkel Ben-Ari.)

#### Travel Bursary Awards

The Commission on European Affairs has provided 50 travel bursaries to support the presentation of scientific papers at the congress by young investigators under 45 years of age. A Bursary Award Symposium will be held on Wednesday 30<sup>th</sup> June in Hall 4 (Nafsica), 14:30 – 16:00 to enhance awareness of these awards and present work by six of the top authors.

#### Travel Bursary Award Symposium Speakers

Beretta S (Italy)  
 Ferreira H (Portugal)  
 Jahodova A (Czech Republic)  
 Lebrun A (France)  
 Shazadi K (United Kingdom)  
 Wong-Kisiel L (USA)

#### Travel Bursary Awardees

Akman O (Turkey)  
 Balosso S (Italy)  
 Broli M (Italy)  
 Cantalupo G (Italy)  
 Carcak N (Turkey)  
 Carmichael D (United Kingdom)  
 Chipaux M (France)  
 Chowdhury F (United Kingdom)  
 Ciumas C (France)  
 Cojutti P G (Italy)  
 Cosic-Cerovac N (Serbia)  
 Duca V (Moldova)  
 Duffy B (United Kingdom)  
 Girod S (France)  
 Grinenko O (Russia)  
 Gulcebi Idrizoglu M (Turkey)  
 Han V (Slovakia)  
 Jason T (Czech Republic)  
 Jovic-Jakubi B (Serbia)  
 Keihaninejad S (United Kingdom)  
 Kistsen V (Belarus)  
 Kjaer D (Denmark)  
 Kotaskova J (Czech Republic)  
 Kovac S (United Kingdom)  
 Kravljanc R (Serbia)  
 Kudr M (Czech Republic)  
 Librizzi L (Italy)  
 Lopes A F (Portugal)  
 Mameniskiene R (Lithuania)  
 Monti G (Italy)  
 Morin M (France)  
 Oksana G (Russia)  
 Pugnaghi M (Italy)  
 Pujar S (United Kingdom)  
 Rakitin A (Estonia)  
 Rejdak K (Poland)  
 Sruk A (Croatia)  
 Sterjev Z (Macadonia)  
 Suleymanova E (Russia)  
 Tzadok M (Israel)  
 Valanciene I (Lithuania)  
 Vlooswijk M (Netherlands)  
 Witt J A (Germany)  
 Xintong W (Germany)



## GENERAL SCIENTIFIC INFORMATION

### The Morris-Cooile Prize

This prize, awarded by the ILAE, is the initiative of Mr and Mrs Christopher Morris-Cooile, who have endowed the prize. The annual prize of €10,000 is awarded for the paper published in *Epilepsia* during the preceding year which has, in the judges' opinion, made the most significant advance in knowledge in the field of epilepsy.

The winner has been awarded to Yao-Chung Chuang (Taiwan) for his paper entitled "Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis". *EPILEPSIA* 50:1579-1586 Tan TY, Lu CH, Chuang HY, Lin TK, Liou CW, Chang WN, Chuang YC (2009).

### SPECIAL FEATURES

#### Chairs' Symposium

Following on from previous European Congresses on Epileptology, the Chairs' Symposium will feature as an important element of the scientific programme. The Symposium will take place on Monday 28<sup>th</sup> June, 09:00 – 11:00 in Hall 1 (Jupiter) and is entitled "The paradoxes of the paroxysms: seizure precipitating factors and underlying mechanisms".

#### Neurobiology Symposium

The Neurobiology Symposium will take place on Tuesday 29<sup>th</sup> June, 14:30 – 16:00 in Hall 1 (Jupiter). Epilepsy is often accompanied by massive reactive gliosis, but the role of glial cells in seizures and epileptogenesis is still elusive. Several recent studies clearly indicate that glial cells take an active part in the formation, function and plasticity of synapses. It is the aim of the proposed symposium to present new developments and findings on the neuron=glia crosstalk in experimental and human epileptic brain. This symposium intends to bring together established scientists with various backgrounds to discuss different aspects of this new, topical field and the potential for developing novel strategies to treat epilepsy. The title this year is: "Epilepsy, Dementia, Alzheimer's Disease and the Temporal Lobe".



### Pre-Congress sessions on Sunday, June 27<sup>th</sup>, 2010 from 09:00 – 13:30

(2 x 120 min + 30 min coffee break)  
There will be two parallel mini courses on basic science: From Bench to Bedside.  
Please note that pre-registration is obligatory. Fee is €50; EUREPA Members €40.

### Main Congress early morning sessions:

There will be 3 parallel series of 4 courses each morning between 07:30 and 09:00 Monday – Thursday. No pre-registration required, open and all free of charge to congress participants.

### 1<sup>st</sup> series: HOW TO DO? TEACHING SESSIONS ON PRACTICAL CLINICAL RELEVANCE

Topic: Seizure Monitoring in the EMU  
setting: Practical issues

### 2<sup>nd</sup> series: CASE ORIENTED LEARNING SESSIONS

There will be four courses entitled "Aging and comorbidity", "Paediatrics", "Epilepsy Surgery", and "Classification and/or differential diagnosis".

### 3<sup>rd</sup> series: INTRODUCTION SESSIONS TO THE VIREPA (Virtual Epilepsy Academy) PROGRAMME

There will be four courses entitled "EEG in diagnosis and treatment of epilepsy" (supported by the ILAE Commission on Diagnostic Methods), "Genetics of Epilepsy" (supported by the ILAE Genetics' Commission), "Neuroimaging" (supported by the ILAE Commission on Diagnostic Methods), and "Clinical Pharmacology and Pharmacotherapy" (supported by the ILAE Commission on Therapeutic Strategies).



## GENERAL SCIENTIFIC INFORMATION

### European Chapter Convention

The European Chapter Convention 2010, organized by the European Advisory Council of ILAE (EAC), will take place on Saturday 26<sup>th</sup> June in Hall 8 (Lindos) from 14:00 to 19:00.

Registrations for the Chapter Convention will open from 13:00 and a coffee break will be scheduled for all participants during the convention.

Each European Chapter has been invited to send two representatives to the European Chapter Convention. The convention will mainly comprise of focus group discussions to facilitate communication on common issues.

### CME Accreditation

The 9<sup>th</sup> European Congress on Epileptology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Please view [www.uems.net](http://www.uems.net) for further details.

The 9<sup>th</sup> European Congress on Epileptology is designated for a maximum of 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA. Please view [www.ama-assn.org](http://www.ama-assn.org) for further details.

The statement of accreditation will be incorporated into the attendance certificates issued to fully registered delegates during the congress. Please contact the Congress Secretariat in the Registration Area if you require further information on the issuance of CME Accreditation.

### Video Sessions


Video sessions will take place on Sunday 27<sup>th</sup> June (14:30-16:00) and on Thursday 1<sup>st</sup> July (11:30-13:00) in Hall 7 (Colossus).

The video sessions have two aims; to introduce the technical side of seizure recordings and to demonstrate the evaluation of the recorded seizure. The Chair will select videos from those submitted by participants prior to the congress and these will be analyzed together with the audience and evaluated with regards to technique and interpretations of certain seizures.

### Scientific Exhibit

Medtronic will hold a sponsored Scientific Exhibit of posters in the Capsis Convention Centre on Monday 28<sup>th</sup> June and Tuesday 29<sup>th</sup> June, from 09:00 to 12:00.





## FULL WEEK TIMETABLE

	Saturday 26 <sup>th</sup> June	Sunday 27 <sup>th</sup> June		Monday 28 <sup>th</sup> June		
07:30-08:00	Greek National Seminar			Teaching Sessions / Workshops 07.30-09.00	"How To Do" Course 07.30-09.00	Elekta Breakfast Symposium 07.30-09.00
08:00-08:30						
08:30-09:00						
09:00-09:30		EUREPA Course on Basic Science 09.00 - 13.30	EUREPA Course on Basic Science 09.00 - 13.30	Posters on Display all day - Poster Tours (13.30-14.30)	Chairs' Symposium 09.00-11.00	
09:30-10:00						
10:00-10:30						
10:30-11:00					Coffee Break	
11:00-11:30		Platform Sessions 11.30-13.00				
11:30-12:00						
12:00-12:30						
12:30-13:00						
13:00-13:30		Lunch & Posters				
13:30-14:00						
14:00-14:30						
14:30-15:00	Video Session 14.30-16.00		Discussion Groups / Workshops 14.30-16.00			
15:00-15:30			Coffee Break			
15:30-16:00						
16:00-16:30	ILAE European Chapter Convention	GlaxoSmithKline Satellite Symposium 16.30-18.00		Eisai Europe Ltd Satellite Symposium 16.30-18.00		
16:30-17:00						
17:00-17:30						
17:30-18:00						
18:00-18:30						
18:30-19:00		Welcome Ceremony 18.30-19.30		Merritt-Putnam Symposium 18.30-20.00		
19:00-19:30						
19:30-20:00		Reception 19.30-20.30				
20:00-20:30						
20:30-21:00						



## SCIENTIFIC PROGRAMME

### FULL WEEK TIMETABLE

Tuesday 29 <sup>th</sup> June			Wednesday 30 <sup>th</sup> June			Thursday 1 <sup>st</sup> July		
Teaching Sessions / Workshops 07.30-09.00		"How To Do" Course 07.30-09.00	Teaching Sessions / Workshops 07.30-09.00		"How To Do" Course 07.30-09.00	Teaching Sessions / Workshops 07.30-09.00	"How To Do" Course 07.30-09.00	07:30-08:00
Posters on Display all day - Poster Tours (13.30-14.30)	Main Session 09.00-11.00	Main Session 09.00-11.00	Posters on Display all day - Poster Tours (13.30-14.30)	Main Session 09.00-11.00	Main Session 09.00-11.00	Symposium of Excellence in Epileptology 09.00-11.00		08:00-08:30
	Coffee Break			Coffee Break		Coffee Break		08:30-09:00
	Platform Sessions 11.30-13.00			Platform Sessions 11.30-13.00		Discussion Groups/ Workshops 11.30-13.00		09:00-09:30
	Lunch & Posters			Lunch & Posters				09:30-10:00
	Neurobiology Symposium 14.30-16.00	Discussion Groups / Workshops 14.30-16.00		Bursary Award Symposium 14.30-16.00	Discussion Groups / Workshops 14.30-16.00			10:00-10:30
	Coffee Break			Coffee Break				10:30-11:00
	UCB Pharma Satellite Symposium 16.30-18.00			Discussion Groups / Workshops 16.30-18.00		Biocodex Satellite Symposium 16.30-18.00		11:00-11:30
								11:30-12:00
								12:00-12:30
								12:30-13:00
								13:00-13:30
								13:30-14:00
								14:00-14:30
								14:30-15:00
								15:00-15:30
								15:30-16:00
								16:00-16:30
								16:30-17:00
								17:00-17:30
								17:30-18:00
								18:00-18:30
								18:30-19:00
								19:00-19:30
								19:30-20:00
								20:00-20:30
								20:30-21:00



**SCIENTIFIC PROGRAMME****SUNDAY, 27TH JUNE 2010****SUNDAY, 27TH JUNE 2010**

	Hall 1 (Jupiter)	Hall 7 (Colossus)	Hall 8 (Lindos)			
07:30-08:00						
08:00-08:30						
08:30-09:00						
09:00-09:30		Eurepa Course on Basic Science Epilepsy genetics: from basic research to clinical application	Eurepa Course on Basic Science Cortical dysplasia			
09:30-10:00						
10:00-10:30						
10:30-11:00						
11:00-11:30						
11:30-12:00						
12:00-12:30						
12:30-13:00						
13:00-13:30						
13:30-14:00						
14:00-14:30						
14:30-15:00		Video Session				
15:00-15:30						
15:30-16:00						
16:00-16:30						
16:30-17:00	GlaxoSmithKline Satellite Symposium					
17:00-17:30						
17:30-18:00						
18:00-18:30						
18:30-19:00	Welcome Ceremony					
19:00-19:30						
19:30-20:00	Reception					
20:00-20:30						
20:30-21:00						



## SCIENTIFIC PROGRAMME

SUNDAY, 27<sup>TH</sup> JUNE 2010

09:00-13:30

Eurepa Course on Basic Science

**Epilepsy genetics: from basic research to clinical application**

**Hall 7 (Colossus)**

Chairs: Lerche H (Germany), Serratosa J (Spain)

**Classical monogenic defects causing idiopathic epilepsies**

De Jonghe P (Belgium)

**Towards identifying common variants predisposing to epilepsy and pharmacoresponse**

Koeleman B (Netherlands)

**Ion channel and transporter defects in epilepsies**

Schorge S (United Kingdom)

**Myoclonic epilepsy syndromes**

Serratosa J (Spain)

**Cortical malformations and West syndrome**

Guerrini R (Italy)

**Phenotyping and genetic testing: when and which gene?**

Marini C (Italy)

**Phenotyping and genetic testing: when and which gene?**

Nabbout R (France)

**Phenotyping and genetic testing: when and which gene?**

Striano P (Italy)

09:00-13:30

Eurepa Course on Basic Science

**Cortical dysplasia**

**Hall 8 (Lindos)**

Chairs: Özhara Ç (Turkey), Blümcke I (Germany)

**Basic mechanisms in cortical dysplasias**

Avanzini G (Italy)

**Animal models of cortical dysplasias**

Battaglia G (Italy)

**Clinico pathological classification of cortical dysplasias**

Blümcke I (Germany)

**Electro-clinical presentation of cortical dysplasias**

Tassi L (Italy)

**Imaging of cortical dysplasias**

Duncan J (United Kingdom)

**Surgery and outcome**

Kahane P (France)



## SCIENTIFIC PROGRAMME

### SUNDAY, 27TH JUNE 2010

14:30-16:00

#### Video Session

Hall 7 (Colossus)

Chairs: Özbara Ç (Turkey), Plouin P (France)

Plouin P (France)

16:30-18:00

Satellite Symposium

**GlaxoSmithKline**

**Drug-resistant epilepsy: defining the problem,  
seeking the solution**

Hall 1 (Jupiter)

Chair: Duncan J (United Kingdom)

**Quantifying the burden of drug-resistant epilepsy**  
Beghi E (Italy)

**Defining the disease to refine the treatment**  
Arzimanoglou A (France)

**Novel strategies for treatment of drug-resistant epilepsy**  
Carreño M del Mar (Spain)

18:30-19:30

#### Welcome Ceremony

Hall 1 (Jupiter)





## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

MONDAY, 28<sup>TH</sup> JUNE 2010

	Poster Hall	Hall 1 (Jupiter)	Hall 2 (Roses)	Hall 3 (Delphi)		
07:30-08:00		Elekta Breakfast Symposium	Teaching Session Seizure, arousal or parasomnia?	Workshop Epileptogenesis: mechanisms and prevention		
08:00-08:30	Poster Set-Up					
08:30-09:00						
09:00-09:30	Posters on Display	Chairs Symposium The paradoxes of the paroxysms				
09:30-10:00						
10:00-10:30						
10:30-11:00						
11:00-11:30						
11:30-12:00		Coffee Break 11:00 - 11.30				
12:00-12:30			Platform Session Genetics	Platform Session Paediatric epileptology		
12:30-13:00						
13:00-13:30			Lunch 13:00 - 14.30			
13:30-14:00		Poster Tours				
14:00-14:30						
14:30-15:00	Posters on Display	DG - Generic products of antiepileptic drugs (AEDs): is it an issue?	Michael Foundation Symposium	DG - Seizure prediction in epilepsy: from modelling to seizure prevention		
15:00-15:30		Coffee Break 16:00 - 16.30				
15:30-16:00						
16:00-16:30		Eisai Europe Ltd Satellite Symposium				
16:30-17:00						
17:00-17:30						
17:30-18:00						
18:00-18:30						
18:30-19:00						
19:00-19:30	Merritt-Putnam Symposium					
19:30-20:00						
20:00-20:30						
20:30-21:00						

Legend	
Adult Epileptology	Neuropsychology
Alternative Therapies	Non-Epileptic Paroxysmal Events
Basic Science	Paediatric Epileptology
Clinical Neurophysiology	Psychiatry
Diagnosis	Sleep and Epilepsy
Drug Therapy	Social Issues
Epilepsy Syndromes in Children and Adults	Surgical Treatment
Genetics	Treatment
Neuroimaging	Other





## SCIENTIFIC PROGRAMME

### MONDAY, 28<sup>TH</sup> JUNE 2010

Hall 4 (Nafsica)	Hall 5 (Nefeli)	Hall 6 (Marika)	Hall 7 (Colossus)	
"How To Do" Seizure monitoring in the EMU setting	Teaching Session Brain stimulation for epilepsy	Eurepa Session Aging and comorbidity	Eurepa Session EEG in the diagnosis and treatment of epilepsy	07:30-08:00
				08:00-08:30
				08:30-09:00
				09:00-09:30
				09:30-10:00
				10:00-10:30
				10:30-11:00
				11:00-11:30
Coffee Break 11:00 - 11.30				11:00-11:30
Platform Session Epilepsy surgery	Platform Session Neuroimaging I: imaging progress in TLE and beyond	Platform Session Drug therapy: pregnancy and AED adverse effects	CEA - EU Symposium	11:30-12:00
				12:00-12:30
				12:30-13:00
				13:00-13:30
Lunch 13:00 - 14.30				13:30-14:00
				14:00-14:30
DG - Structural genomic variation in human seizure disorders		DG - Idiopathic childhood "focal" seizure susceptibility		14:30-15:00
				15:00-15:30
				15:30-16:00
Coffee Break 16:00 - 16.30				16:00-16:30
				16:30-17:00
				17:00-17:30
				17:30-18:00
				18:00-18:30
				18:30-19:00
				19:00-19:30
				19:30-20:00
				20:00-20:30
				20:30-21:00

MONDAY, 28<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

07:30-09:00

Breakfast Symposium

**Elekta**

**Clinical MEG in epilepsy**

**Hall 1 (Jupiter)**

Chair: Boon P (Belgium)

**Short overview of MEG basics and clinical MEG indications for epilepsy in adults**

Stefan H (Germany)

**Clinical MEG indications for epilepsy in children**

Van Bogaert P (Belgium)

07:30-09:00

Teaching Session

**Seizure, arousal or parasomnia? A road map into the borderlands**

**Hall 2 (Roses)**

Chair: De Weerd A (Netherlands)

**Seizure and arousal: egg or chicken?**

Kelemen A (Hungary)

**Seizure, arousal or parasomnia: how best to ruin a good nights sleep**

De Weerd A (Netherlands)

**Seizure, arousal or parasomnia: is there truth in depth?**

Nobili L (Italy)

07:30-09:00

Workshop

**Epileptogenesis: mechanisms and prevention**

**Hall 3 (Delphi)**

Chair: Bernard C (France)

**Epigenetic factor mediate HCN1 channelopathy**

Bernard C (France)

**T-type calcium channel upregulation as a pro-epileptogenic factor**

Becker A (Germany)

**Preventing epileptogenesis: anti-inflammatory strategy**

Vezzani AM (Italy)

**Preventing epileptogenesis: growth factors strategy**

Simonato M (Italy)



## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

07:30-09:00

How to do? Seizure Monitoring in the EMU Setting

**How to do? Safety in the EMU**

**Hall 4 (Nafsica)**

Chair: Canevini MP (Italy)

**How to provide a safe EMU environment?**

Canevini MP (Italy)

**How to safely taper or withdraw AED treatment for seizure provocation**

Claus S (Netherlands)

**How to prevent or deal with seizure related adverse events**

Rubboli G (Italy)

07:30-09:00

Teaching Session

**Brain stimulation for epilepsy: current status and future prospects**

**Hall 5 (Nefeli)**

Chair: Velis D (Netherlands)

**Vagal-nerve stimulation: state-of-the-art review**

Selway R (United Kingdom)

**Transcranial magnetic stimulation: diagnostic and therapeutic aspects**

Kimiskidis V (Greece)

**Emerging neurostimulation paradigms: direct cortical and closed-loop stimulation**

Velis D (Netherlands)

MONDAY, 28<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

07:30-09:00

Case Oriented Learning Session

**EUREPA session: aging and comorbidity**

**Hall 6 (Marika)**

Chair: Guekht A (Russia)

**Epilepsy and comorbidity in the elderly**

Guekht A (Russia)

**Contribution of EEG in elderly patients with epilepsy and other co-morbidities**

Neufeld M (Israel)

**Neuroimaging in the diagnosis and differential diagnosis of epilepsy in the elderly**

Trinka E (Austria)

07:30-09:00

Teaching Session · Introduction to VIREPA

**EUREPA session: EEG in the diagnosis and treatment of epilepsy (supported by the ILAE Commission on Diagnostic Methods)**

**Hall 7 (Colossus)**

Chair: Van Emde Boas W (Netherlands)

**EEG in the diagnosis and management of epilepsy: an orderly approach**

Van Emde Boas W (Netherlands)

**Paediatric EEG in epilepsy: age dependent issues**

Plouin P (France)

MONDAY, 28<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

09:00-11:00

Chairs Symposium

**The paradoxes of the paroxysms: seizure precipitating factors and underlying mechanisms**

**Hall 1 (Jupiter)**

Chairs: Baulac M (France), Kostopoulos G (Greece)

**How do brain synchronization mechanisms promote ictogenesis?**

Buzsaki G (USA)

**The double face of the GABAergic system in seizure onset**

Avoli M (Canada)

**Sleep, arousal and seizures**

Nobili L (Italy)

**Is it a sudden event?**

Navarro V (France)

MONDAY, 28<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Genetics**

**Hall 2 (Roses)**

Chairs: Serratosa J (Spain), Papavasiliou A (Greece)

- 001 **Infantile onset focal epilepsy and epileptic encephalopathies associated with PCDH19 gene mutations: new de novo and familial mutations**  
Marini C1, Mei D1, Parmeggiani L1, Norci V1, Calado E2, Moreira A2, Ferrari A1, Pisano T1, Battaglia D1, Guerrini R1 (1Italy, 2Portugal)
- 002 **Phenotyping of IGE patients with a photoparoxysmal EEG response (PPR) for European genetic studies: two main phenotypes appear to be similar in Northern and Southern European countries**  
Kasteleijn-Nolst Trenité D1, de Kovel C1, Jovic-Jakubi B2, Baykan B3, Visscher F1, Janssen A1, Verrotti A4, Schippers H1, Sonsma A1, Koeleman B1, Lindhout D1, Elia M4, Stylianidou G5, Mikati M6, Cerminara C4, Incorpora G4, Augustijn P1, Latella A4, Bianchi A4, Carpay J1, Stroink H1 (1Netherlands, 2Serbia, 3Turkey, 4Italy, 5Cyprus, 6Lebanon)
- 003 **A nonsense mutation of GABRG2 found in a severe epilepsy phenotype and which leads to a trafficking abnormality of GABAA receptors**  
Ishii A, Fukuma G, Kanaumi T, Ueno S, Kakimura N, Takeda S, Takashima S, Hirose S (Japan)
- 004 **The association between carbamazepine-induced cutaneous adverse drug reactions with HLA-B\*1502 allele in mainland of China**  
Wu X1,2, An D2, Hu F2, Stefan H1, Zhou D2 (1Germany, 2China)
- 005 **Identification of a 15q13.3 microdeletion in clinically affected and unaffected members in a pedigree with idiopathic generalized epilepsy**  
Chowdhury F A, Hindocha N, Flomen R, Richardson M P, Nashef L, Makoff A (United Kingdom)



## SCIENTIFIC PROGRAMME

### MONDAY, 28<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Paediatric epileptology**

**Hall 3 (Delphi)**

Chairs: Dravet C (France), Zafeiriou DI (Greece)

- 006 **The many faces of Glut1 deficiency — we always have to re-think on our “old” patients**  
Tzadok M, Proper K, Matot I, Marcu S, Nissenkorn A, Anikster Y, Menascu S, Bercovich D, Ben-Zeev B (Israel)
- 007 **Immune-mediated and inflammatory disease in etiology of epilepsy parialis continua in children**  
Kravljanc R, Jovic N, Djuric M, Pekmezovic T (Serbia)
- 008 **Infantile epileptic encephalopathy with late onset-spasms: report of 19 patients**  
Bouvet-Mourcia A, Lamblin M-D, Pandit F, Vallée L, Auvin S (France)
- 009 **Early prognostic factors in patients with severe myoclonic epilepsy in infancy (SMEI)**  
Petrelli C, Passamonti C, Cesaroni E, Zamponi N (Italy)
- 010 **Risk factors for seizure prognosis in myoclonic-astatic epilepsy**  
Tatishvili N, Kipiani T, Japaridze N, Tatishvili S (Georgia)
- 011 **Epileptic encephalopathy — seizure and developmental outcome after functional hemispherotomy**  
Gröppel G, Dressler A, Mühlebner A, Pahs G, Porsche B, Czech T, Kasprian G, Prayer D, Feucht M (Austria)

MONDAY, 28<sup>TH</sup> JUNE 2010





## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Epilepsy surgery**

**Hall 4 (Nafsica)**

Chairs: Fountas K (Greece), Malmgren K (Sweden)

- 012 **Radiofrequency thermocoagulation (RFTC) of ictal onset zone be means of stereoelectroencephalographic (SEEG) electrodes**  
Dimova P S<sup>1</sup>, Minotti L<sup>2</sup>, Kahane P<sup>2</sup>, Hoffmann D<sup>2</sup> (1Bulgaria, 2France)
- 013 **The TimeToStop study II. The relation between timing of antiepileptic drug withdrawal and seizure recurrence after childhood epilepsy surgery**  
Boshuisen K, Uiterwaal C S P M, van Nieuwenhuizen O, Braun K P J, the TimeToStop Study Group (Netherlands)
- 014 **Effectiveness of neurosurgical treatment for seizure control in patients with cerebral arteriovenous malformation**  
Kostiuk K, Tsymbaliuk V, Tsimeyko O, Yakovenko L (Ukraine)
- 015 **Hypermotor seizures in patients with temporal lobe epilepsy: a retrospective analysis of clinical features and outcome after temporal lobe resection**  
Staack A M, Bilic S, Scholly J, Steinhoff B J (Germany)
- 016 **The posterior face of hypermotor seizures**  
Montavont A, Catenoix H, Isnard J, Kahane P, Ryvlin P (France)
- 017 **Long-term developments in presurgical evaluation and surgical treatment of epilepsy at one tertiary center — part II: surgical outcome**  
Bien C G, Raabe A L, Schramm J, Becker A, Urbach H, Elger C E (Germany)



## SCIENTIFIC PROGRAMME

### MONDAY, 28<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Neuroimaging I: imaging progress in TLE and beyond**

**Hall 5 (Nefeli)**

Chairs: Hammers A (United Kingdom), Kapsalaki EZ (Greece)

- 018 **Brain-wide survey of anatomical structures as classifiers in temporal lobe epilepsy using automatic segmentation and structure selection**  
Keihaninejad S<sup>1</sup>, Heckemann R A<sup>1,2</sup>, Gousias I S<sup>1</sup>, Hajnal J V<sup>1</sup>, Duncan J S<sup>1</sup>, Aljabar P<sup>1</sup>, Rueckert D<sup>1</sup>, Hammers A<sup>1,2</sup>  
(<sup>1</sup>United Kingdom, <sup>2</sup>France)
- 019 **Polymicrogyria: an underrecognized cause of epilepsy in patients with hereditary haemorrhagic telangiectasia (Rendu-Osler disease)?**  
Hermier M, Montavont A, Dupuis-Girod S, Cho T-H, Honnorat J, Plauchu H (France)
- 020 **Abnormality of thalamic substructure in mesial temporal lobe epilepsy assessed using novel imaging methods**  
Richardson M P, Traynor C, Deoni S, Crum W, Barker G (United Kingdom)
- 021 **Reorganisation of language in temporal lobe epilepsy and prediction of effects of temporal lobe resection**  
Bonelli S, Powell R, Yogarajah M, Focke N, Thompson P, Symms M, Koepp M, Duncan J (United Kingdom)
- 022 **Reliability of MRI findings in temporal lobe epilepsy associated with focal cortical dysplasia**  
Marusic P<sup>1</sup>, Fauser S<sup>2</sup>, Krysl D<sup>1</sup>, Schulze-Bonhage A<sup>2</sup>  
(<sup>1</sup>Czech Republic, <sup>2</sup>Germany)
- 023 **Temporal lobe function in frontal lobe epilepsy: an fMRI study of long term memory in frontal lobe epilepsy**  
Centeno M, Vollmar C, Thompson P, Bonelli S, O'Muircheartaigh J, Kumari V, Symms M, Barker G, Duncan J, Richardson M, Koepp M (United Kingdom)

MONDAY, 28<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Drug therapy: pregnancy and AED adverse effects**

**Hall 6 (Marika)**

Chairs: Karlovasitou A (Greece), Morrow J (United Kingdom)

- 024 **Adverse antiepileptic drug effects in newly-diagnosed epilepsy: a case-control study**  
Perucca P<sup>1</sup>, Jacoby A<sup>2</sup>, Marson A G<sup>2</sup>, Baker G A<sup>2</sup>, Lane S<sup>2</sup>,  
Benn E K<sup>3</sup>, Gilliam F G<sup>3</sup>, Hesdorffer D C<sup>3</sup> (1Italy, 2United Kingdom, 3USA)
- 025 **The impact of antiepileptic polytherapy on mood and cognitive function**  
Rösche J, Kundt G, Uhlmann C, Weber R, Fröscher W (Germany)
- 026 **Developmental abilities of children exposed in utero to antiepileptic drugs: a comparison between sodium valproate and levetiracetam**  
Shallcross R, Bromley R L, Irwin B, Morrow J I, Baker G A, The Liverpool and Manchester Neurodevelopment Group & The UK Pregnancy and Epilepsy Register (United Kingdom)
- 027 **Preschool behavioural problems after prenatal exposure to antiepileptic drugs: a follow-up study**  
Kjaer D<sup>1</sup>, Christensen J<sup>1</sup>, Bech B H<sup>1</sup>, Pedersen L H<sup>1</sup>, Vestergaard M<sup>1</sup>, Olsen J<sup>1,2</sup> (1Denmark, 2USA)
- 028 **Malformation risks after monotherapy exposure to antiepileptic drugs: first report from EURAP**  
Battino D<sup>1</sup>, Bonizzoni E<sup>1</sup>, Craig J<sup>2</sup>, Lindhout D<sup>3</sup>, Perucca E<sup>1</sup>, Sabers A<sup>4</sup>, Tomson T<sup>5</sup>, Vajda F<sup>6</sup>, on behalf of the collaborative EURAP study group (1Italy, 2United Kingdom, 3Netherlands, 4Denmark, 5Sweden, 6Australia)
- 029 **Malformation risks of antiepileptic drugs (AEDs) in pregnancy: an update from the UK Epilepsy and Pregnancy Register**  
Kennedy F<sup>1</sup>, Morrow J<sup>1</sup>, Hunt S<sup>1</sup>, Russell A<sup>1</sup>, Smithson W H<sup>1</sup>, Parsons L<sup>1</sup>, Robertson I<sup>1</sup>, Irwin B<sup>1</sup>, Delanty N<sup>2</sup>, Morrison P J<sup>1</sup>, Craig J<sup>1</sup>, UK Pregnancy and Epilepsy Register (1United Kingdom, 2Ireland)



## SCIENTIFIC PROGRAMME

### MONDAY, 28<sup>TH</sup> JUNE 2010

#### 11:30-13:00

Discussion Group

**CEA — EU Symposium**

**Funding of epilepsy research in Europe**

**Hall 7 (Colossus)**

Chairs: Bialer M (Israel), Pitkanen A (Finland)

**Need of research funding: a voice of the patient**

Williams E (United Kingdom)

**EU funding instruments**

Tosetti P (Belgium)

**Industry as a partner of EU research funding for epilepsy**

Salonen R (Finland)

#### 14:30-16:00

Discussion Group

**Generic products of antiepileptic drugs**

**(AEDs): is it an issue?**

**Hall 1 (Jupiter)**

Chair: Johannessen S (Norway)

**Update on regulatory process in approving generic products**

Macheras P (Greece)

**Generic antiepileptic drugs: pro**

Johannessen S (Norway)

**Generic antiepileptic drugs: con**

Kraemer G (Switzerland)

**Generic products of antiepileptic drugs: let's separate the science from the politics**

Bialer M (Israel)



## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

14:30-16:00

Special Symposium

**The Michael Foundation Symposium**

**Hall 2 (Roses)**

**Pharmacoresistance and blood-brain barrier:  
assessment of P-gp function from bench to  
bedside**

Chair: Wolf P (Denmark)

**P-gp overexpression vs blood-brain barrier damage in the  
epileptic brain: implications for pharmacoresistence**  
Vezzani AM (Italy)

**Blood-brain barrier breakdown and brain dysfunction**  
Friedman A (Israel)

**Inhibition of P-gp: a new therapeutic concept?**  
Loeschner W (Germany)

**Imaging P-gp function in epilepsy**  
Koepp MJ (United Kingdom)

14:30-16:00

Discussion Group

**Seizure prediction in epilepsy: from modelling  
to seizure prevention**

**Hall 3 (Delphi)**

Chair: Schelter B (Germany)

**From EEG signals recorded in human partial epilepsies to  
dynamic transitions in brain activity: insights from computational  
models**  
Wendling F (France)

**Recent advances in seizure prediction**  
Feldwisch H (Germany)

**Can the micro-electrodes recordings improve the seizure  
prediction strategies?**  
Navarro V (France)

**Electrical stimulation of the seizure focus**  
Boon P (Belgium)



## SCIENTIFIC PROGRAMME

### MONDAY, 28<sup>TH</sup> JUNE 2010

14:30-16:00

Discussion Group

**Structural genomic variation in human seizure disorders: emerging themes in epilepsy genetics**

**Hall 4 (Nafsica)**

Chair: De Jonghe P (Belgium)

**Listen to your genome and talk to your patients: the architecture of the human genome and the challenges of phenotyping**  
Helbig I (Germany)

**State of the art: epilepsies as comorbidities in classical microdeletion syndromes**  
Steensbjerre Moller R (Denmark)

**An under recognised source of genetic morbidity: microdeletions and microduplications in idiopathic epilepsy syndromes**  
Zara F (Italy)

**A glimpse at the future: analysis of genome-wide copy number variations in large datasets and the question of pathogenicity**  
De Kovel C (Netherlands)

MONDAY, 28<sup>TH</sup> JUNE 2010

14:30-16:00

Discussion Group

**Idiopathic childhood “focal” seizure susceptibility**

**Hall 6 (Marika)**

Chair: Ferrie C (United Kingdom)

**Clinical aspects and genetics**  
Livingston J (United Kingdom)

**EEG aspects (including MEG) and relevance to pathophysiology**  
Grosso S (Italy)

**Principles of management and treatment (acute early phase - follow up)**  
Covanis T (Greece)

**Psychosocial aspects, parental reactions and needs**  
Valeta T (Greece)



## SCIENTIFIC PROGRAMME

MONDAY, 28<sup>TH</sup> JUNE 2010

16:30-18:00

Satellite Symposium  
**Eisai Europe Ltd**  
**Talking About a Revolution**

**Hall 1 (Jupiter)**

Chair: Glauser T (USA)

Glauser T (USA)  
Ben-Menachem E (Sweden)  
Trinka E (Austria)  
Ryvlin P (France)  
Gil-Nagel A (Spain)  
Cramer J (USA)

18:30-20:00

Satellite Symposium  
**Merritt-Putnam Symposium**  
**Challenges in assessing the efficacy of AEDs**

**Hall 1 (Jupiter)**

Chair: Perucca E (Italy)

**Challenges in demonstrating efficacy in monotherapy trials –  
from regulatory concerns to clinical applications**

Baulac M (France)

**Improving the design and the reporting of efficacy trials in  
epilepsy**

French J (USA)

**Assessing the potential usefulness of new AEDs in paediatric  
epilepsies – can we do better?**

Arzimanoglou A (France)







## SCIENTIFIC PROGRAMME

TUESDAY, 29TH JUNE 2010

	Poster Hall	Hall 1 (Jupiter)	Hall 2 (Roses)	Hall 3 (Delphi)
07:30-08:00				
08:00-08:30			Eurepa Session Paediatrics	Workshop Cognitive disturbances and epileptiform activity
08:30-09:00	Poster Set-Up			
09:00-09:30	Posters on Display	Main Session Advances in techniques to delineate the epileptogenic zone		
09:30-10:00				
10:00-10:30				
10:30-11:00				
11:00-11:30			Coffee Break 11:00 - 11:30	
11:30-12:00			Platform Session Epilepsy syndromes in adults	Platform Session Clinical epileptology
12:00-12:30				
12:30-13:00				
13:00-13:30			Lunch 13:00 - 14:30	
13:30-14:00	Poster Tours			
14:00-14:30				
14:30-15:00	Posters on Display	Neurobiology Symposium	DG - New insights into epilepsy management in children	DG - Clinical and basic concepts of IGE revisited
15:00-15:30				
15:30-16:00				
16:00-16:30		Coffee Break 16:00 - 16:30		
16:30-17:00		UCB Pharma SA Satellite Symposium		
17:00-17:30				
17:30-18:00				
18:00-18:30				
18:30-19:00				
19:00-19:30				
19:30-20:00				
20:00-20:30				
20:30-21:00				

TUESDAY, 29TH JUNE 2010

Legend	
Adult Epileptology	Neuropsychology
Alternative Therapies	Non-Epileptic Paroxysmal Events
Basic Science	Paediatric Epileptology
Clinical Neurophysiology	Psychiatry
Diagnosis	Sleep and Epilepsy
Drug Therapy	Social Issues
Epilepsy Syndromes in Children and Adults	Surgical Treatment
Genetics	Treatment
Neuroimaging	Other



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

Hall 4 (Nafsica)	Hall 5 (Nefeli)	Hall 6 (Marika)	Hall 7 (Colossus)	
"How To Do" Seizure monitoring in the EMU setting	Teaching Session Interpreting video EEG data in a surgical perspective	Eurepa Session Genetics of epilepsy	Workshop Infantile spasms: how to get rid of the catastrophe	07:30-08:00
				08:00-08:30
		Main Session AED development, selection and use relevant to gender and age		08:30-09:00
				09:00-09:30
				09:30-10:00
				10:00-10:30
				10:30-11:00
Coffee Break 11:00 - 11:30				11:00-11:30
Platform Session Clinical trials	Platform Session Neuroimaging II	Platform Session Neurobiology of epilepsy I	Platform Session QOL and psychosocial impact of epilepsy	11:30-12:00
				12:00-12:30
				12:30-13:00
				13:00-13:30
Lunch 13:00 - 14:30				13:30-14:00
				14:00-14:30
DG - Valproic acid (VPA) an old and established antiepileptic drug that keeps surprising	DG - New developments in K <sup>+</sup> -channel involvement in epilepsy	Workshop Mapping brain functions using intracranial electrodes	DG - Imaging the connections of the eloquent brain and epileptogenic foci	14:30-15:00
				15:00-15:30
				15:30-16:00
Coffee Break 16:00 - 16:30				16:00-16:30
				16:30-17:00
				17:00-17:30
				17:30-18:00
				18:00-18:30
				18:30-19:00
				19:00-19:30
				19:30-20:00
				20:00-20:30
				20:30-21:00

TUESDAY, 29<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

TUESDAY, 29TH JUNE 2010

07:30-09:00

Case-Oriented Learning Session

**EUREPA session: Paediatrics**

**Hall 2 (Roses)**

Chair: Plouin P (France)

**Clinical case 1 (genetics)**

Vigevano F (Italy)

**Clinical case 2 (metabolic diseases)**

Wolf N (Netherlands)

**Clinical case 3 (syndromic approach)**

Bahi Buisson N (France)

07:30-09:00

Workshop

**Are cognitive disturbances and epileptiform activity at night related?**

**Hall 3 (Delphi)**

Chair: Larsson PG (Norway)

**Cognitive disturbances including autism in patients with continuous spike wave during slow sleep (CSWS)**

Deonna T (Switzerland)

**Nocturnal epileptiform activity in patients with ADHD**

Silvestri R (Italy)

**Is the epileptiform activity the reason for cognitive impairment or only an epiphenomenon**

Holmes G (USA)

**Treatment of cognitive disturbances in patients with CSWS**

Eeg-Olofsson O (Sweden)

TUESDAY, 29TH JUNE 2010



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

07:30-09:00

How to do? Seizure Monitoring in the EMU Setting  
**How to do? How to observe and test patients and  
report seizures recorded in the EMU**

Hall 4 (Nafsica)

Chair: Beniczky S (Denmark)

**Seizure observation: Dos and don'ts**  
Gallmetzer P (Austria)

**Interaction with the patient: Dos and don'ts**  
Fogarasi A (Hungary)

**How to report the seizures recorded in the epilepsy  
monitoring unit**  
Beniczky S (Denmark)

07:30-09:00

Teaching Session

**Interpretating video EEG data in a surgical perspective**

Hall 5 (Nefeli)

Chair: Kahane P (France)

**Analysis of interictal scalp EEG data in a surgical perspective**  
Baumgartner C (Austria)

**Ictal and postictal clinical signs that reliably lateralize and  
localize the epileptogenic zone**  
Rosenow F (Germany)

**Significance of the first ictal scalp EEG changes and seizure  
spread patterns**  
Tassi L (Italy)

**Pitfalls and caveats of video EEG findings in children**  
Cross H (United Kingdom)

TUESDAY, 29<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

TUESDAY, 29TH JUNE 2010

07:30-09:00

Teaching Session · Introduction to VIREPA

**EUREPA session: Genetics of epilepsy (supported by the ILAE Commission on Genetics)**

**Hall 6 (Marika)**

Chair: Lerche H (Germany)

**Genetic basis of the epilepsies**

Zara F (Italy)

**Pathogenesis of genetic epilepsies**

Lerche H (Germany)

07:30-09:00

Workshop

**Infantile spasms: how to get rid of the catastrophe**

**Hall 7 (Colossus)**

Chairs: Moshe SL (USA), Riikonen R (Finland)

**Models of infantile spasms**

Galanopoulou A (USA)

**Can the EEG predict the outcome?**

Granata T (Italy)

**What can we learn from the ARX mutation?**

Noebels J (USA)

**How to treat; evidence based studies**

Lux A (United Kingdom)



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

09:00-11:00

Main Session

**Advances in techniques to delineate the epileptogenic zone**

**Hall 1 (Jupiter)**

Chairs: Baumgartner C (Austria), Schulze-Bonhage A (Germany)

**Hemodynamic correlates of epileptic activity using fMRI and their potential clinical role**

Lemieux L (United Kingdom)

**Spectroscopic imaging in presurgical evaluation of epilepsy patients**

Krsek P (Czech Republic)

**Approaches to focus localization using modern PET tracers**

Ryvlin P (France)

**Identification of superficial and deep sources of epileptic activity by magnetoencephalography**

Ioannides A (Cyprus)

**From single cell recordings to high frequency oscillations: novel indicators of epileptogenicity**

Jacobs J (Germany)

09:00-11:00

Main Session

**AED development, selection and use relevant to gender and age**

**Hall 6 (Marika)**

Chairs: Brodie M (United Kingdom), Tomson T (Sweden)

**Clinical trials of AEDs: new EMEA guidelines versus clinical needs in different age groups**

Baulac M (France)

**Towards a syndrome-based AED selection in children**

Covanis T (Greece)

**AED selection and use in women of childbearing potential**

Morrow J (United Kingdom)

**AED selection and use in the elderly: pharmacodynamic and pharmacokinetic considerations**

Perucca E (Italy)

**Idiosyncratic adverse effects: are they age-dependent and if so why?**

Pirmohamed M (United Kingdom)

TUESDAY, 29<sup>TH</sup> JUNE 2010





## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Epilepsy syndromes in adults**

**Hall 2 (Roses)**

Chair: Kramer U (Israel)

030

**Reflex traits in juvenile myoclonic epilepsy**

Macedo J, Guaranha M, Guilhoto L, Yacubian E M,  
UNIPETE (Brazil)

031

**Diagnosis of epilepsy syndrome following a first seizure  
and its correlation with long-term follow-up: longitudinal  
study of 132 patients from the emergency room**

Sierra-Marcos A, Edo M C, Toledo M, Rovira R, Sueiras M,  
Santamarina E, Quintana M, Salas-Puig X, Álvarez-Sabín J (Spain)

032

**Adult-onset Rasmussen's Encephalitis: the crucial role of the  
mesiotemporal-opercular-insular network in determining a  
common electro-clinical pattern**

Casciato S, Di Bonaventura C, Fattouch J, Di Gennaro G,  
Quarato P P, Lapenta L, Vaudano A E, Esposito V, Manfredi M,  
Prencipe M, Giallonardo A T (Italy)

033

**The GRENAT database: a new tool to recruit epileptic patients  
for multicentre clinical trials**

Chipaux M, GRENAT Group (France)

034

**Does it exist a subgroup of juvenile myoclonic epilepsy patients  
with a self-limited course? Supporting evidence from a long-term  
clinico-EEG study**

Giannakodimos S, Alexoudi A, Karageorgiou C E (Greece)

035

**Defining the autism-epilepsy phenotype**

Cuccaro M, Tuchman R, Hamilton K, Gilbert J R, Wright H H,  
Abramson R K, Pericak-Vance M A (USA)



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session  
**Clinical epileptology**

**Hall 3 (Delphi)**

Chair: Reetta Kälviäinen (Finland)

- 036 **Frequency of cardiac symptoms in a Swedish patient population with epilepsy**  
Mentesidou E, Caceres R, Lindell C, Åkerstedt L, Landtblom A-M (Sweden)
- 037 **EEG patterns in nonconvulsive status epilepticus on the intensive care unit**  
De Maria G, Perone G, Guarneri B, Antonini L (Italy)
- 038 **Epilepsy in ancient Greece: from a superstition to a disease**  
Tozios S, Theofanidis D, Dargini M, Garganis K (Greece)
- 039 **A nurse-led clinic for adults with epilepsy and learning disability experiencing prolonged and/or repeated tonic-clonic seizures in the community to reduce risk of status epilepticus and the risk of sudden unexpected death in epilepsy (SUDEP)**  
Lewis S A (United Kingdom)
- 040 **Late-onset temporal lobe epilepsy with positive antithyroid antibodies: is it an autoimmune epilepsy?**  
Miró J, Falip M, Aiguabella M, Juncadella M, Fortuny R, Veciana M, Fernández S, Castañer S (Spain)
- 041 **Late-onset epilepsy, mild cognitive impairment and anti-voltage-gated potassium (VGKC) antibodies: an observational study on the effects of an oral prednisolone course**  
Thijss R D<sup>1</sup>, Verschuuren J J<sup>1</sup>, Sander J W<sup>1,2</sup> (<sup>1</sup>Netherlands, <sup>2</sup>United Kingdom)

TUESDAY, 29<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Clinical trials**

**Hall 4 (Nafsica)**

Chairs: Ben-Menachem E (Sweden), Piperidou C (Greece)

- 042 **Retigabine provides effective adjunctive therapy in adults with refractory epilepsy with partial-onset seizures, irrespective of age, gender and race**  
Yacubian E M<sup>1</sup>, Abou-Khalil B<sup>2</sup>, Elger C<sup>3</sup>, Hall S<sup>2</sup>, VanLandingham K E<sup>2</sup>, on behalf of the RESTORE 1 and RESTORE 2 Study Investigators (<sup>1</sup>Brazil, <sup>2</sup>USA, <sup>3</sup>Germany)
- 043 **Efficacy, safety, and tolerability of Carisbamate 800 and 1200 mg/day as adjunctive therapy in patients with partial onset seizures; randomized, double-blind, placebo-controlled trial**  
Halford J J<sup>1</sup>, Ben-Menachem E<sup>2</sup>, Kwan P<sup>3</sup>, Ness S<sup>1</sup>, Schmitt J<sup>1</sup>, Eerdekens M<sup>4</sup>, Novak G<sup>1</sup> (<sup>1</sup>USA, <sup>2</sup>Sweden, <sup>3</sup>China, <sup>4</sup>Belgium)
- 044 **Levetiracetam monotherapy: outcomes from an epilepsy clinic**  
Kelly K, Stephen L J, Brodie M J (United Kingdom)
- 045 **Long-term efficacy of lacosamide for partial-onset seizures: an interim evaluation of completer cohorts exposed to lacosamide for up to 5 years**  
French J<sup>1</sup>, Ben-Menachem E<sup>2</sup>, Isojarvi J<sup>1</sup>, Hebert D<sup>1</sup>, Doty P<sup>1</sup> (<sup>1</sup>USA, <sup>2</sup>Sweden)
- 046 **Tolerability of eslicarbazepine acetate by treatment phase in adults with refractory partial seizures: a combined analysis of three randomised, double-blind, placebo-controlled trials**  
Steinhoff B<sup>1</sup>, Elger C<sup>1</sup>, Ben-Menachem E<sup>2</sup>, Gil-Nagel A<sup>3</sup>, Maia J<sup>4</sup>, Nunes T<sup>4</sup>, Soares-da-Silva P<sup>4</sup> (<sup>1</sup>Germany, <sup>2</sup>Sweden, <sup>3</sup>Spain, <sup>4</sup>Portugal)
- 047 **Reporting of adverse events is poor in epilepsy trials and has not improved following CONSORT guidance**  
Shukralla A, Powell G, Tudor Smith C, Marson A (United Kingdom)



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session  
**Neuroimaging II**

**Hall 5 (Nefeli)**

Chairs: Gotsis E (Greece), Koeppe MJ (United Kingdom)

- 048 **Memory deficits are related to disturbance of prefrontal networks rather than hippocampal dysfunction in cryptogenic localization-related epilepsy**  
Vlooswijk M C<sup>1</sup>, Jansen J F<sup>2</sup>, Jeukens C R<sup>1</sup>, Majoie M H<sup>1</sup>, Hofman P A<sup>1</sup>, de Krom M C<sup>1</sup>, Aldenkamp A P<sup>1</sup>, Backes W H<sup>1</sup> (<sup>1</sup>Netherlands, <sup>2</sup>USA)
- 049 **Hippocampal deep brain stimulation reveals decreased rCBF in the hippocampus of the rat: a  $\mu$ SPECT study**  
Wyckhuys T<sup>1</sup>, Van Nieuwenhuijse B<sup>1</sup>, Staelens S<sup>1</sup>, Deleye S<sup>1</sup>, Hallez H<sup>1</sup>, Vonck K<sup>1</sup>, Wadman W<sup>1,2</sup>, Boon P<sup>1</sup> (<sup>1</sup>Belgium, <sup>2</sup>Netherlands)
- 050 **The effect of methylphenidate on N-back task performance in boys with epilepsy and/or ADHD: a behavioural and functional MRI study**  
Bechtel N, Penner I-K, Klarhöfer M, Scheffler K, Opwis K, Weber P (Switzerland)
- 051 **Changes in resting-state connectivity after experimental hemispherectomy reflect functional reorganization and network alterations**  
Otte W M, Dijkhuizen R M, van Rijen P C, Gosselaar P H, van Meer M P A, van Nieuwenhuizen O, Braun K P J (Netherlands)
- 052 **Concomitant recordings of intracranial EEG and fMRI: MRI safety study on RF-induced electrode heating in a phantom model and animals**  
Ciumas C<sup>1</sup>, Schaefer G<sup>2</sup>, Koch C<sup>2</sup>, Perrin E<sup>1</sup>, Bouvard S<sup>2</sup>, Canet-Soulas E<sup>1</sup>, Comte J-C<sup>1</sup>, Ibarrola D<sup>1</sup>, Polo G<sup>1</sup>, Moya J<sup>1</sup>, Rylvlin P<sup>1</sup> (<sup>1</sup>France, <sup>2</sup>Germany)
- 053 **Simultaneous intracranial EEG-fMRI in patients with epilepsy**  
Carmichael D<sup>1</sup>, Vulliemoz S<sup>1,2</sup>, Rosenkranz K<sup>1</sup>, Diehl B<sup>1</sup>, Walker M<sup>1</sup>, Rodionov R<sup>1</sup>, McEvoy A<sup>1</sup>, Lemieux L<sup>1</sup> (<sup>1</sup>United Kingdom, <sup>2</sup>Switzerland)

TUESDAY, 29<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

TUESDAY, 29TH JUNE 2010

11:30-13:00

Platform Session

**Neurobiology of epilepsy I**

**Hall 6 (Marika)**

Chairs: Friedman A (Israel), Pandis D (Greece)

- 054 **Expression of IL-1 beta induced by epileptiform activity in the isolated guinea pig brain in vitro**  
Librizzi L, Ravizza T, Vezzani A, de Curtis M (Italy)
- 055 **Perirhinal cortical kindling in genetic absence epilepsy rat strains**  
Akman O, Karson A, Ates N, Onat F (Turkey)
- 056 **Cortical hypersynchronicity and epileptogenesis following photothrombotic stroke: potential prevention using SPG stimulation-induced vasodilatation**  
Levi H<sup>1</sup>, Weissberg I<sup>1</sup>, Shoknecht K<sup>2</sup>, Freidman A<sup>1</sup>  
(<sup>1</sup>Israel, <sup>2</sup>Germany)
- 057 **Two distinct patterns of hippocampal neurogenesis in vivo and in vitro can be identified in patients with mesial temporal lobe epilepsy and correlate with each patient's ability to store and recall memory**  
Coras R<sup>1</sup>, Siebzehnriibl F<sup>2</sup>, Pauli E<sup>1</sup>, Kobow K<sup>1</sup>, Hahnen E<sup>1</sup>, Weigel D<sup>1</sup>, Buchfelder M<sup>1</sup>, Stefan H<sup>1</sup>, Blümcke I<sup>1</sup> (<sup>1</sup>Germany, <sup>2</sup>USA)
- 058 **Does perinatal cortical photothrombic ischemic stroke induce epileptogenesis in rats?**  
Jason T, Hrachova A, Festrova V, Mikulecka A, Kubova H, Otahal J (Czech Republic)
- 059 **Neuronal heparanase may facilitate the migration of infiltrating monocytes in the rat hippocampus following status epilepticus**  
Bonnet C, Navarro-y-Garcia F P, Georges B, Bezin L (France)



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Quality of life and psychosocial impact of epilepsy** Hall 7 (Colossus)

Chairs: Vigevano F (Italy), Guekht A (Russia)

060 **The impact of antiepileptic drug treatment on attention and executive functions**

Witt J-A, Helmstaedter C (Germany)

061 **Social cognition in mesial temporal lobe epilepsy**

Stroebele A, Stefan H, Pauli E (Germany)

062 **The burden among caregivers of patients with epilepsy: impact and predictors**

Karakis I<sup>1</sup>, Cole A J<sup>1</sup>, Montouris G D<sup>1</sup>, Tsiakiri A<sup>2</sup>, Piperidou C<sup>2</sup> (<sup>1</sup>USA, <sup>2</sup>Greece)

063 **A survey of knowledge and attitudes towards epilepsy in residents of the Western district in Tottori Prefecture, Japan**

Yoshioka S-I, Fukuda M, Tokushima Y (Japan)

064 **Family functioning and quality of life in adult patients with epilepsy and their family members: a descriptive study**

Mahrer-Imhof R, Jaggi S, Müller M, Bonomo A, Eggenschwiler P (Switzerland)

065 **Seizure free interval: is it a reliable limitation for drivers with epilepsy?**

Polychronopoulos P, Houliara V, Frima M, Papathanasopoulos P, Chroni E (Greece)

14:30-16:00

Special Symposium

**The Neurobiology Symposium: epilepsy, dementia, Alzheimer's disease and the temporal lobe** Hall 1 (Jupiter)

Chairs: Noebels J (USA), Nehlig A (France)

**Introduction**

Noebels J (USA)

**Links between Alzheimer's disease/dementia and epilepsy**

Larner AJ (United Kingdom)

**What can animal models of Alzheimer's disease teach us about brain excitability**

Tanila H (Finland)

TUESDAY, 29<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

14:30-16:00

Discussion Group

**New insight into epilepsy management in children:  
proposed by the European Paediatric Neurology Society**

**Hall 2 (Roses)**

Chairs: Arzimanoglou A (France), Youroukos S (Greece)

**Epilepsy as a presentation of neuro-metabolic disorders**  
Wolf N (Netherlands)

**Epilepsy as a presentation of autoimmune diseases**  
Vincent A (United Kingdom)

**Genetic insights to early onset epileptic encephalopathies**  
Bahi Buisson N (France)

**Focal epilepsies with generalized manifestations**  
Cross H (United Kingdom)

14:30-16:00

Discussion Group

**Clinical and basic concepts of IGE revisited**  
Chair: Kostopoulos G (Greece)

**Hall 3 (Delphi)**

**Is absence epilepsy truly generalized?**  
van Luijckelaar G (Netherlands)

**Are absence and limbic seizures mutually exclusive?**  
Onat F (Turkey)

**Idiopathic absence and symptomatic focal epilepsy  
syndromes in humans; the clinical evidence**  
Elwes R (United Kingdom)

**Channelopathies as a genetic cause for epilepsy:  
the relation to idiopathy**  
Avanzini G (Italy)



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

14:30-16:00

Discussion Group

**Valproic Acid (VPA) an old and established  
antiepileptic drug that keeps surprising**

**Hall 4 (Nafsica)**

Chair: Perucca E (Italy)

**The role of histone deacetylase (HDAC) in VPA  
efficacy and teratogenicity**

Loeschner W (Germany)

**VPA and cognitive decline: adverse effects versus  
therapeutic potential in Alzheimer's disease**

Holmberg B (Sweden)

**A re-appraisal of VPA drug interactions and, implications  
for its use in novel potential indications**

Sills G (United Kingdom)

**How can we develop a successful second generation to  
VPA drug?**

Bialer M (Israel)

14:30-16:00

Discussion Group

**New developments in K<sup>+</sup>-channel involvement  
in epilepsy**

**Hall 5 (Nefeli)**

Chair: Koehling R (Germany)

**Axonal KCNQ-channels regulate neuronal excitability  
and synaptic transmission**

Storm J (Norway)

**Atypical gating of KCNQ-channels in BNFC**

Taglialetta M (Italy)

**Critical reduction of SK-channels in a model of TLE**

Kirschstein T (Germany)

**K<sup>+</sup>-buffering via Kir channels is reduced in seizure-induced  
blood-brain-barrier disruption**

Friedman A (Israel)

TUESDAY, 29<sup>TH</sup> JUNE 2010





## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

14:30-16:00

Workshop

**Mapping brain functions using intracranial electrodes** Hall 6 (Marika)

Chair: Elger C (Germany)

**Mapping the human brain using electrical currents:  
where are we today?**

Leijten F (Netherlands)

**What evoked potentials tell us on the functional anatomy  
and connectivity of the human brain?**

Brazdil M (Czech Republic)

**Dynamic spectral imaging as an online exploratory tool  
of brain functions**

Lachaux JP (France)

**Do micro-recordings add anything new to what can be  
done using macro-electrodes?**

Fried I (Israel)

14:30-16:00

Discussion Group

**Imaging the connections of the eloquent brain and  
epileptogenic foci** Hall 7 (Colossus)

Chair: Duncan J (United Kingdom)

**Imaging visual pathways in temporal lobe epilepsy surgery**

Nilsson D (Sweden)

**Connectivity of language and memory circuits in temporal  
lobe epilepsy**

Yogarajah M (United Kingdom)

**Identifying the connectivity of the epileptogenic zone**

Vulliemoz S (Switzerland)

**The future applications of tractography to defining the  
relationship of eloquent and epileptogenic cortex and to  
planning surgery**

Duncan J (United Kingdom)



## SCIENTIFIC PROGRAMME

TUESDAY, 29<sup>TH</sup> JUNE 2010

16:30-18:00

Satellite Symposium

**UCB Pharma SA**

**A new vision for epilepsy management? From key learnings to new developments in the next decade**

**Hall 1 (Jupiter)**

Chair: Tomson T (Sweden)

**Antiepileptic drug therapy: the story so far**

Brodie M (United Kingdom)

**Forthcoming developments in drug treatment: will they fill the treatment gaps?**

Ryvlin P (France)

**Achieving a new vision for pharmacological treatment of epilepsy: from anticonvulsants to antiepileptics**

Klitgaard H (Belgium)

**Achieving a new vision for pharmacological treatment of epilepsy: a clinical perspective**

Schmitdt D (Germany)

**Fifteen minutes: the last word on tomorrow's world**

Tomson T (Sweden)

TUESDAY, 29<sup>TH</sup> JUNE 2010

**SCIENTIFIC PROGRAMME****WEDNESDAY, 30TH JUNE 2010**

	Poster Hall	Hall 1 (Jupiter)	Hall 2 (Roses)	Hall 3 (Delphi)
07:30-08:00			Teaching Session Paediatric epilepsy surgery in practice	Teaching Session MRI postprocessing in epilepsy
08:00-08:30	Poster Set-Up			
08:30-09:00				
09:00-09:30	Posters on Display	Main Session Challenging the concept of idiopathic epilepsies		
09:30-10:00				
10:00-10:30				
10:30-11:00				
11:00-11:30		Coffee Break 11:00 - 11:30		
11:30-12:00			Platform Session Epilepsy syndromes in children	Platform Session Clinical neurophysiology
12:00-12:30				
12:30-13:00				
13:00-13:30	Poster Tours	Lunch 13:00 - 14:30		
13:30-14:00				
14:00-14:30	Posters on Display	DG - Paediatric epilepsy surgery: state of the art on special syndromes	DG - Epileptic networks and lesions	DG - Controversies in IGE
14:30-15:00				
15:00-15:30				
15:30-16:00		Coffee Break 16:00 - 16:30		
16:00-16:30		Biocodex Satellite Symposium		Workshop The multiple challenges of insular epilepsy
16:30-17:00				
17:00-17:30				
17:30-18:00				
18:00-18:30				
18:30-19:00				
19:00-19:30				
19:30-20:00				
20:00-20:30				
20:30-21:00				

WEDNESDAY, 30TH JUNE 2010

Legend	
Adult Epileptology	Neuropsychology
Alternative Therapies	Non-Epileptic Paroxysmal Events
Basic Science	Paediatric Epileptology
Clinical Neurophysiology	Psychiatry
Diagnosis	Sleep and Epilepsy
Drug Therapy	Social Issues
Epilepsy Syndromes in Children and Adults	Surgical Treatment
Genetics	Treatment
Neuroimaging	Other



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

Hall 4 (Nafsica)	Hall 5 (Nefeli)	Hall 6 (Marika)	Hall 7 (Colossus)	
"How To Do" Seizure monitoring in the EMU setting	Eurepa Session Neuroimaging		Eurepa Session Epilepsy surgery	07:30-08:00
				08:00-08:30
				08:30-09:00
		Main Session Predicting epileptogenesis: How far are we from reaching the goal?		09:00-09:30
				09:30-10:00
				10:00-10:30
				10:30-11:00
Coffee Break 11:00 - 11:30				11:00-11:30
Platform Session Drug therapy: miscellaneous	Platform Session Neurobiology of epilepsy II	Platform Session Mortality and neurobehavioural issues in epilepsy		11:30-12:00
				12:00-12:30
				12:30-13:00
Lunch 13:00 - 14:30				13:00-13:30
				13:30-14:00
				14:00-14:30
Bursary Award Symposium	Workshop Neurobiology of memory dysfunction in temporal lobe epilepsies	DG - Photosensitivity: from focal abnormality to generalized seizures	DG - Interpreting ictal semiology	14:30-15:00
				15:00-15:30
				15:30-16:00
Coffee Break 16:00 - 16:30				16:00-16:30
Workshop Absence seizures and absence epilepsies across the ages		Teaching Session Frontal lobe seizures	Workshop Endogenous anticonvulsive mechanisms activated by seizures	16:30-17:00
				17:00-17:30
				17:30-18:00
				18:00-18:30
				18:30-19:00
				19:00-19:30
				19:30-20:00
20:00-20:30				
				20:30-21:00

WEDNESDAY, 30<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

07:30-09:00

Teaching Session

**Paediatric epilepsy surgery in practice:  
the U-task experience**

**Hall 2 (Roses)**

Chairs: Arzimanoglou A (France),  
Van Nieuwenhuizen O (Netherlands)

**A case of catastrophic epilepsy treated by hemispherotomy**  
Braun K (Netherlands)

**A case of lesional temporal lobe epilepsy treated by  
lesionectomy on the basis of video-EEG monitoring data only**  
Strobl K (Germany)

**A case of lesional extratemporal epilepsy treated after  
invasive monitoring**  
Tassi L (Italy)

**A case of an MRI-negative patient studied by Stereo-EEG**  
Ryvlin P (France)

07:30-09:00

Teaching Session

**MRI postprocessing in epilepsy**

**Hall 3 (Delphi)**

Chair: Trinko E (Austria)

**Overview of MRI postprocessing techniques in the  
presurgical evaluation of epilepsy patients**  
Huppertz HJ (Switzerland)

**Diagnostic value of morphometric MRI analysis in clinical  
and pre-clinical settings**  
Wellmer J (Germany)

**Automatic detection and quantification of hippocampal  
pathology on MRI — results and clinical applications**  
Hammers A (United Kingdom)

**Diffusion-based MRI and tractography in epilepsy**  
Yogarajah M (United Kingdom)



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

07:30-09:00

How to do? Seizure Monitoring in the EMU Setting  
**How to do? Digital video/EEG seizure monitoring:  
 how to get more bang for your buck** Hall 4 (Nafsica)

Chair: Velis D (Netherlands)

**Digital video-EEG data acquisition: the ins and outs of it**  
 Velis D (Netherlands)

**Choice of montages: the long and short of it**  
 Beniczky S (Denmark)

**Efficient spike detection: the tricks of the trade**  
 Larsson PG (Norway)

07:30-09:00

Teaching Session - Introduction to VIREPA  
**EUREPA session: Neuroimaging (supported by the  
 ILAE Commission on Diagnostic Methods)** Hall 5 (Nefeli)

Chair: Chiron C (France)

**Role of neuroimaging in presurgical evaluation in adults**  
 Marusic P (Czech Republic)

**Why, when and how to perform PET and SPECT in a  
 child with focal epilepsy?**  
 Chiron C (France)

07:30-09:00

Case Oriented Learning Session  
**EUREPA session: Epilepsy surgery** Hall 7 (Colossus)

Chair: Özhara Ç (Turkey)

**Clinical case 1**  
 Kahane P (France)

**Clinical case 2**  
 Stefan H (Germany)

**Clinical case 3**  
 Francione S (Italy)

WEDNESDAY, 30<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

09:00-11:00

Main Session

**Challenging the concept of idiopathic epilepsies**

**Hall 1 (Jupiter)**

Chair: Koutroumanidis M (United Kingdom)

**Clinical EEG (ictal - interictal) evidence**

Guerrini R (Italy)

**Evidence from analysis of clinical seizures and interictal findings with advanced neurophysiological and neuroimaging techniques**

Kimiskidis V (Greece)

**Mechanisms of their dependence on arousal level**

Halasz P (Hungary)

**In search of a satisfactory terminology (taxonomic implications)**

Wolf P (Denmark)

09:00-11:00

Main Session

**Predicting epileptogenesis: how far are we from reaching the goal?**

**Hall 6 (Marika)**

Chair: de Curtis M (Italy)

**Predictors and biomarkers, definitions and general concepts**

Shorvon S (United Kingdom)

**Neurobiological markers of epileptogenesis**

Pitkanen A (Finland)

**Practical benefits of predicting epileptogenesis: when and how biomarkers can be helpful**

Engel J (USA)

**Biological and clinical predictors of pharmacoresistance**

Shiller Y (Israel)



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Epilepsy syndromes in children**

**Hall 2 (Roses)**

Chairs: Capovilla G (Italy), Hughes E (United Kingdom)

- 066 **Long term outcome of benign childhood epilepsy with centrotemporal spikes: Dutch Study of Epilepsy in Childhood**  
Callenbach P M C, Bouma P A D, Geerts A T, Arts W F M, Stroink H, Peeters E A J, van Donselaar C A, Peters A C B, Brouwer O F (Netherlands)
- 067 **Mortality following childhood convulsive status epilepticus: results from STEPSOUT**  
Pujar S S, Scott R C, Neville B G, Chin R F (United Kingdom)
- 068 **Characterization of eyelid myoclonia in a series of patients with juvenile myoclonic epilepsy**  
Guaranha M S, da Silva J M, Guilhoto L F, Caboclo L O S, Yacubian E M T (Brazil)
- 069 **Epilepsy in childhood and adolescence: etiology and aspects of treatment in an unusual population**  
Manreza M L G, Sampaio L P B, Reed U C (Brazil)
- 070 **Clinical and neurophysiological features of progressive myoclonus epilepsy (PME) associated with SCARB2 mutations without renal failure**  
Rubboli G<sup>1</sup>, Franceschetti S<sup>1</sup>, Canafoglia L<sup>1</sup>, Gambardella A<sup>1</sup>, Riguzzi P<sup>1</sup>, Dibbens L M<sup>2</sup>, Andermann F<sup>3</sup>, Bayly M A<sup>2</sup>, Joensuu T<sup>4</sup>, Vears D F<sup>2</sup>, Wallace R<sup>2</sup>, Bassuk A G<sup>5</sup>, Power D A<sup>2</sup>, Tassinari C A<sup>1</sup>, Andermann E<sup>3</sup>, Pasini E<sup>1</sup>, Lehesjoki A E<sup>4</sup>, Berkovic S F<sup>2</sup>, Michelucci R<sup>1</sup> (<sup>1</sup>Italy, <sup>2</sup>Australia, <sup>3</sup>Canada, <sup>4</sup>Finland, <sup>5</sup>USA)
- 071 **Focal interictal and ictal EEG abnormalities in childhood absence epilepsy**  
Koutroumanidis M<sup>1</sup>, Tsiptsios D<sup>1</sup>, Kokkinos V<sup>1,2</sup>  
(<sup>1</sup>United Kingdom, <sup>2</sup>Greece)





## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Clinical neurophysiology**

**Hall 3 (Delphi)**

Chairs: Dinopoulos A (Greece), Kimiskidis V (Greece)

- 072      **A prominent sensory role of human insula:  
a Stereo-EEG study**  
Pugnaghi M, Meletti S, Cardinale F, Castana L, Tassi L (Italy)
- 073      **Modulation of the paroxystic activity in a premotor dysplasia  
by stimulations of the ipsilateral centromedian thalamic  
nucleus during a presurgical stereo-electroencephalographic  
exploration for partial drug-resistant epilepsy**  
Pasnicu A, Denoyer Y, Haegelen C, Pasqualini E,  
Biraben A (France)
- 074      **Scalp EEG source analysis in extratemporal lobe seizures:  
comparison with intracranial findings**  
Kovac S<sup>1,2</sup>, Miserocchi A<sup>1,3</sup>, Scott C<sup>1</sup>, Allen P<sup>1</sup>, Mantoan L<sup>1</sup>,  
Smith S<sup>1</sup>, Walker M<sup>1</sup>, Mc Evoy A<sup>1</sup>, Scherg M<sup>2</sup>, Hoehstetter K<sup>2</sup>,  
Diehl B<sup>1</sup> (1United Kingdom, 2Germany, 3Italy)
- 075      **Magnetoencephalography (MEG), single pulse electrical  
stimulation (SPES) and their concordance with the seizure  
onset zone (SOZ) in the electrocorticogram (ECoG)**  
Agirre-Arrizubieta Z, Thai J N, Valentin A, Furlong P L, Seri S,  
Elwes R D, Alarcon G (United Kingdom)
- 076      **Absence of interictal scalp EEG findings in central lobe epilepsy:  
a retrospective cohort study**  
Ristic A J<sup>1,2</sup>, Alexopoulos A V<sup>2</sup>, Bingaman W E<sup>2</sup>, Najm I M<sup>2</sup>  
(1Serbia, 2USA)
- 077      **Computer assisted identification of the epileptic zone based  
on characterization of the ictal patterns by quantitative  
frequency analysis of intracranial EEG recording**  
Gnatkovsky V, Francione S, Tassi L, Lo Russo G,  
de Curtis M (Italy)



## SCIENTIFIC PROGRAMME

### WEDNESDAY, 30<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Drug therapy: miscellaneous**

**Hall 4 (Nafsica)**

Chairs: Patsalos P (United Kingdom),  
Polychronopoulos P (Greece)

- 078 **Light and shade of therapeutic drug monitoring of antiepileptic drugs**  
Cojutti P G, Furlanut M, Franceschi L (Italy)
- 079 **Antiepileptic drug-induced osteopathy**  
Graf W, Harsch I A, Kerling F, Wenczel E, Stefan H (Germany)
- 080 **ABCB1 gene variant influences the maintenance dose of carbamazepine in patients with epilepsy**  
Sterjev Z, Kiteva G, Nestorovska A K, Nadica M, Zorica S, Dimovski A, Suturkova L (Macedonia, the Former Yugoslav Republic of)
- 081 **An evaluation of the effect of eslicarbazepine acetate on metabolic parameters: a pooled analysis of three double-blind phase III clinical studies**  
Elger C<sup>1</sup>, Halász P<sup>2</sup>, Ben-Menachem E<sup>3</sup>, Gil-Nagel A<sup>4</sup>, Maia J<sup>5</sup>, Nunes T<sup>5</sup>, Soares-da-Silva P<sup>5</sup> (<sup>1</sup>Germany, <sup>2</sup>Hungary, <sup>3</sup>Sweden, <sup>4</sup>Spain, <sup>5</sup>Portugal)
- 082 **Changes in lamotrigine pharmacokinetics induced by antitubercular drugs**  
Haan G-J D, Edelbroek P, Bartels C (Netherlands)
- 083 **The effects of topiramate and sodium valproate therapies on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, resistin levels in children with idiopathic partial and generalized epilepsy**  
Sonmez M, Zaman D, Aksoy A, Değer O, Aliyazıcıoğlu R, Fazlıoğlu K, Karaguzel G (Turkey)



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

11:30-13:15

Platform Session

**Neurobiology of epilepsy II**

**Hall 5 (Nefeli)**

Chairs: Onat F (Turkey), Evangeliou A (Greece)

- 084      **High-frequency network activity in a model of non-lesional temporal lobe epilepsy**  
Jiruska P, Finnerty G, Powell A D, Lofti N,  
Jefferys J G R (United Kingdom)
- 085      **Prenatal administration of levetiracetam impedes later expression of seizures and mossy fiber sprouting in a rodent model of cortical dysplasia**  
Alexopoulos A V<sup>1</sup>, O'Dwyer R<sup>1</sup>, Tiniakos D G<sup>2</sup>, Kyroudi A<sup>2</sup>,  
Kittas C<sup>2</sup>, Najm J<sup>1</sup> (1USA, 2Greece)
- 086      **Increased promoter methylation and sustained down-regulation of hippocampal mGluR2 expression after status epilepticus in rat experimental temporal lobe epilepsy**  
Kobow K, Fritzsche I, Njunting M, Hauke J, Hahnen E,  
Blümcke I (Germany)
- 087      **Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy**  
Wendt H, Soerensen J, Potschka H, Wotjak C T (Germany)
- 088      **Experimental occipital lobe seizure status in cats: the role of lateral geniculate body upon secondary generalization**  
Tanaka T, Saito M, Sato M, Anei R, Hodozuka A, Fujita T (Japan)
- 089      **The cellular basis of the inflammatory response following status epilepticus**  
Duffy B A, Choy M, Scott R C, Gadian D G, Anthony D C,  
Lythgoe M F (United Kingdom)
- 090      **Byproducts of protein, lipid and DNA oxidative damage in epileptic seizure**  
Ercegovac M, Jovic N, Simic T, Sokic D, Djukic T,  
Pljesa Ercegovac M (Serbia)



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

11:30-13:00

Platform Session

**Mortality and neurobehavioural issues in epilepsy**

**Hall 6 (Marika)**

Chairs: Kraemer G (Switzerland), Rajna P (Hungary)

- 091 **Evaluation of psychiatric symptoms in epilepsy psychosis using Brief Psychiatric Rating Scale**  
Ito M, Adachi N, Adachi T, Kato M, Onuma T, Matsubara R, Hara K, Okazaki M (Japan)
- 092 **Antiepileptic drugs in the treatment of psychiatric disorders**  
Kaufman K R (USA)
- 093 **Suicide attempt in epilepsy: incidence and risk factors**  
Hesdorffer D C<sup>1</sup>, Ishihara L<sup>2</sup>, Mynelpalli L<sup>3</sup>, Webb D J<sup>2</sup>, Weil J<sup>2</sup>, Hauser W A<sup>1</sup> (<sup>1</sup>USA, <sup>2</sup>United Kingdom, <sup>3</sup>India)
- 094 **Efficacy and safety of pregabalin in patients with refractory focal epilepsy and anxiety disorder**  
Brandt C<sup>1</sup>, Schoendienst M<sup>1</sup>, Trentowska M<sup>1</sup>, May T W<sup>1</sup>, Pohlmann-Eden B<sup>2</sup>, Tuschen-Caffier B<sup>1</sup>, Schrecke M<sup>1</sup>, Fueratsch N<sup>1</sup>, Witte-Boelt K<sup>1</sup>, Ebner A<sup>1</sup> (<sup>1</sup>Germany, <sup>2</sup>Canada)
- 095 **Comparison of mortality risk in newly-diagnosed and chronic epilepsy in adults: 13 years of follow-up in an Estonian population**  
Rakitin A<sup>1</sup>, Liik M<sup>1</sup>, Õun A<sup>2</sup>, Haldre S<sup>1</sup> (<sup>1</sup>Estonia, <sup>2</sup>Finland)
- 096 **Health outcomes in patients with epilepsy: mortality, life expectancy and sudden unexplained death in epilepsy: a cohort study in Tyrol**  
Granbichler C A, Bergmann M, Kuchukhidze G, Ndayisaba J-P, Oberaigner W, Trinka E (Austria)



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

14:30-16:00

Discussion Group

**Paediatric epilepsy surgery: state of the art on special syndromes**

**Hall 1 (Jupiter)**

Chair: Cross H (United Kingdom)

**Rasmussen's encephalitis**

Bien C (Germany)

**Hypothalamic hamartomas**

Delalande O (France)

**Sturge-Weber syndrome**

Arzimanoglou A (France)

**Tuberous sclerosis**

Van Nieuwenhuizen O (Netherlands)

14:30-16:00

Discussion Group

**Epileptic networks and lesions**

**Hall 2 (Roses)**

Chair: Stefan H (Germany)

**Epileptic networks**

van Luijckelaar G (Netherlands)

**Lesion detection by MRI postprocessing**

Huppertz HJ (Switzerland)

**High frequency oscillations (HFO) and epileptic activity**

Rampp S (Germany)

**Networks and surgical treatment**

Chauvel P (France)



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

14:30-16:00

Discussion Group  
**Controversies in IGE**

**Hall 3 (Delphi)**

Chair: Shorvon S (United Kingdom)

**Syndromes in development and decline**  
Hirsch E (France)

**Syndromes in development and decline**  
Walker M (United Kingdom)

**Paediatric and adult epileptology vantage points of IGEs:  
how different are they and how can they merge?**  
Dulac O (France)

**Paediatric and adult epileptology vantage points of IGEs:  
how different are they and how can they merge?**  
Agathonikou A (Greece)



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

14:30-16:00

Special Symposium

**Bursary Award Symposium**

**Hall 4 (Nafsica)**

Chairs: Kostopoulos G (Greece), Johannessen S (Norway)

- 097 **Surgical strategies in tuberous sclerosis patients: effectiveness of extended tuberectomias**  
Jahodova A, Krsek P, Marusic P, Tomasek M, Krijtova H, Kudr M, Petrak B, Rybar J, Tichy M, Komarek V (Czech Republic)
- 098 **Comprehensive information imparted to patients with epilepsy and comorbidity and decreased prevalence of adverse treatment effects: the EDU-COM study**  
Beretta S, Beghi E, Bogliun G, Gerardi F, Ferrarese C, and the EDU-COM study group (Italy)
- 099 **Is blood-brain barrier disruption related to chronic epilepsy?**  
Lebrun A, Morin M, Rousset M-C, Lerner-Natoli M (France)
- 100 **Genetic variability in drug metabolising enzymes as determinant of carbamazepine dose requirement in newly diagnosed epilepsy**  
Shazadi K, Sills G J, Alfrevic A, Pirmohamed M, Marson A G (United Kingdom)
- 101 **Assessment of thalamic pathology in patients with unilateral mesial temporal lobe epilepsy and hippocampal sclerosis (MTLE-HS) by means of voxel-based morphometry (VBM), T2-relaxometry and ADC mapping**  
Ferreira H A, Rua C, Andrade A, Manaças R M, Gonçalves-Pereira P M (Portugal)
- 102 **Subtraction ictal SPECT coregistered to MRI (SISCOM) in evaluating children with normal MRI for epilepsy surgery: clinical use and surgical outcome**  
Wong-Kisiel L, Witte R, Wirrell E (USA)



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

14:30-16:00

Workshop

**Neurobiology of memory dysfunction in temporal lobe epilepsies**

Hall 5 (Nefeli)

Chair: Helmstaedter C (Germany)

**Functional and anatomical organization of memory formation in the temporal lobe**

Helmstaedter C (Germany)

**Hippocampal granule but not pyramidal cell loss predicts memory impairment in TLE patients**

Pauli E (Germany)

**The diverse regenerative capacity of the human hippocampus and its impact on memory formation in TLE patients**

Blümcke I (Germany)

**Neurobiology of adult hippocampal neurogenesis under physiological and pathophysiological conditions**

Kuhn HG (Sweden)

14:30-16:00

Discussion Group

**Photosensitivity: from focal abnormality to generalized seizures**

Hall 6 (Marika)

Chair: Kasteleijn-Nolst Trenité D (Netherlands)

**Links between photosensitivity and idiopathic generalized epilepsy**

Stephani U (Germany)

**Photosensitivity as a focal epileptic phenomenon**

Siniatchkin M (Germany)

**How to provoke the generalized photoparoxysmal response in photosensitive subjects?**

Parra J (Spain)

**How to prevent the local increase of cortical excitability in photosensitive subjects?**

Kasteleijn-Nolst Trenité D (Netherlands)

WEDNESDAY, 30<sup>TH</sup> JUNE 2010





## SCIENTIFIC PROGRAMME

WEDNESDAY, 30TH JUNE 2010

14:30-16:00

Discussion Group  
**Interpreting ictal semiology: localizing automatisms or emergence of inborn behaviors?**

Hall 7 (Colossus)

Chair: Tassinari CA (Italy)

**Gestural and oral automatisms**  
Özhara Ç (Turkey)

**The spectrum of complex motor behaviours**  
Gardella E (Italy)

**Age-dependent seizure semiology**  
Holthausen H (Germany)

**An ethological perspective of ictal automatisms as fixed action patterns**  
Tassinari CA (Italy)

16:30-18:00

Satellite Symposium  
**Biocodex**  
**Update on Dravet Syndrome**

Hall 1 (Jupiter)

Chairs: Dravet C (France), Covanis T (Greece)

**Dravet Syndrome's history**  
Dravet C (France)

**Genetic overview**  
De Jonghe P (Belgium)

**Cognitive impact of the disease**  
Guerrini R (Italy)

**Current therapeutic modalities**  
Chiron C (France)

**Global management**  
Ceulemans B (Belgium)



## SCIENTIFIC PROGRAMME

### WEDNESDAY, 30<sup>TH</sup> JUNE 2010

16:30-18:00

Workshop

#### **The multiple challenges of insular epilepsy**

**Hall 3 (Delphi)**

Chairs: Francione S (Italy), Trinka E (Austria)

#### **Seizures originating in the insula: the great electro-clinical mimicker**

Ryvlin P (France)

#### **Invasive investigation of the insula: methodology and results from stimulation**

Kahane P (France)

#### **Surgical approaches to insular epilepsy**

Bouthillier A (Canada)

16:30-18:00

Workshop

#### **Absence seizures and absence epilepsies across the ages: electroclinical correlation**

**Hall 4 (Nafsica)**

Chairs: Jovic N (Serbia), Nikanorova M (Denmark)

#### **Absence seizures and syndromes variability under age of 3 years old**

Stephani U (Germany)

#### **Absence seizures and syndromes variability in childhood and adolescence**

Giannakodimos S (Greece)

#### **Absence seizures and syndromes variability in adults**

Genton P (France)

WEDNESDAY, 30<sup>TH</sup> JUNE 2010



## SCIENTIFIC PROGRAMME

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

16:30-18:00

Teaching Session

**Frontal lobe seizures: from basic mechanisms to semiology and therapeutic approach**

Hall 6 (Marika)

Chair: Martins Da Silva A (Portugal)

**Frontal lobe: seizures semiology and seizures origin**  
Chauvel P (France)

**Frontal lobe seizures and sleep behaviour events**  
Manni R (Italy)

**Frontal lobe seizures: therapeutic approaches**  
Elger C (Germany)

16:30-18:00

Workshop

**Endogenous anticonvulsive mechanisms activated by seizures**

Hall 7 (Colossus)


Chair: Sperk G (Austria)

**Tonic inhibition in epilepsy - the brain fights back**  
Walker M (United Kingdom)

**Dynamic expression of neuropeptides as endogenous antiepileptic principle**  
Sperk G (Austria)

**The endogenous cannabinoid system in seizure protection and its impairment in seizure generation**  
Maglóczy Z (Hungary)

**Neurogenesis and plasticity: do they reduce excitability?**  
Kokaia M (Sweden)





## SCIENTIFIC PROGRAMME

THURSDAY, 1ST JULY 2010

	Hall 1 (Jupiter)	Hall 2 (Roses)	Hall 3 (Delphi)
07:30-08:00		<b>Workshop</b> Patients management in epilepsy surgery failure	<b>Teaching Session</b> New findings from epilepsy genomics
08:00-08:30			
08:30-09:00			
09:00-09:30	<b>The Symposium of Excellence in Epileptology</b>		
09:30-10:00			
10:00-10:30			
10:30-11:00			
11:00-11:30	<b>Coffee Break 11:00 - 11:30</b>		
11:30-12:00			<b>DG - The boundary between focal and generalised idiopathic paediatric epilepsies</b>
12:00-12:30			
12:30-13:00			

Legend	
Adult Epileptology	Neuropsychology
Alternative Therapies	Non-Epileptic Paroxysmal Events
Basic Science	Paediatric Epileptology
Clinical Neurophysiology	Psychiatry
Diagnosis	Sleep and Epilepsy
Drug Therapy	Social Issues
Epilepsy Syndromes in Children and Adults	Surgical Treatment
Genetics	Treatment
Neuroimaging	Other



## SCIENTIFIC PROGRAMME

THURSDAY, 1<sup>ST</sup> JULY 2010

Hall 4 (Nafsica)	Hall 5 (Nefeli)	Hall 6 (Marika)	Hall 7 (Colossus)	
"How To Do" Seizure monitoring in the EMU setting	Eurepa Session Classification and/or differential diagnosis	Eurepa Session Clinical pharmacology and pharmacotherapy		07:30-08:00
				08:00-08:30
				08:30-09:00
				09:00-09:30
				09:30-10:00
				10:00-10:30
				10:30-11:00
Coffee Break 11:00 - 11:30				11:00-11:30
DG: Acute symptomatic seizures: risk factors or symptom of epilepsy?		DG - Recent advances in SUDEP	Video Session	11:30-12:00
				12:00-12:30
				12:30-13:00



## SCIENTIFIC PROGRAMME

THURSDAY, 1<sup>ST</sup> JULY 2010

07:30-09:00

Workshop

**Patients management in epilepsy surgery failure**

**Hall 2 (Roses)**

Chair: Seeck M (Switzerland)

**What is an epilepsy surgical failure in adults?**

Steinhoff B (Germany)

**What is an epilepsy surgical failure in children?**

Van Nieuwenhuizen O (Netherlands)

**Pharmacological and vagal nerve stimulation in epilepsy surgery failure**

Hirsch E (France)

**Re operation in epilepsy surgery failure**

Francione S (Italy)

07:30-09:00

Teaching Session

**New findings from epilepsy genomics: implications for clinical practice and research**

**Hall 3 (Delphi)**

Chair: Lindhout D (Netherlands)

**Genomics and basic mechanisms: new directions**

LeGuern E (France)

**Genomics: exploring the functional consequences in humans**

Sisodiya S (United Kingdom)

**Genomics: implications for clinical practice**

Guerrini R (Italy)



## SCIENTIFIC PROGRAMME

### THURSDAY, 1<sup>ST</sup> JULY 2010

07:30-09:00

How to do? Seizure monitoring in the EMU Setting  
**How to do? How to work with infants, children and parents in the EMU**

**Hall 4 (Nafsica)**

Chair: Plouin P (France)

**How to work with infants and children in the EMU**  
 Pressler R (United Kingdom)

**How to do invasive monitoring in infants and children**  
 Fohlen M (France)

**How to work with parents in the EMU**  
 Polster T (Germany)

07:30-09:00

Case Oriented Learning Session  
**EUREPA session: Classification and/or differential diagnosis**

**Hall 5 (Nefeli)**

Chair: Van Emde Boas W (Netherlands)

**Clinical case 1**  
 Özhara Ç (Turkey)

**Clinical case 2**  
 Kelemen A (Hungary)

**Clinical case 3**  
 Van Emde Boas W (Netherlands)

07:30-09:00

Teaching Session - Introduction to VIREPA  
**EUREPA Session: Clinical pharmacology and pharmacotherapy (supported by the ILAE Commission on Therapeutic Strategies)**

**Hall 6 (Marika)**

Chairs: French J (USA), Perucca E (Italy)

**Critical interpretation of AED trials in epilepsy**  
 Perucca E (Italy)

**Drug treatment of resistant epilepsy**  
 French J (USA)





## SCIENTIFIC PROGRAMME

THURSDAY, 1<sup>ST</sup> JULY 2010

09:00-11:00

Special Symposium

**The symposium of excellence in epileptology**

**Hall 1 (Jupiter)**

Chairs: Bialer M (Israel), Tomson T (Sweden)

**Road to refractory epilepsy**

Brodie M (United Kingdom)

**Neuronal migration disorders and epilepsy: antiepileptic drugs can be adverse agents**

Represa A (France)

**Long-term antiepileptic drug therapy contributes to acceleration of atherosclerosis**

Chuang YC (Taiwan, Republic of China)

11:30-13:00

Discussion Group

**The boundary between focal and generalised idiopathic paediatric epilepsies**

**Hall 3 (Delphi)**

Chair: Vigevano F (Italy)

**Generalized aspects in idiopathic focal epilepsies**

Fusco L (Italy)

**Focal aspects in idiopathic generalized epilepsies**

Ferrie C (United Kingdom)

**The concept of age-dependent hypexcitability**

Moshe SL (United States)

**How our therapeutic approach will change?**

Genton P (France)



## SCIENTIFIC PROGRAMME

### THURSDAY, 1<sup>ST</sup> JULY 2010

#### 11:30-13:00

Discussion Group

**Acute symptomatic seizures: risk factors or symptom of epilepsy?** Hall 4 (Nafsica)

Chair: Beghi E (Italy)

**Basic mechanisms of acute symptomatic seizures**  
de Curtis M (Italy)

**Acute symptomatic seizures and underlying brain injury: epidemiological criteria for causation**  
Sander JW (United Kingdom)

**Acute symptomatic seizures: risk factors for epilepsy?**  
Beghi E (Italy)

**Is the concept of acute symptomatic seizures valid?**  
Guerrini R (Italy)

#### 11:30-13:00

Discussion Group

**Recent advances in SUDEP** Hall 6 (Marika)

Chairs: Stefan H (Germany), Tinuper P (Italy)

**Update on incidence and risk factors**  
Nashef L (United Kingdom)

**SUDEP mechanisms: lessons from experimental studies**  
Koehling R (Germany)

**SUDEP mechanisms: insights from MORTEMUS**  
Ryvlin P (France)

**What next? Proposal for a prospective European study (MORTEMUS II)**  
Tomson T (Sweden)

#### 11:30-13:00

Video Sessions

Hall 7 (Colossus)

Chairs: Thomas P (France), Capovilla G (Italy)

Capovilla G (Italy)  
Thomas P (France)  
Garganis K (Greece)

**Occipital Epilepsy with FOS in a patient with cerebral calcification**  
Ferlazzo E (Italy)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster Session: neurobiology and basic sciences I

### Poster Area

Chair: de Curtis M (Italy)

- p103 **Alterations in gene expression in the dentate gyrus in epilepsy and epileptogenesis in the amygdala stimulation model of the temporal lobe epilepsy**  
Lukasiuk K, Mieczkowski J, Sliwa A (Poland)
- p104 **Upregulation of polysialylated NCAM and cadherin in the hippocampus of the epileptic mutant EL mouse during development**  
Murashima Y L, Yoshii M (Japan)
- p105 **Glutamine synthetase (GS) in a temporal lobe epilepsy (TLE) model exhibits modified subcellular expression pattern**  
Papageorgiou I E, Kann O, Gabriel S, Heinemann U (Germany)
- p106 **Human astrocytes in culture respond to albumin with an increase in cytosolic calcium and DNA synthesis**  
Pastor J, Herrera I, Ortega G J, Sola R G (Spain)
- p107 **Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with epilepsy and stiff-person syndrome, but without type 1 diabetes**  
Soilu-Hänninen M<sup>1</sup>, Hänninen A<sup>1</sup>, Hampe C S<sup>2</sup>, Deptula A<sup>2</sup>, Geubtner K<sup>2</sup>, Knip M<sup>1</sup>, Reijonen H<sup>2</sup> (<sup>1</sup>Finland, <sup>2</sup>USA)
- p108 **Effects of experimental noise pollution on hyperthermic-induced seizures in wistar rat infants**  
Zobeiri M, Moghimi A, Behnam Rasouli M, Moradpour M (Iran, Islamic Republic of)
- p109 **Cortico-thalamo-cortical interactions during absence seizures**  
Lüttjohann A, Gupta D, van Luijckelaar G (Netherlands)
- p110 **Value of spectral analysis in differentiating atypical prolonged benign epileptiform variant from a seizure: a case report**  
Ramesha K N, Richardson N, McGrane C, Brunnhuber F (United Kingdom)
- p111 **Correlation analysis of continuous EEG recordings of WAG/Rij rats with genetically determined absence epilepsy for the purpose of developing a prediction or an early seizure registration technique**  
Aristov A V, Berdiev R K, Chepurnova N E, Gnezditsky V V (Russia)



## POSTER SESSIONS

### MONDAY, 28<sup>TH</sup> JUNE 2010

- p112                    **Postnatal malnutrition in rats increase the susceptibility to experimental model of epilepsy induced by pilocarpine**  
Cabral F R, Priel M R, Lima E, Do Vale T G, Torres L B, Pereira F, Amado D, Cavalheiro E A, Naffah-Mazzacoratti M G (Brazil)
- p113                    **Alterations of phasic and tonic GABAA receptors-mediated inhibition in human pyramidal neurons from peritumoral tissue adjacent to brain gliomas**  
Chudomel O, Šroubek J, Zámečník J, Steindler J, Syková E, Mareš J, Bojar M (Czech Republic)
- p114                    **Molecular characterization of dyslamination in focal cortical dysplasia without Balloon cells**  
Fauser S, Nakagawa J, Huber S, Häussler U, Prinz M, Schulze-Bonhage A, Zentner J, Haas C A (Germany)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster Session: neurobiology and basic sciences II

### Poster Area

Chairs: Bernard C (France), Kostopoulos G (Greece)

- p115 **Dynamic characterization of neuronal spiking during ictal activity in the medial entorhinal cortex of the isolated guinea pig brain**  
Trombin F, Gnatkovsky V, de Curtis M (Italy)
- p116 **Neurofeedback training in absence epilepsy**  
van Luijckelaar G, Osterhagen L, Breteler R (Netherlands)
- p117 **Do glial network play a role in epileptogenesis? A study in a genetic model of absence epilepsy: the GAERS (Genetic Absence Epilepsy Rats from Strasbourg)**  
Girod S, Laharie A-M, Depaulis A, Guillemain I (France)
- p118 **The autoantibodies to glutamate receptors investigation in neurological diseases in children**  
Globa O, Sorokina E, Bazarnaya N, Kuzenkova L, Pinelis V (Russia)
- p119 **Does status epilepticus in 12-day-old rats lead to impairment of cognitive functions later in the life?**  
Kubova H<sup>1</sup>, Mikulecka A<sup>1</sup>, Suleymanova O<sup>1,2</sup>, Mares P<sup>1</sup>  
(<sup>1</sup>Czech Republic, <sup>2</sup>Russia)
- p120 **Inflammation in human mesial temporal lobe epilepsy with hippocampal sclerosis: preliminary evaluation**  
Leal B, Rangel R, Carvalho C, Moreira L, Chaves J, Silva A M, Lima J L, Santos A, Magalhães T, Pires M M, Honavar M, Silva B M, Costa P P (Portugal)
- p121 **Hippocampal neurotransmission in the pentylenetetrazole kindling model: role of extrasynaptic GABAA receptors**  
Simonsen C, Winther C, Hansen S L, Kristiansen U (Denmark)
- p122 **Astroglial loss and edema formation in the rat piriform cortex and hippocampus following pilocarpine-induced status epilepticus**  
Song H K, Kang T C, Shin D J, Hallym Institute of Epilepsy Research (Korea, Republic of)
- p123 **The effect of hypercapnia on the development of severe tonic-clonic seizures**  
Suleymanova E, Kussmaul A, Pavlov N, Chepurnova N (Russia)



## POSTER SESSIONS

### MONDAY, 28<sup>TH</sup> JUNE 2010

- p124                      **Ro-25-6981, a selective activity-dependent blocker of NMDA receptors containing NR2B subunit in a model of cortical epileptic afterdischarges in developing rats**  
Szczurowska E, Mareš P (Czech Republic)
- p125                      **Pharmacological blockade of olfactory system changes of spike-wave discharges regulation in WAG/Rij rats**  
Zybina A<sup>1</sup>, Abbasova K R<sup>1</sup>, Chepurnova N<sup>1</sup>, Van Luijckelaar G<sup>2</sup> (<sup>1</sup>Russia, <sup>2</sup>Netherlands)
- p126                      **The role of T- and B- cells in seizures and epilepsy**  
Zardoni D, Maroso M, Balosso S, Ravizza T, Noe' F M, Vezzani A (Italy)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: cerebral dysplasias and epilepsy

Poster Area

Chair: Covanis T (Greece)

- p127 **Drug resistant epilepsy in a child with tuberous sclerosis complex treated with ketogenic diet: a case report**  
Bachański M, Kasprzyk-Obara J, Domańska-Pakieła D, Chmielik J, Rokicki D, Kmiec T (Poland)
- p128 **Different clinical expressions of subcortical band heterotopia in males**  
Buenache Espartosa R, Mateo Martinez G, Morillo P, Labarga E, San Millan J, Lorenzo G (Spain)
- p129 **Infantile spasms and pigmentary mosaicism**  
Hansen L K, Bygum A, Krogh L (Denmark)
- p130 **Does removal of the subependymal giant cell astrocytoma in patients with tuberous sclerosis complex improve their seizure control?**  
Jovic N, Grujicic D (Serbia)
- p131 **Focal epilepsy - from infantile spasms at birth to functional right hemiparesis**  
Moreno T, Leal A (Portugal)
- p132 **Typing of focal cortical dysplasia (FCD): the Vienna experience**  
Muehlebnner A, Feucht M, Prayer D, Czech T, Hainfellner J A (Austria)
- p133 **Surgical pathologies and MRI between epileptic spasms and partial seizures in children**  
Otsubo H, Inage Y, Halliday W (Canada)
- p134 **Septo-optic dysplasia and epilepsy**  
Ryzí M, Ošlejšková H, Magnová O (Czech Republic)
- p135 **Rare and atypical occipital epilepsy secondary to cortical dysplasia: 2 case report**  
Sanmarti F, Donaire A, Setoain X, Martinez S, Galvez H, Ortez C (Spain)
- p136 **Resective surgery for intractable epilepsy in the first five years of life: the Mayo Clinic experience**  
Wirrell E, Hnojikova M, Nickels K, Buchhalter J, Raffel C, Wetjen N (USA)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: surgical treatment I

### Poster Area

Chair: Wolf P (Denmark)

- p137 **The TimeToStop study I. Antiepileptic drug withdrawal policies after childhood epilepsy surgery in Europe**  
Boshuisen K, Uiterwaal C S P M, van Nieuwenhuizen O, Braun K P J, the TimeToStop Study Group (Netherlands)
- p138 **Outcome of vagal nerve stimulation in drug-resistant epilepsy: efficacy and tolerability**  
Chiesa V, Marras C E, Casazza M, Vignoli A, Villani F, Franzini A, Zambrelli E, Granata T, La Briola F, Gardella E, Messina G, Tassi L, Broggi G, Canevini M P (Italy)
- p139 **Outcome after cortico-amygdalo-hippocampectomy in patients with temporal lobe epilepsy and normal MRI**  
Cukiert A, Burattini J A, Mariani P P, Agapito D, Fernandes S T, Cukiert C M, Argentoni-Balochi M, Baise C, Forster C R, Mello V A (Brazil)
- p140 **Deep brain stimulation (DBS) for refractory epilepsy: unique targeting in different epileptic syndromes**  
Cukiert C, Cukiert A, Burattini J A, Mariani P P, Agapito D, Fernandes S T, Baise C, Argentoni-Balochi M, Forster C R, Mello V A (Brazil)
- p141 **Prospective longitudinal 10-year employment and seizure outcome of resective epilepsy surgery in Sweden**  
Edelvik A, Flink R, Rydenhag B, Malmgren K (Sweden)
- p142 **Extra-temporal medically refractory epilepsy due to focal cortical dysplasia: prognostic factors of surgical outcome**  
Fountas K N<sup>1</sup>, Kapsalaki E Z<sup>1</sup>, Giannakodimos S<sup>1</sup>, Kapsalakis I Z<sup>1</sup>, Smith J R<sup>2</sup> (<sup>1</sup>Greece, <sup>2</sup>USA)
- p143 **Extratemporal surface EEG features do not preclude successful surgical outcomes in drug-resistant epilepsy patients with unilateral temporal MRI lesions**  
Garganis K, Kokkinos V, Harushukuri J, Zountsas V, Karipidis N, Kontogiannis K, Emmanuel A (Greece)
- p144 **Clinical and SEEG characteristics of patients with insular resections for refractory focal epilepsy**  
Gul G<sup>1</sup>, Dimova P S<sup>2</sup>, Minotti L<sup>3</sup>, Hoffmann D<sup>3</sup>, Chabardès S<sup>3</sup>, Seigneuret E<sup>3</sup>, Kahane P<sup>3</sup> (<sup>1</sup>Turkey, <sup>2</sup>Bulgaria, <sup>3</sup>France)





## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: neuroimaging I

Poster Area

Chair: Duncan J (United Kingdom)

- p145 **Imaging transporter-associated pharmacoresistance: difference in the impact of the P-glycoprotein modulator tariquidar on the brain kinetics of [18F]MPPF in pharmacoresistant and epileptic rats**  
Bartmann H, Fuest C, Schlichtiger J, La Fougere C, Cumming P, Böning G, Wängler B, Just T, Winter P, Pekcec A, Soerensen J, Bartenstein P, Potschka H (Germany)
- p146 **Brain pathology associated with epilepsy, disclosed by MRI: our experience**  
Cekic B, Jovic N (Serbia)
- p147 **Diagnostic yield and predictive value of pharmacologically provoked ictal SPET in pre-surgical evaluation of temporal and extratemporal epilepsies**  
Colicchio G, Barba C, Di Giuda D, Fuggetta F, Giordano A, Meglio M, Papacci F (Italy)
- p148 **Neurophysiological activity underlying altered brain metabolism in epileptic encephalopathy with continuous spike-waves during sleep: a multimodal functional imaging study**  
De Tiège X, Trotta N, Op de Beeck M, Bourguignon M, Goldman S, Van Bogaert P (Belgium)
- p149 **Diffusion tensor imaging characteristics of the arcuate fasciculus are not related to a decline in language functioning following temporal lobectomy**  
Diehl B<sup>1</sup>, Piao Z<sup>2</sup>, Lapresto E<sup>2</sup>, Liu P<sup>2</sup>, Tkach J<sup>2</sup>, Bingaman W<sup>2</sup>, Duncan J S<sup>1</sup>, Busch R M<sup>2</sup> (<sup>1</sup>United Kingdom, <sup>2</sup>USA)
- p150 **Functional connectivity is a sensitive predictor of epilepsy diagnosis after the first seizure**  
Douw L, de Groot M, van Dellen E, Heimans J J, Ronner H E, Stam C J, Reijneveld J C (Netherlands)
- p151 **Use of multicompartmental SPECT image analysis in temporal lobe epilepsy**  
Elisevich K<sup>1</sup>, Jafari-Khouzani K<sup>1</sup>, Karvelis K<sup>1</sup>, Soltanian-Zadeh H<sup>1,2</sup> (<sup>1</sup>USA, <sup>2</sup>Iran, Islamic Republic of)
- p152 **Proton MR spectroscopy of metabolite concentration in young patients with cryptogenic partial epilepsy**  
Emich Widera E, Sokół M, Polnik A, Kazek B, Wicher M (Poland)



## POSTER SESSIONS

### MONDAY, 28<sup>TH</sup> JUNE 2010

- p153      **Multimodal approach to pharmacoresistant focal epilepsy: PET/MRI/SISCOM co-registration**  
 Fernández S, Donaire A, Seres E, Setoain X, Bargalló N, Falcon C, Sanmartí F, Maestro I, Rumià J, Pintor L, Boget T, Aparicio J, Carreño M, Epilepsy Unit (Spain)
- p154      **Localizing value of ictal local hyperperfusion MRI changes**  
 Guzman L, Lacuey N, Salvadó M, Sierra A, Toledo M, Rovira Marron R, Sueiras M, Munuera J, Lorenzo C, Rovira A, Álvarez-Sabin J, Santamarina E, Salas-Puig X (Spain)
- p155      **Multi-voxel magnetic resonance spectroscopy at 3 Tesla in patients with idiopathic generalized tonic-clonic seizures**  
 Hammen T, Doelken M, Doerfler A, Stefan H (Germany)
- p156      **Impact of P-glycoprotein on the distribution of [18F]MPPF in pharmacoresistant temporal lobe epilepsy**  
 Hammers A<sup>1</sup>, Bouvard S<sup>1</sup>, Lothe A<sup>1</sup>, Costes N<sup>1</sup>, Pereira de Souza Neto E<sup>1</sup>, Keihaninejad S<sup>1</sup>, Le Bars D<sup>1</sup>, Didelot A<sup>1</sup>, Mauguière F<sup>1</sup>, Koepp M J<sup>2</sup>, Hirsch E<sup>1</sup>, Ryvlin P<sup>1</sup> (1France, 2United Kingdom)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: status epilepticus

### Poster Area

Chair: Shorvon S (United Kingdom)

- p157 **Three years in the treatment of status epilepticus with intravenous levetiracetam**  
Eue S, Berndt A, Grumbt M, Macieik-Zuj G, Müller M, Schulze A, Sepsi O (Germany)
- p158 **Epidemiological and clinical characteristics of non-convulsive status epilepticus in a tertiary-level hospital in the North-west of Spain**  
Fernandez-Ferro J, Moreno E, Pardo J, Peleteiro M, Rodriguez-Orsorio X, Lopez F, Corredera E, Lema M (Spain)
- p159 **Stimulus-sensitive post-anoxic focal motor seizures evolving into generalised myoclonic status epilepticus: a video-EEG study**  
Fernández-Torre J L, Santos-Sánchez C, Hernández-Hernández M A, Casariego-Pola F (Spain)
- p160 **Practical classification of status epilepticus**  
Karlo V (Russia)
- p161 **Spectral modulation of the slow component of rhythmic EEG activity before the end of ictus in non-convulsive focal status epilepticus**  
Kokkinos V<sup>1,2</sup>, Garganis K<sup>1</sup>, Koutroumanidis M<sup>2</sup>, Kostopoulos G K<sup>1</sup> (<sup>1</sup>Greece, <sup>2</sup>United Kingdom)
- p162 **Symptomatic non convulsive status epilepticus controlled after oral treatment with Zonisamide and Levetiracetam**  
Lazzaro A T, Miscusi M, Romeo L, Nicolucci P (Italy)
- p163 **Clinical and electroencephalographic features of aphasic status epilepticus**  
Lee B I, Heo K, Cho Y J, Lee M K (Korea, Republic of)
- p164 **Non-Rasmussen, non-stroke epilepsy partialis continua (EPC)**  
Mameniskiė R<sup>1</sup>, Wolf P<sup>2</sup>, and the European Study Group on Epilepsia partialis continua (<sup>1</sup>Lithuania, <sup>2</sup>Denmark)
- p165 **Refractory status epilepticus with lethal outcome: a case report**  
Marak R, Uvizi R, Tuckova L, Herzig R, Skoloudik D, Kanovsky P (Czech Republic)



## POSTER SESSIONS

### MONDAY, 28<sup>TH</sup> JUNE 2010

- p166      **Repetitive seizures and status epilepticus: clinical presentation and prognosis based on prospective analysis of patients treated at the Department of Neurology; Medical University of Lublin (2006-2009)**  
Rejdak K, Kowal A, Wolak M, Czajka-Belz A, Paklerska E, Stelmasiak Z (Poland)
- p167      **Nursing intervention in status epilepticus**  
Theofanidis D, Tozios S, Dargini M, Garganis K (Greece)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: clinical neurophysiology I

Poster Area

Chair: Avanzini G (Italy)

- p168 **The epileptic seizures diagnosis by echoencephalography and telemedicine**  
Andreev V M (Russia)
- p169 **Clinical utility of EEG in alcohol-related acute symptomatic seizures in hospital**  
Asmane S, Vitols E, Kalvelis N (Latvia)
- p170 **Respiratory changes with seizures in localization-related epilepsy: analysis of peri-ictal hypercapnia and airflow patterns**  
Bateman L M, Seyal M, Albertson T E, Lin T-C, Li C-S (USA)
- p171 **The slow-wave component of the interictal epileptiform EEG discharges**  
Beniczky S, Terney D, Skaarup C N, Alving J, Wolf P (Denmark)
- p172 **Sensitivity and specificity of electric source imaging in focal epilepsy: a prospective study of 150 operated patients**  
Brodbeck V<sup>1,2</sup>, Lantz G<sup>2</sup>, Spinelli L<sup>2</sup>, Lascano A M<sup>2</sup>, Pollo C<sup>2</sup>, Schaller K<sup>2</sup>, Seeck M<sup>2</sup>, Michel C M<sup>2</sup> (<sup>1</sup>Germany, <sup>2</sup>Switzerland)
- p173 **Quantitative analysis of upper limb automatisms in temporal and frontal lobe epilepsy**  
Cunha J P S<sup>1</sup>, Fernandes J M<sup>1</sup>, Peters A<sup>2</sup>, Bilgin C<sup>2</sup>, Rémi J<sup>2</sup>, Mirzadjanona Z<sup>2</sup>, Gonzalez-Victores J A<sup>2</sup>, Noachtar S<sup>2</sup> (<sup>1</sup>Portugal, <sup>2</sup>Germany)
- p174 **Cortical effect of antiepileptic therapy in Unverricht-Lundborg syndrome: a quantitative EEG study using LORETA analysis**  
Füle K, Jobbágy Z, Kondákor I (Hungary)
- p175 **The yield of sleep-deprived EEG in patients admitted following a first recognized seizure**  
Gandelman-Martón R, Theitler J (Israel)
- p176 **Don't close your eyes for epilepsy! Self-induction of epileptic seizures by slow eye-movement**  
Hemminga D F, van Hemert-van der Poel J C (Netherlands)



## POSTER SESSIONS

### MONDAY, 28<sup>TH</sup> JUNE 2010

- p177      **Photosensitivity: the role of duration of antiepileptic drug treatment**  
Jocic-Jakubi B<sup>1</sup>, Jovanovic M<sup>1</sup>, Stankovic Jankovic D<sup>1</sup>,  
Kasteleijn-Nolst Trenité D<sup>2</sup> (<sup>1</sup>Serbia and Montenegro,  
<sup>2</sup>Netherlands)
- p178      **Neurophysiologic indicators of epileptogenesis and surgical treatment of temporal lobe epilepsy**  
Kasumov V R, Stepanova T S, Bersnev V P, Kasumov R D,  
Kravtsova S V, Sebelev K I (Russia)
- p179      **Automatic diagnostic system for paroxysmal activity detection**  
Kisten V, Laurentsyeva S, Evstigneev V, Golovko V (Belarus)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: clinical neurophysiology III

### Poster Area

Chair: Brodie M (United Kingdom)

- p180 **Source localisation methods applied to subdural EEG recordings in frontal lobe epilepsy**  
Ramantani G, Ball T, Schulze-Bonhage A, Dümpelmann M (Germany)
- p181 **BESA epilepsy: a new clinical software for fast evaluation of interictal spikes in long-term EEG**  
Scherer M<sup>1</sup>, Ille N<sup>1</sup>, Weckesser D<sup>1</sup>, Ebert A<sup>1</sup>, Larsson P G<sup>2</sup>, Henning O<sup>2</sup>, Boppel T<sup>1</sup>, Bast T<sup>1</sup> (<sup>1</sup>Germany, <sup>2</sup>Norway)
- p182 **How localizing are the focal EEG epileptiform abnormalities? EEG/MRI concordance study**  
Siddiqui K A, Sinha S, Mobin M (Saudi Arabia)
- p183 **2D versus 3D approaches to movement quantification in epileptic seizures: simulations and real seizures comparative evaluation**  
Silva Cunha J P<sup>1</sup>, Fernandes J M<sup>1</sup>, Bento V<sup>1</sup>, Paula L<sup>1</sup>, Dias E<sup>1</sup>, Bilgin C<sup>2</sup>, Noachtar S<sup>2</sup> (<sup>1</sup>Portugal, <sup>2</sup>Germany)
- p184 **Detection of major epileptic seizures with heart rate changes: feasibility test of a state-of-the-art wearable sensor**  
van Bussel M J P<sup>1</sup>, Arends J B A M<sup>1</sup>, Massé F<sup>1</sup>, Serteyn A<sup>2</sup>, Tan I Y<sup>1</sup>, Penders J<sup>1</sup>, Griep P A M<sup>1</sup> (<sup>1</sup>Netherlands, <sup>2</sup>Belgium)
- p185 **A novel implantable vagus nerve stimulation system (ADNS-300): pilot trial at Ghent University Hospital**  
El Tahry R, Raedt R, De Herdt V, Van Dycke A, Meurs A, Dewaele F, Van Roost D, Doguet P, Delbeke J, Vonck K, Boon P (Belgium)
- p186 **Interictal and ictal dynamics of network topology in focal epilepsy: a case study**  
Gaitatzis A, Velis D N, Claus S P, Kalitzin S N, Stam C J (Netherlands)
- p187 **Language lateralization in childhood-onset focal epilepsy: evidence from fMRI**  
Pahs G, Rankin P, Cross J H, Northam G, Vargha-Khadem F, Baldeweg T (United Kingdom)
- p188 **Serum neuron-specific enolase in posttraumatic epilepsy**  
Rashidova N (Uzbekistan)



## POSTER SESSIONS

### MONDAY, 28<sup>TH</sup> JUNE 2010

- p189      **Evaluation of cardiac autonomic function in complex partial seizures: a study with heart rate variability measures**  
Sajish C, Sathyaprabha TN, Sinha S, Chandra PS, Raju TR (India)
- p190      **Overcoming the unpredictability of seizures: patients' views towards EEG-based prediction devices**  
Schulze-Bonhage A<sup>1</sup>, Sales F<sup>2</sup>, Wagner K<sup>1</sup>, Carius A<sup>1</sup>, Schelle A<sup>1</sup>, Teotonio R<sup>2</sup>, Ihle M<sup>1</sup> (<sup>1</sup>Germany, <sup>2</sup>Portugal)
- p191      **Heart rate decrease associated with fast seizure components and increased vagal activity in rats**  
Sevcencu C, Hereby K R, Struijk J J (Denmark)





## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: epilepsy syndromes in development I

Poster Area

Chair: Koutroumanidis M (United Kingdom)

- p192 **Rasmussen syndrome (RS): surprising developments. What therapeutic decisions adopted?**  
Alarcón-Martínez H, Casas-Fernández C, Álvarez-Linera J, Vicente-Santos T, Ibañez-Micó S, Valera-Párraga F, Martínez-Salcedo E, Domingo-Jiménez R, Puche-Mira A (Spain)
- p193 **Which prognosis for focal epilepsies without known causes in infancy?**  
Battaglia D, Lettori D, Graziano A, Del Re M, Chieffo D, Mercuri E, Guzzetta F (Italy)
- p194 **Clinical and electroencephalographic features of Rett's syndrome: differences between classic form and Hanefeld's variant**  
Borelli P, Pini G, Bigoni S, Felloni B, Scusa M F, Di Marco P, Bonuccelli U, Zappella M (Italy)
- p195 **West syndrome: etiological and prognostic aspects in 48 cases**  
Borkovic M (Serbia)
- p196 **The occurrence of epileptiform activity on EEG and epilepsy in children with hyperkinetic disorder: a retrospective study**  
Cahova P, Hostalkova P, Hnojčikova M, Pejcochova J, Oslejskova H (Czech Republic)
- p197 **Febrile and benign seizure associated with acute gastroenteritis in children**  
Cha B H, Yoon S H, Jeong S-W, Whang K (Korea, Republic of)
- p198 **Convulsions during gastroenteritis in the spectrum of benign partial epilepsies in infancy: a 30 case serie and video-EEG ictal recording in two patients**  
Cusmai R<sup>1</sup>, Cantonetti L<sup>1</sup>, Vigeveno F<sup>1</sup>, Jovic-Jakubi B<sup>2</sup> (1Italy, 2Serbia)
- p199 **Levetiracetam treatment of children with sleep-activated epileptiform activity: a placebo controlled double-blind cross-over study**  
Eriksson A-S, Larsson P G, Heminghyt E, Rytter E (Norway)
- p200 **Neonatal stress increases vulnerability to pilocarpine induced seizure**  
Fadaei Asl A, Saboory E (Iran, Islamic Republic of)



## POSTER SESSIONS

### MONDAY, 28<sup>TH</sup> JUNE 2010

p201

**Gliomatosis cerebri presenting as epilepsia partialis continua:  
a case-report**

Garcia-Fructuoso G, Alamar M, Candela S, Regueira M,  
Nunes T F, Rumià J, Guillen A, Donaire A, Campistol J,  
Pineda M, Sanmartí F X, Costa J M (Spain)

p202

**Epilepsy in arteriovenous malformations**

Jamroz E, Szwed-Białożył B, Paprocka J, Mandera M,  
Kluczevska E (Poland)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

**Poster session: neuropsychology I**

**Poster Area**

Chair: Schulze Bonhage A (Germany)

p203

**The Wada test: here to stay?**

Alpherts W, Vermeulen J, Hendriks M, Klein M (Netherlands)

p204

**Cognitive networks dysfunction in left temporal lobe epilepsy**

Alvarez-Carriles J C, García-Martínez A, Moral A, Novelli A, Salas-Puig X (Spain)

p205

**Making plans and decisions in patients with sleep related hypermotor seizures**

Bonora A, Molinari M A, Monti G, Benuzzi F, Gasparini E, Pugnaghi M, Nichelli P, Meletti S (Italy)

p206

**Impaired intelligence scores are frequent in children with frontal lobe epilepsy**

Braakman H M H, Overvliet G M, Vles J S H, Aldenkamp A P (Netherlands)

p207

**Impaired object identification processing in childhood idiopathic occipital epilepsy**

Brancati C, Barba C, Metitieri T, Pellacani S, Melani F, Viggiano M P, Guerrini R (Italy)

p208

**Depression and anxiety in patients with epilepsy**

Candrlic M, Juric S, Vladetic M, Butkovic-Soldo S (Croatia)

p209

**Facial emotion recognition in children with history of febrile seizures**

Cantalupo G<sup>1</sup>, Meletti S<sup>1</sup>, Miduri A<sup>1</sup>, Mazzotta S<sup>1</sup>, Rios-Pohl L<sup>2</sup>, Boria S<sup>1</sup>, Benuzzi F<sup>1</sup>, Pisani F<sup>1</sup>, Tassinari C A<sup>1</sup>, Cossu G<sup>1</sup> (1Italy, 2Chile)

p210

**Autobiographical memory deficits in patients with unilateral TLE**

Herfurth K, Stefan H, Pauli E (Germany)

p211

**Is epilepsy affecting the cognitive functions in children with cerebral palsy and normal intelligence?**

Jelic S B, Jovic N J (Serbia and Montenegro)

p212

**Spatial navigation in temporal lobe epilepsy patients**

Kotaskova J, Marusic P, Vlcek K, Lacco J, Kajukova B, Javurkova A (Czech Republic)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: acute symptomatic seizures

### Poster Area

Chair: Guekht A (Russia)

- p213 **Early seizures in patients with spontaneous intracranial haemorrhage: incidence, associated factors and influence on outcome**  
De Herdt V<sup>1,2</sup>, Dumont F<sup>2</sup>, Hénou H<sup>2</sup>, Derambure P<sup>2</sup>, Vonck K<sup>1</sup>, Leys D<sup>2</sup>, Cordonnier C<sup>2</sup> (1Belgium, 2France)
- p214 **The risk of seizures after minor brain injury**  
Gilad R, Katz Y, Eilam A, Dabby R, Sabeh M, Lampl Y (Israel)
- p215 **Etiologic factors in patient with epilepsy in the Department of Neurology in Pristina, Kosovo**  
Govori Berisha V, Vranica S, Humolli I, Paračka L (Kosovo, Republic of)
- p216 **Analysis of the initial ictal phenomenon in patients with temporal lobe epilepsy**  
Hoffmann J M, Elger C E, Kleefuss-Lie A A (Germany)
- p217 **Post stroke seizures: prospective study from a tertiary referral centre in North India**  
Madakasira P V, Bhatia R, Singh M B, Tripathi M, Prasad K (India)
- p218 **Hyperfamiliarity for unknown faces: a rare post-ictal symptom of acute symptomatic focal seizures**  
Michelucci R, Riguzzi P, Rubboli G, Volpi L, Meletti S, Pasini E, Santoro F, Pittau F, Benuzzi F (Italy)
- p219 **An observational study on the incidence of early-onset poststroke epileptic seizures**  
Specchio L M, Notariello M, Zoccolella S, Goffredo R, Biancardi E, Vanacore N, Pascarella M G, Grasso R, Trivisano M, Rinaldi G (Italy)
- p220 **Generalized seizure: a rare and immediate presentation of cardiac myxoma cerebral complication**  
Cuciureanu D I (Romania)
- p221 **C-reactive protein and seizure in patients with focal epilepsy: a video-EEG study**  
Alapirtti T, Waris M, Fallah M, Soilu-Hänninen M, Mäkinen R, Kharazmi E, Peltola J (Finland)
- p222 **Takotsubo cardiomyopathy induced by epileptic seizures: a case report**  
Benna P, Montalenti E (Italy)
- p223 **New-onset seizures in kidney transplant patient: a case report and literature review**  
Kaprelyan A, Ikononov V, Teodorova I (Bulgaria)
- p224 **Seizures after doxylamine succinate overdose**  
Kim W-J, Cho H, Lee M J, Sim J E (Korea, Republic of)
- p225 **The influence of biometeorological changes on tonic-clonic seizures frequency in epilepsy in Bielsko Biala, South Poland**  
Manko-Juraszek R (Poland)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy I

Poster Area

Chair: Perucca E (Italy)

- p226 **Clinical relevance of genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics in children with epilepsy**  
Cvitanovic-Sojat L, Malenica M, Gjergja Juraski R (Croatia)
- p227 **Pharmacokinetic evaluation of oral lacosamide in phase II/III clinical trials: a pooled analysis**  
Cawello W<sup>1</sup>, Andreas J-O<sup>1</sup>, Hebert D<sup>2</sup>, Eggert-Formella A<sup>2</sup> (1Germany, 2USA)
- p228 **Lacosamide saliva and serum concentrations in patients with epilepsy**  
Greenaway C L, Ratnaraj N, Sander J W, Patsalos P N (United Kingdom)
- p229 **Plasma lamotrigine levels of patients with polymorphic UGT1A4 enzymes**  
Gulcebi Idriz Oglu M, Ozkaynakci A, Goren M Z, Ozkara C, Gulhan R, Onat F (Turkey)
- p230 **Evaluation of lacosamide efficacy and safety as adjunctive therapy in patients receiving traditional sodium channel blocking AEDs**  
Isojarvi J<sup>1</sup>, Hebert D<sup>1</sup>, Doty P<sup>1</sup>, Zackheim J<sup>1</sup>, Davies K<sup>1</sup>, Sake J-K<sup>2</sup>, Eggert-Formella A<sup>1</sup> (1USA, 2Belgium)
- p231 **Rapid titration of lacosamide with simultaneous reduction in concomitant AEDs is well tolerated and effective in reducing seizures in patients with drug-resistant partial-onset epilepsy**  
Krauss G, Griffiths A, Swords S, Cole A, Bean A (USA)
- p232 **Long-term prognosis in patients with epilepsy**  
Neligan A, Bell G S, Johnson A L, Goodridge D M, Shorvon S D, Sander J W (United Kingdom)
- p233 **Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist following once- and multiple-daily dosing**  
Templeton D (United Kingdom)
- p234 **Efficacy of retigabine 600, 900 or 1200mg/day based on baseline total partial-seizure frequency in adults with refractory epilepsy**  
Brodie M<sup>1</sup>, Abou-Khalil B<sup>2</sup>, Hall S<sup>2</sup>, Shaikh S<sup>1</sup>, on behalf of the RESTORE 1 and RESTORE 2 Study Investigators (1United Kingdom, 2USA)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy IV

### Poster Area

Chair: Johannessen S (Norway)

- p235 **Comparison of the efficacy and safety of using antiepileptic drugs topiramate and Phenobarbital in treatment of symptomatic focal forms of epilepsy in children**  
Sivkova S, Zaykova F, Marulina V, Prusakov V (Russia)
- p236 **Design and current status of the CATZ study: a phase III, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of adjunctive zonisamide in paediatric patients with partial-onset seizures**  
Rosati A<sup>1</sup>, Pellacani S<sup>1</sup>, van Maanen R<sup>2</sup>, Segieth J<sup>2</sup>, Guerrini R<sup>1</sup> (1Italy, 2United Kingdom)
- p237 **Focal rolandic epileptiform discharge treatment improves behavior in children with behavioral problems without epileptic seizures**  
Knezevic-Pogancev M (Serbia)
- p238 **Clobazam add-on therapy for the treatment of epileptic encephalopathy**  
Lee E H, Jeong M H, Ko T-S (Korea, Republic of)
- p239 **Second-line antiepileptic drugs in children with intractable epilepsies: clinical audit of uses and outcomes for Clobazam and Topiramate**  
Lewis T, Mills J, Mughal K, Ali I, Ugur A, Whitehouse W P (United Kingdom)
- p240 **Efficacy of levetiracetam in two pediatric patients with refractory status epilepticus**  
Mateo G, Buenache R, Morillo P, Pedrera A, Quintana P, Lorenzo G (Spain)
- p241 **Second-line antiepileptic drugs in children with intractable epilepsies: clinical audit of uses and outcomes for lamotrigine and gabapentin**  
Mills J, Lewis T, Mughal K, Ali I, Ugur A, Whitehouse W P (United Kingdom)
- p242 **Use of rectal diazepam in aborting seizures in children following caregiver education: Singapore experience**  
Ong H-T, Dong L, Tay S, Low P-S (Singapore)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy VII

### Poster Area

Chair: Tomson T (Sweden)

- p243      **Pregnancy and epilepsy**  
Kruja J, Mijo S, Zekja I, Alimehmeti I, Kapiszyi M (Albania)
- p244      **Reduction defects in two fetuses prenatally exposed to clobazam**  
Bulk S, de Krom M C, Engelsman M, Lindhout D (Netherlands)
- p245      **Major malformations associated with maternal use of antiepileptic drugs in Samara region**  
Yakunina A, Kalinin V (Russia)
- p246      **Surveillance of Croatian pregnant women with epilepsy and effects of antiepileptic drugs exposure in their offspring**  
Miskov S, Gjergja Juraski R, Ivicovic Bakulic T, Cvitanovic Sojat L, Mikula I, Bosnjak Pasic M, Bosnjak J, Demarin V (Croatia)
- p247      **Obstetric and neonatal outcome of pregnancies in women with epilepsy. Prospective study**  
Majkowska-Zwolinska B, Jędrzejczak J, Rebeś Z (Poland)
- p248      **Two sisters with menstrual cycle menarche induced by levetiracetam**  
Panico A, Marchi M D, Zuliani C (Italy)
- p249      **Valproate affects the number of cortical cells in the developing rat brain**  
Sabers A, Nyengaard J R, Scheel-Krüger J, Olsen Alstrup A, Møller A (Denmark)



## POSTER SESSIONS

MONDAY, 28<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy VIII

### Poster Area

Chair: Kalviainen R (Finland)

- p250 **Effectiveness of rufinamide in different epilepsy syndromes**  
Straub H-B, Friedo A-L, Bohlmann K (Germany)
- p251 **A Meta-analysis of retention rate and a computational modeling of retention of second generation antiepileptic drugs in people with partial onset seizures**  
Sander J W<sup>1</sup>, Holmes G L<sup>2</sup>, Cramer J A<sup>2</sup>, Zhang N<sup>2</sup>, Wada D R<sup>2</sup>, Wiegand F<sup>2</sup> (<sup>1</sup>United Kingdom, <sup>2</sup>USA)
- p252 **Italian version of the adverse events profile questionnaire in patients with epilepsy: translation, reliability and stability**  
Tozzi R, Fattore C, Galimberti C A, Franco V, Gatti G, Malerba A, Mazzucchelli I, Messina S, Canevini M P, La Briola F (Italy)
- p253 **Clinical experience with topiramate in Korean patients with epilepsy**  
Cho Y W, Yi S D, Kim J H, Jung K-Y, Shon Y-M, Shin W C, Seo D-W, Hwang H (Korea, Republic of)
- p254 **Therapeutic habits and practices in treatment of epilepsy in Slovak Republic**  
Donath V (Slovakia)
- p255 **A national audit of epilepsy specialist nurse prescribing practice in the United Kingdom**  
Goodwin M, Higgins S, Lewis S (United Kingdom)
- p256 **Oxcarbazepine in brain tumor-related epilepsy: efficacy, side effects and impact on quality of life**  
Maschio M, Dinapoli L, Sperati F, Fabi A, Pace A, Vidiri A, Muti P (Italy)
- p257 **The cognitive consequences of resecting non-lesional tissues in temporal lobe epilepsy surgery: evidence from MRI and histopathologically negative patients**  
Helmstaedter C, Bien C G (Germany)





## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy X

### Poster Area

Trinka E (Austria)

- p258 **Long-term maintenance of efficacy with retigabine 600-1200mg/day in adult patients with refractory epilepsy: extension study of RESTORE 1**  
Leroy R<sup>1</sup>, Rosenfeld W<sup>1</sup>, Hall S<sup>1</sup>, VanLandingham K E<sup>1</sup>, Lotay N<sup>2</sup>, on behalf of the RESTORE 1 Study Investigators (1USA, 2United Kingdom)
- p259 **Long-term maintenance of efficacy with retigabine 600-1200 mg/day in adult patients with refractory epilepsy: extension study of RESTORE 2**  
Lerche H<sup>1</sup>, Leroy R<sup>2</sup>, Hall S<sup>2</sup>, VanLandingham K E<sup>2</sup>, Lotay N<sup>3</sup>, on behalf of the RESTORE 2 Study Investigators (1Germany, 2USA, 3United Kingdom)
- p260 **The relationship between predicted retigabine exposure and efficacy/safety endpoints: a pooled pharmacokinetic/pharmacodynamic analysis of RESTORE 1 and 2**  
VanLandingham K E<sup>1</sup>, Tompson D J<sup>2</sup>, on behalf of the RESTORE 1 and RESTORE 2 Study Investigators (1USA, 2United Kingdom)
- p261 **Efficacy of retigabine 600-1200mg/day in patients with refractory epilepsy with partial-onset seizure: integrated analysis of three randomized studies**  
Porter R J<sup>1</sup>, Brodie M J<sup>2</sup>, VanLandingham K E<sup>1</sup>, Shaikh S<sup>2</sup>, Hall S<sup>1</sup>, on behalf of the Study 205 and RESTORE 1 and RESTORE 2 Study Investigators (1USA, 2United Kingdom)
- p262 **First experiences with Zonisamide (ZNS) as adjunctive therapy in refractory epileptic children and young adults**  
Rasmini P, Besana D (Italy)
- p263 **A prospective audit of adjunctive zonisamide in an everyday clinical setting**  
Stephen L J, Kelly K, Wilson E A, Parker P, Brodie M J (United Kingdom)
- p264 **Zonisamide in the treatment of drug-resistant epilepsy: observational study in Northeast Italy**  
Filippo D, Saladini M, Ermani M, Serena M, Zanoni T, Pauletto G, Garofalo P G, Durisotti C, Marotti E, Bongiovanni L G, Candeggio R M, Campagnaro A, Faggi G, Manfioli V, Paladin F, Battistin L (Italy)
- p265 **Applying retrospectively the new definition of drug resistant epilepsy to patients referred for epilepsy surgery**  
Aparicio Calvo J, Donaire Pedraza A, Carreño Martínez M D M (Spain)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster Session: neurobiology and basic sciences III

### Poster Area

Chairs: Vezzani AM (Italy), Walker M (United Kingdom)

- p266 **Study of the role of T-type calcium channels in a mouse model of temporal lobe epilepsy**  
Sakkaki S, Françon D, Lerner-Natoli M, Lory P (France)
- p267 **Isoxylitones [E/Z isomeric mixture] attenuates changes in levels of BDNF and c-fos in various regions of mice brain undergoing chemical kindling: implications for antiepileptogenic properties**  
Simjee S U, Shaheen F, Atta-ur-Rahman A, Choudhary M I, Kabir N, Jamali S, Shah S U A, Ashraf N, Epilepsy Research Group (Pakistan)
- p268 **Interleukin-1 changes in epilepsy?**  
Aalbers M, Rijkers K, Hoogland G, Huijbers M, Philippens M, Vles J, Steinbusch H, Majoie M (Netherlands)
- p269 **Hippocampal expression and distribution of CB1 receptors in the amazonian rodent proechimys: an animal model of resistance to epilepsy**  
Araujo B H, Torres L B, Cossa A C, Naffah Mazzacoratti M G, Cavalheiro E A (Brazil)
- p270 **Anticonvulsant action of adenosine A1 receptor agonist CCPA in immature rats**  
Mares P (Czech Republic)
- p271 **The interaction of melatonin and agmatine on pentylenetetrazole-induced clonic seizure threshold in mice**  
Moezi L, Shafaroodi H, Hojati A, Dehpour A R (Iran, Islamic Republic of)
- p272 **VEGF: a new target to prevent blood-brain barrier disruption in epilepsy?**  
Morin M, De Bock F, Lebrun A, Bockaert J, Lerner-Natoli M (France)
- p273 **GABAA-current run-down in the hippocampus occurs at the time of the first spontaneous seizure in the pilocarpine model**  
Palma E<sup>1</sup>, Mazzuferi M<sup>1</sup>, Martinello K<sup>1</sup>, Roseti C<sup>1</sup>, Fucile S<sup>1</sup>, Fabene P<sup>1</sup>, Schio F<sup>1</sup>, Pellitteri M<sup>1</sup>, Sperk G<sup>2</sup>, Miledi R<sup>3,4</sup>, Eusebi F<sup>1</sup>, Simonato M<sup>1</sup> (<sup>1</sup>Italy, <sup>2</sup>Austria, <sup>3</sup>USA, <sup>4</sup>Mexico)
- p274 **Vagus nerve stimulation-induced  $\Delta$ FOSB changes in the rat brain stem**  
Rijkers K<sup>1</sup>, Majoie M<sup>1</sup>, Aalbers M<sup>1</sup>, Philippens M<sup>1</sup>, Doenni V<sup>1</sup>, Vles J<sup>1</sup>, Steinbusch H<sup>1</sup>, Hopkins D<sup>2</sup>, Hoogland G<sup>1</sup> (<sup>1</sup>Netherlands, <sup>2</sup>Canada)
- p275 **Study the effect of prenatal predatory stress on neonatal seizures in rat**  
Saboory E, Roshan-Milani S, Heshmatian B (Iran, Islamic Republic of)
- p276 **ICE/Caspase 1 inhibition reduces spontaneous seizures in a mouse model of chronic epilepsy refractory to anticonvulsant drugs (AED)**  
Balosso S<sup>1</sup>, Maroso M<sup>1</sup>, Vanzulli I<sup>1</sup>, Zardoni D<sup>1</sup>, Ravizza T<sup>1</sup>, Wright C<sup>2</sup>, French J<sup>2</sup>, Vezzani A<sup>1</sup> (<sup>1</sup>Italy, <sup>2</sup>USA)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster Session: neurobiology and basic sciences IV

### Poster Area

Chairs: O'Brien T (Australia), de Curtis M (Italy)

- p277 **Effects of gabapentin, carbamazepine and CNQX on cognitive functions and behavior in rats with pilocarpine-induced status epilepticus**  
Gulec G, Isbil Buyukcoskun N, Kahveci N (Turkey)
- p278 **Neuroprotective effects of recombinant human erythropoietin in the developing brain of rat after lithium-pilocarpin induced status epilepticus**  
Hiz Kurul S, Caglayan Sozmen S, Yis U, Tugyan K, Baykara B, Yilmaz O (Turkey)
- p279 **Single nucleotide polymorphisms in the Sprague Dawley CaMKII $\delta$  gene are associated with increased seizure susceptibility**  
Hoogland G<sup>1</sup>, Rijkers K<sup>1</sup>, Mescheriakova J<sup>1</sup>, Lemmens E M P<sup>1,2</sup>, Wijk X M R V<sup>1</sup>, Philippens M<sup>1</sup>, Schijns O E M G<sup>1</sup>, Vles J S H<sup>1</sup>, Majoie M<sup>1</sup> (<sup>1</sup>Netherlands, <sup>2</sup>Belgium)
- p280 **A new seizure model of TLE by intrahippocampal injections of low-dose KA and the effect of focal DBS**  
Huang L, Kraanen S, van Luijtelaar G (Netherlands)
- p281 **Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat**  
Kahveci N, Gulec G, Isbil Buyukcoskun N (Turkey)
- p282 **Comparison of FDG-PET findings between group with human umbilical cord blood derived mesenchymal stem cell transplantation and group without in lithium-pilocarpine model of epilepsy**  
Kang J K, Park G Y, Seo M-S, Joo E-K, Lee E M, Seo Y J, Im K C, Kim J S, Kang K-S (Korea, Republic of)
- p283 **Effect of 7-nitroindazole a neuronal nitric oxide synthase inhibitor on cortical epileptic activity in rats**  
Brozickova C, Jindrova M, Kubova H, Otahal J (Czech Republic)
- p284 **The effects of valproic acid and oxcarbazepine on rat uterine implantation**  
Cansu A, Gorgen S G, Erdogan D, Coskun Z K (Turkey)



## POSTER SESSIONS

### TUESDAY, 29<sup>TH</sup> JUNE 2010

- p285                    **The effect of a chemical absence model on the progression of kindling in wistar rats**  
Carcak N<sup>1</sup>, Sahiner M<sup>1</sup>, Ketenci S<sup>1</sup>, Eskazan E<sup>1</sup>, Snead C<sup>2</sup>, Onat F<sup>1</sup> (<sup>1</sup>Turkey, <sup>2</sup>Canada)
- p286                    **Septo-hippocampal networks in chronic epilepsy**  
Colom L V (USA)
- p287                    **Beneficial effects of somatostatin analogues against kainic acid-induced seizures in the rat**  
Kokkinou E, Vasilaki A, Asproдини E (Greece)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: surgical treatment II

### Poster Area

Özhara Ç (Turkey)

p288

#### **Comparison of selective temporal lobectomy between children and adults with intractable temporal lobe epilepsy**

Kang H-C, Lee Y J, Chung H J, Kim H D, Heo K, Lee B I, Kim D S, Jang J W, Kim T S, Lee J S (Korea, Republic of)

p289

#### **The effectiveness of interictal epileptiform activity during electrocorticography as predictor of post-surgical outcome in patients with lesional epilepsy**

Kipervasser S<sup>1</sup>, Firas F<sup>1</sup>, Rabshtein E<sup>1</sup>, Fried I<sup>1,2</sup>, Parmet Y<sup>1</sup>, Neufeld M<sup>1</sup> (1Israel, 2USA)

p290

#### **Refractory temporal lobe epilepsy due to ganglioglioma associated with focal cortical dysplasia**

Krysl D, Krijtova H, Tomasek M, Mohapl M, Zámečník J, Marusič P (Czech Republic)

p291

#### **Preoperative depression as a negative prognostic factor in epilepsy surgery for mesial temporal lobe epilepsy**

Lackmayer K, Lehner-Baumgartner E, Czech T, Aull-Watschinger S, Distel F, Gallmetzer P, Pataraia E, Pirker S, Baumgartner C (Austria)

p292

#### **SEEG-guided thermocoagulations for periventricular nodular heterotopia treatment: a case report**

Landré E, Turak B, Chassoux F, Boutin M, Devaux B (France)

p293

#### **Cognitive outcome 10 years after temporal lobe epilepsy surgery: a prospective controlled study**

Malmgren K, Andersson-Roswall L, Samuelsson H, Engman E (Sweden)

p294

#### **Corpus callosotomy for intractable epilepsies in early childhood**

Otsuki T, Takahashi A, Kaido T, Kaneko Y, Nakagawa E, Sugai K, Sasaki M (Japan)

p295

#### **The usefulness of tractography integrated neuronavigation obtaining from diffusion tensor image in pediatric epilepsy surgery**

Park E-K, Eom S, Kim D-S, Lee Y-H, Shim K-W (Korea, Republic of)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: neuroimaging II

### Poster Area

Chair: Duncan J (United Kingdom)

- p296 **Mr imaging and spectroscopy in patients with Rasmussen encephalitis**  
Kozic D, Ostojic J (Serbia)
- p297 **Disadvantages of MR imaging in detection of disorders with cerebral calcifications in patients with epilepsy**  
Kozic D, Todorovic-Djilas L, Semnic R (Serbia)
- p298 **Consequences of overlooked parenchymal CT sign of cerebral venous thrombosis associated with epilepsy**  
Kozic D, Zarkov M, Radovanovic B, Ivanovski D (Serbia)
- p299 **Functional integrity of polymicrogyria: an fMRI study**  
Kuchukhidze G<sup>1</sup>, Koppelstaetter F<sup>1</sup>, Unterberger I<sup>1</sup>, Dobesberger J<sup>1</sup>, Walser G<sup>1</sup>, Larch J<sup>1</sup>, Delazer M<sup>1</sup>, Gotwald T<sup>1</sup>, Felber S<sup>2</sup>, Trinka E<sup>1</sup> (<sup>1</sup>Austria, <sup>2</sup>Germany)
- p300 **Predictive factors of ictal SPECT findings in pediatric patients with focal cortical dysplasia**  
Kudr M<sup>1</sup>, Krsek P<sup>1</sup>, Maton B<sup>2</sup>, Malone S<sup>2</sup>, Jahodova A<sup>1</sup>, Jayakar P<sup>2</sup>, Dunoyer C<sup>2</sup>, Resnick T<sup>2</sup>, Duchowny M<sup>2</sup> (<sup>1</sup>Czech Republic, <sup>2</sup>USA)
- p301 **Near-infrared spectroscopy as a tool for studying refractory**  
Lassonde M, Florea O, Tremblay J, Vannasing P, Nguyen D (Canada)
- p302 **Disruptions of the default mode network in patients with primary generalized epilepsy**  
McGill M, Milhalm M, Carlson C, DuBois J, Quinn B, Wang H, Kuzniecky R, Devinsky O, French J, Halgren E, Castellano X, Thesen T (USA)
- p303 **Quantification of opioid receptor following spontaneous epileptic seizures; correction of [<sup>11</sup>C]diprenorphine PET data for the partial-volume effect**  
McGinnity C J<sup>1</sup>, Shidahara M<sup>2</sup>, Keihaninejad S<sup>1</sup>, Riaño Barros D A<sup>1</sup>, Gousias I S<sup>1</sup>, Heckemann R A<sup>3</sup>, Koepp M J<sup>1</sup>, Turkheimer F E<sup>1</sup>, Hammers A<sup>1,3</sup> (<sup>1</sup>United Kingdom, <sup>2</sup>Japan, <sup>3</sup>France)
- p304 **Anatomical accuracy and feasibility of probabilistic and deterministic tractography of the optic radiation**  
Nilsson D T, Rydenhag B, Malmgren K, Starck G, Ljungberg M (Sweden)
- p305 **Complementary use of gradient magnetic-field topography (GMFT) and equivalent current dipole (ECD) for magnetoencephalography in presurgical evaluation of intractable neocortical epilepsy**  
Iida K<sup>1</sup>, Hashizume A<sup>1</sup>, Kagawa K<sup>1</sup>, Nishimoto T<sup>1</sup>, Kiura Y<sup>1</sup>, Hanaya R<sup>1</sup>, Arita K<sup>1</sup>, Otsubo H<sup>2</sup>, Kurisu K<sup>1</sup> (<sup>1</sup>Japan, <sup>2</sup>Canada)
- p306 **Diffusion tensor imaging with tract-based spatial statistics reveals widespread white matter degeneration in Unverricht-Lundborg disease (EPM1): translational study in humans and Cstb-deficient mice**  
Kälviäinen R, Koskenkorva P, Manninen O, Lehtimäki K, Kopra O, Gröhn O, Vanninen R, Lehesjoki A-E (Finland)
- p307 **Preoperative and postoperative evaluation of white matter tracts in patients with refractory temporal lobe epilepsy**  
Kapsalaki E Z, Protogerou G, Tsougos I, Kapsalakis I Z, Giannakodimos, S, Fountas K N (Greece)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

**Poster session: alternative therapies and epilepsy  
in the elderly**

**Poster Area**

Chair: Shorvon S (United Kingdom)

- p308 **Immunomodulating therapies in refractory partial epilepsies in children without clinical and laboratory evidence of inflammation**  
Boldyreva S R (Russia)
- p309 **Evaluation of an educational programme for patients with epilepsy**  
Dupont S, Gueguen B, Gonnaud P M, Picot M-C, Godefroi H, Boumedien D, Magar Y (France)
- p310 **Long-term outcome of vagus nerve stimulation (VNS) in children with Dravet syndrome (DS)**  
Feucht M, Pahs G, Gröppel G, Mühlebner A, Porsche B, Dressler A, Reinprecht A, Novak K (Austria)
- p311 **Modulation of seizure susceptibility by spinal cord stimulation**  
Harreby K R, Sevcencu C, Struijk J J (Denmark)
- p312 **Towards an easier and safer ketogenic diet**  
Nathan J, Chadha B (India)
- p313 **Sustained efficacy and tolerability of vagus nerve stimulation in epilepsy: a 14-year experience in Italian tertiary-care epilepsy center**  
Pelliccia V, Pizzanelli C, Giorgi F S, Galli R, Perini D, Baldini M, Iudice A, Parenti G, Murri L (Italy)
- p314 **Long term cognitive outcome after bilateral chronic stimulation of anterior thalamic nucleus in patients with intractable epilepsy**  
Shon Y-M, Kim J H, Kim D W, Lee S Y, Lee K J (Korea, Republic of)
- p315 **Acute drug administration as part of treatment strategies for epilepsy**  
Wolf P (Denmark)
- p316 **Open trial of the omega-3 fatty acid, eicosapentaenoic acid, in 10 patients with refractory epilepsy**  
Yuen A W<sup>1</sup>, Flugel D<sup>2</sup>, Poepel A<sup>2</sup>, Bell G S<sup>1</sup>, Sander J W<sup>1,3</sup>  
(<sup>1</sup>United Kingdom, <sup>2</sup>Switzerland, <sup>3</sup>Netherlands)



## POSTER SESSIONS

### TUESDAY, 29<sup>TH</sup> JUNE 2010

- p317                    **Risk factors of epilepsy in women in the reproductive period**  
Duca V, Groppa S (Moldova, Republic of)
- p318                    **Absolute bioavailability of divalproex sodium extended-release  
in elderly patients with epilepsy by a stable isotope technique**  
Ramsay R E, Reed R, Marino S, Rarick J, Leppik I, Birnbaum A,  
Rommel R P (USA)
- p319                    **Epileptic seizures in patients with cerebrovascular disease**  
Ristic S T, Ristic D T, Vukasinovic N, Milosevic V (Serbia)
- p320                    **Predicting epilepsy in patient with open head injuries caused  
by war missiles**  
Susak R, Splavski B, Juric S, Vladetic M (Croatia)





## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: clinical neurophysiology II

Poster Area

Chair: Avanzini G (Italy)

- p321 **EEG in idiopathic generalised epilepsies misdiagnosed as localisation-related cryptogenic epilepsies treated with inappropriate AEDs**  
Kiteva-Trencevska G (Macedonia, the Former Yugoslav Republic of)
- p322 **In-phase synchronized gamma oscillations precede spike-and-wave complexes in human absence seizure**  
Kohsaka S, Shiraishi H, Saitoh S, Kohsaka M (Japan)
- p323 **A novel portable seizure detection alarm system: preliminary results**  
Kramer U<sup>1</sup>, Kipervasser S<sup>1</sup>, Shlitner A<sup>1</sup>, Kuzniecky R<sup>2</sup> (1Israel, 2USA)
- p324 **The analysis and prognosis of epilepsy in periventricular nodular heterotopia; audit of 14 cases**  
Kuscu D, Gul G, Korkut E, Kirbas D (Turkey)
- p325 **Localization of Interictal spike using EEG-fMRI and EEG source modeling**  
Lee E M, Kang J K, Oh S-S, Song M S, Chung J-Y, Jung K-Y, Im D-M, Park H W (Korea, Republic of)
- p326 **Electrocorticography and cortical stimulation during awake craniotomies**  
Miserocchi A<sup>1,2</sup>, Kovac S<sup>2,3</sup>, Scott C<sup>2</sup>, Morris R<sup>2</sup>, Diehl B<sup>2</sup>, McEvoy A<sup>2</sup> (1Italy, 2United Kingdom, 3Germany)
- p327 **Ambulatory EEG, a cost effective solution for increasing necessities of video EEG telemetry in adult population**  
Moien-Afshari F, Tellez Zenteno J F, Hernandez-Ronquillo L (Canada)
- p328 **Magnetic source imaging study on the role of supplementary motor area in reading epilepsy**  
Op de Beeck M<sup>1</sup>, Legros B<sup>1</sup>, Gaspard N<sup>1</sup>, Bourguignon M<sup>1</sup>, Jurysta F<sup>1</sup>, Van Bogaert P<sup>1</sup>, Goldman S<sup>1</sup>, Jousmaki V<sup>2</sup>, De Tiège X<sup>1</sup> (1Belgium, 2Finland)
- p329 **Intraoperative epileptic seizures in a series of patients affected by primary brain tumours**  
Pauletto G, Budai R, Coccolo D, Lettieri C, Mondani M, Bergonzi P, Skrap M, Eleopra R (Italy)



## POSTER SESSIONS

### TUESDAY, 29<sup>TH</sup> JUNE 2010

- p330                    **Role of a standardized partial sleep-deprived EEG protocol in the diagnosis of epilepsy, and its correlation to clinical and neuroimaging data**  
Perini D, Giorgi F S, Bonanni E, Caserta A, Bartolini E, Pizzanelli C, Iudice A, Pelliccia V, Murri L (Italy)
- p331                    **An inexpensive alternative for outpatient video-EEG recording**  
Rahey S, Sadler R M, Godwin P (Canada)
- p332                    **Idiopathic generalized epilepsies show greater occipital EEG alpha power after sleep deprivation**  
Rajsic N, Sundric Z, Tomovic M, Marinkovic J (Serbia)
- p333                    **Using electrocorticographic signals in a brain-computer interface (BCI) paradigm**  
Shih J, Krusienski D (USA)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: sleep and epilepsy

### Poster Area

Chair: Trinkla E (Austria)

- p334 **Night-time monitoring of children and young people with complex epilepsy and learning disability: the impact on parental sleep and the family's physical and psychosocial wellbeing**  
Bajaj N, Das K B, Scott R C, Aylett S E (United Kingdom)
- p335 **Dream recall and seizures in patients with temporal lobe epilepsy**  
Bentes C, Costa J, Pires J, Pereira P, Paiva T (Portugal)
- p336 **Melatonin in intractable epilepsy: a possible positive effect**  
Goldberg-Stern H, Oren H, Shuper A, Peled N, Garty B-Z (Israel)
- p337 **Sleep architecture and daytime sleepiness in pharmacoresistant epilepsy**  
Haň V, Feketeová E, Tormašiová M, Gdovinová Z (Slovakia)
- p338 **NREM of the first sleep cycle in juvenile absence epilepsy is marked by the lack or significant attenuation of sleep spindles**  
Kokkinos V<sup>1,2</sup>, Koutroumanidis M<sup>1</sup>, Tsiptsios D<sup>1</sup>, Koupparis A<sup>2</sup>, Kostopoulos G K<sup>2</sup> (<sup>1</sup>United Kingdom, <sup>2</sup>Greece)
- p339 **Inter-ictal epileptic activity topographies detected in morning and afternoon post-sleep deprivation EEGs**  
Peralta A R, Bentes C, Henriques I (Portugal)
- p340 **Use of sleep medications prior to presentation to sleep clinic in patients with epilepsy and insomnia: a retrospective study**  
Rodriguez A, Khaund M (USA)
- p341 **NOSEY PARKA - nocturnal seizures in young people: precautions and rescue treatment knowledge audit: early results**  
Sloper E, Jeavons K, Arumugam M, Martin K, Picton C, Brown A, Hollingsworth S, Wolff A, Chow G, Whitehouse W P (United Kingdom)
- p342 **Georgian epilepsy patients with sleep difficulties**  
Zhizhiashvili L, Kasradze S, Maisuradze L (Georgia)
- p343 **Can recording of sleep during the day time replace full night recording in nocturnal epileptiform activity?**  
Evsiukova T, Brockmeier F, Ramm-Petersen A, Larsson P G (Norway)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: epilepsy syndromes in development II

Poster Area

Chair: Covanis T (Greece)

- p344 **The use of topiramate in idiopathic infantile spasms**  
Kwon Y S, Oh S K, Son B K (Korea, Republic of)
- p345 **Is epilepsy a common feature in isolated and associated corpus callosum agenesis?**  
Moutard M L, Isapof A, Billette de Villemeur T (France)
- p346 **The frequency of abnormal EEGs and epilepsy in a population-based cohort of children with autism in Rochester, Minnesota**  
Nickels K, Hostalkova P, Katusic S, Weaver A, Barbaresi W, Wirrell E (USA)
- p347 **Aspects of the intelligence profile of children with (nocturnal) frontal lobe epilepsy**  
Overvliet G M, Braakman H M H, Vles J S H, Aldenkamp A P (Netherlands)
- p348 **Seizure semiology changes with age**  
van Breemen M S, van Campen J S, Braun K P, van Nieuwenhuizen O, Jansen F E (Netherlands)
- p349 **Cognitive outcome of childhood epilepsy in adolescence: utility of the Epilepsy Syndrome Severity Scale for Children (ESSS-C)**  
van Iterson L, Augustijn P B (Netherlands)
- p350 **Incidence of childhood epilepsy in Estonia: a preliminary data**  
Veri K, Talvik I, Napa A, Vaher U, Öiglane-Šlik E, Talvik T (Estonia)
- p351 **A rare cause of myoclonic absence epilepsy: GLUT-1 deficiency**  
Yilmaz S, Akçay A, Serdaroglu G, Tekgul H, Gokben S (Turkey)
- p352 **Infantile convulsions with mild gastroenteritis: epidemiological and clinical characteristics and outcome**  
Yoldi-Petri M E, Durá-Travé T T, Molins-Castiella T T, Aguilera-Albesa S (Spain)
- p353 **Case report: epileptic seizures in a child with porencephaly**  
Jotovska O (Macedonia, the Former Yugoslav Republic of)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: genetics I

### Poster Area

Chair: Baulac M (France)

- p354 **MDR1 polymorphisms in childhood drug resistance epilepsy**  
Alpman A, Ozkınay F, Tekgul H, Gokben S, Pehlivan S, Schalling M, Ozkınay C (Turkey)
- p355 **A large ADPEAF family negative for LGI1. Research for a new locus**  
Bisulli F, Naldi I, Pippucci T, Castegnaro G, Magini P, Licchetta L, Di Vito L, Stipa C, Seri M, Nobile C, Tinuper P (Italy)
- p356 **Photosensitivity in a patient with Hallermann-Streiff syndrome: a casual relationship?**  
Cantonetti L<sup>1</sup>, Staccioli S<sup>1</sup>, Buttinelli C<sup>1</sup>, Digilio M C<sup>1</sup>, Poot M<sup>2</sup>, Veredice C<sup>1</sup>, Koeleman B<sup>2</sup>, Castelli E<sup>1</sup>, Kasteleijn-Nolst Trenité D<sup>2</sup> (1Italy, 2Netherlands)
- p357 **Is there a link between SCN1A mutations and deficient thermoregulation with hyperthermia and anhidrosis under topiramate treatment? Report of two cases**  
Datta A N, Korff C M, Morris M A, Weber P (Switzerland)
- p358 **Frequency and inheritance of microdeletions 15q13.3, 15q11.2 and 16p13.1 in IGE-patients with photoparoxysmal response**  
de Kovel C G F<sup>1</sup>, Koeleman B P C<sup>1</sup>, Lindhout D<sup>1</sup>, Capovilla G<sup>2</sup>, Piccioli M<sup>2</sup>, Pairisi P<sup>2</sup>, Cantonetti L<sup>2</sup>, Brinciotti M<sup>2</sup>, Veggiotti P<sup>2</sup>, Brazzo D<sup>2</sup>, Covanis A<sup>3</sup>, Kasteleijn - Nolst Trenité D<sup>1</sup> (1Netherlands, 2Italy, 3Greece)
- p359 **Coexistence of hipomelanosis of Ito and mosaic Turner syndrome in a 3 year old - a case report**  
Domańska-Pakieła D, Chrzanowska K, Kaczorowska M, Chmielik J, Jóźwiak S (Poland)
- p360 **Expression profile analysis of peripheral blood mononuclear cells in patients with temporal lobe epilepsy**  
Gawlowicz J, Grabek-Gawlowicz M, Kocki J (Poland)
- p361 **Ritscher-Schinzel syndrome — 3C («cranio-cerebello-cardiac») syndrome: a first case report in Croatia**  
Hajsek S, Nankovic S, Petelin-Gadze Z, Bazina A (Croatia)



## POSTER SESSIONS

### TUESDAY, 29<sup>TH</sup> JUNE 2010

- p362 **Rare structural genomic variants in non-syndromic epileptic encephalopathies with and without MRI-detectable structural brain abnormalities**  
 Helbig I<sup>1</sup>, Swinkels M E M<sup>2</sup>, Møller R S<sup>3</sup>, Aten E<sup>2</sup>, Brilstra E H<sup>2</sup>, Ostertag P<sup>1</sup>, Reutlinger C<sup>1</sup>, Caliebe A<sup>1</sup>, Ruivenkamp C A L<sup>2</sup>, Eleveld M J<sup>2</sup>, van 't Slot R<sup>2</sup>, Post J G<sup>2</sup>, Terhal P A<sup>2</sup>, Boor R<sup>1</sup>, von Spiczak S<sup>1</sup>, Muhle H<sup>1</sup>, Klitten L L<sup>3</sup>, van Nieuwenhuizen O<sup>2</sup>, Breuning M<sup>2</sup>, Stephani U<sup>1</sup>, Tommerup N<sup>3</sup>, Hjalgrim H<sup>3</sup>, Lindhout D<sup>2</sup>, Koeleman B P<sup>2</sup>, Poot M<sup>2</sup> (1Germany, 2Netherlands, 3Denmark)
- p363 **Genetically determined epileptic syndrome**  
 Kalochristianakis D Z (Greece)
- p364 **Terminal duplication of chromosome 21 in a patient with mental retardation, facial dysmorphism and severe epilepsy**  
 Klitten L L, Moller R S, Tommerup N, Hjalgrim H (Denmark)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: neuropsychology II

Poster Area

Chair: Brodie M (United Kingdom)

- p365 **Neuropsychological functioning in a group of children with Benign Epilepsy with Centrottemporal Spikes (BECTS)**  
Lopes A F, Simões M, Monteiro J P, Fonseca M J, Ventosa L, Lourenço L, Duarte A, Rocha L, Breia P (Portugal)
- p366 **Assessment of depressive symptoms in patients with epilepsy in routine clinical setting**  
Mameniskiene R, Valanciene I, Jatuzis D, Navickiene E, Budrys V (Lithuania)
- p367 **Emotion recognition in medial temporal lobe epilepsy in the visual and auditory domain**  
Monti G, Bonora A, Benuzzi F, Gasparini E, Pugnaghi M, Nichelli P, Meletti S (Italy)
- p368 **Executive functions in generalized idiopathic epilepsies**  
Steinborn B, Kaczmarek I, Winczewska-Wiktor A, Starczewska M (Poland)
- p369 **Post-surgical memory development - a comparison between young and mid-age groups**  
Tyrlikova I, Rektor I, Kubikova R (Czech Republic)
- p370 **DMS 48: a visual memory test sensitive to differentiate left from right temporal lobe epilepsy**  
Wendling A-S, Wisniewski I, Steinhoff B J (Germany)
- p371 **Sever progressive neuropsychological impairment in a child with cerebellar vermis hypoplasia and epilepsy: 10-year follow-up**  
Wisniewska B, Chamielec M, Chamielec M, Wendorff J (Poland)
- p372 **Double dissociation between antero- and retrograde amnesia in two cases with bilateral hippocampal damage**  
Wisniewski I, Wendling A-S, Keller L, Staack A M, Steinhoff B J (Germany)
- p373 **Cognitive functions in epilepsy**  
Kurzbuch K, Graf W, Kerling F, Pauli E, Stefan H (Germany)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: epileptic encephalopathies

### Poster Area

Chair: Tomson T (Sweden)

- p374 **Epilepsy at the age of seven years in children with neonatal hypoxic-ischemic encephalopathy**  
Cosic-Cerovac N M, Jovic N (Serbia)
- p375 **A highly evocative ictal and interictal EEG pattern in Alpers' disease with POLG1 mutations and onset by status epilepticus**  
de Regnauld de Bellescize J, Blanchard G, Mousson de Camaret B, Lesca G, Panagiotakaki E, Pauyau R, des Portes V, Arzimanoglou A, Ville D (France)
- p376 **Epileptic spasms in cerebral palsy: preliminary results**  
De Rinaldis M, De Agazio G, Losito L, Gennaro L, Trabacca A (Italy)
- p377 **Epilepsy, precocious puberty, immune related diabetes mellitus, and temporal lobe pathology**  
Dinopoulos A, Paschalidou M, Mprotzou T, Papadimitriou A, Papadimitriou D, Paraskeuoulakos E, Nikolaidou P (Greece)
- p378 **Two patients with malignant migrating partial seizures in infancy**  
Djuric M, Kovacevic G, Kravljanc R, Zamurovic D (Serbia)
- p379 **Unilateral Hemispheric Polymicrogyria associated with pharmacoresistant electrical status epilepticus during sleep (ESES) in children: efficiency of vertical parasagittal hemispherotomy (VPH)**  
Fohlen M, Jalin C, Bulteau C, Dorfmueller G, Taussig D, Ferrand-Sorbets S, Delalande O (France)
- p380 **A five-minute sleep segment may be sufficient to diagnose electrographic status epilepticus of sleep (ESES)**  
Hadjiloizou S<sup>1</sup>, Loddenkemper T<sup>2</sup>, Takeoka M<sup>2</sup>, Kothare S<sup>2</sup>, Rotenberg A<sup>2</sup> (<sup>1</sup>Cyprus, <sup>2</sup>USA)
- p381 **Children with SCN1A mutations and epileptic encephalopathies treated with ketogenic or Atkins diet**  
Hjalgrim H, Hansen M B, Miranda M J, Bruusgaard K, Dahl H A, Møller R S, Nikanorova M (Denmark)
- p382 **Initial EEG features and efficacy of vigabatrin in the patients with West syndrome**  
Kim K J, Lim B C, Hwang H, Chae J H, Hwang Y S (Korea, Republic of)





## POSTER SESSIONS

TUESDAY, 29TH JUNE 2010

13:30-14:30

**Poster session: epileptic encephalopathies and neonatal seizures/syndromes**

**Poster Area**

Chair: Koutroumanidis M (United Kingdom)

- p383 **Seizures as a presentation of neuroblastoma in a 5 month old child**  
Monteiro J P, Martins C, Sofia N, Filomena P, Pais P, Calhau P, Fonseca M J (Portugal)
- p384 **Intractable epilepsy in tuberous sclerosis complex: long-term effects of vagus nerve stimulation on seizure control, cognition and behaviour**  
Passamonti C, Petrelli C, Cesaroni E, Zamponi N (Italy)
- p385 **Hypertrophic cardiomyopathy associated with ACTH therapy for childhood seizure disorder**  
Ravid S, Shahar E, Schif A, Khury A (Israel)
- p386 **Electrical status epilepticus during slow wave sleep: clinical and electrophysiological correlation**  
Serdaroglu G, Yilmaz S, Akcay A, Tekgul H, Gokben S (Turkey)
- p387 **Rufinamide for refractory epileptic encephalopathies in childhood**  
Smeyers P, Mulas F (Spain)
- p388 **Natural history of treated new-onset epilepsy in children: a long-term follow-up cohort study in a single center**  
Kim S-H, Shin S S, Lee H Y, Seol I J (Korea, Republic of)
- p389 **Clinical characteristics with risk factors for term neonatal seizures**  
Suh E (Korea, Republic of)
- p390 **A retrospective analysis of levetiracetam efficacy in epileptic syndromes with continuous spike waves during sleep (CSWS)**  
Atkins M D, Nikanorova M (Denmark)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy II

### Poster Area

Chair: Sills G (United Kingdom)

- p391 **Epilepsy, anti-epileptic drugs and premature osteoporosis**  
Beerhorst K, de Krom M, Tan F, Aldenkamp B (Netherlands)
- p392 **The influence of lamotrigine therapy on nitrosative stress and lipid peroxidation in patients with epilepsy**  
Ljubisavljevic S, Spasic M, Visnjic J, Lukic S (Serbia)
- p393 **Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy**  
Lee S-A, Lee H-W, Heo K, Song H-K, Kim O-J, Lee S-M, Kim S-O, Lee B-I (Korea, Republic of)
- p394 **Lamotrigine-intoxication associated with hepatitis C infection: diagnostic and therapeutic challenges**  
Dorn T, Kraemer G (Switzerland)
- p395 **Incidence of rash and hyponatraemia in adult patients with refractory partial seizures treated with adjunctive eslicarbazepine acetate: results from three phase III studies and 1-year open-label extensions**  
Nunes T<sup>1</sup>, Elger C<sup>2</sup>, Ben-Menachem E<sup>3</sup>, Gil-Nagel A<sup>4</sup>, Maia J<sup>1</sup>, Soares-da-Silva P<sup>1</sup> (1Portugal, 2Germany, 3Sweden, 4Spain)
- p396 **Depressive symptoms improve with 1-year eslicarbazepine acetate treatment: a pooled analysis of 3 open-label extensions of phase III studies in patients with partial-onset seizures**  
Cramer J<sup>1</sup>, Hodoba D<sup>2</sup>, Ben-Menachem E<sup>3</sup>, Elger C<sup>4</sup>, Gil-Nagel A<sup>5</sup>, Maia J<sup>6</sup>, Nunes T<sup>6</sup>, Soares-da-Silva P<sup>6</sup> (1USA, 2Croatia, 3Sweden, 4Germany, 5Spain, 6Portugal)
- p397 **Rufinamide as add on therapy in children and adolescents with drug resistant epilepsy and learning difficulties**  
Mahendrakar R, Scott R C, Aylett S E, Das K B (United Kingdom)
- p398 **Vigabatrine induced T2 Hyperintensities in cranial MRI: not only a neuroradiological feature but also associated with acute encephalopathy and dystonia?**  
Dill P, Schneider J, Weber P (Switzerland)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy V

### Poster Area

Chair: Johannessen S (Norway)

- p399 **Adjunctive treatment with Lacosamide: an option for generalized epilepsy?**  
Arnold S, Beige A (Germany)
- p400 **Levetiracetam in idiopathic generalized epilepsy syndromes: open-label, non-comparative, multicenter, long-term follow-up study**  
Delanty N<sup>1</sup>, Jones J<sup>2</sup>, Tonner F<sup>3</sup>, on behalf of the N167 Levetiracetam Study Group (<sup>1</sup>Ireland, <sup>2</sup>USA, <sup>3</sup>Belgium)
- p401 **Safety and efficacy of sustained release lamotrigine as monotherapy / add on therapy in the treatment of epilepsy**  
Dixit V, Singh A, Pradhan S (India)
- p402 **Assessing the consistency of the Photoparoxysmal EEG Response (PPR) over a 12-hour period in placebo-treated photosensitive epilepsy patients: is there a blink, circadian rhythm or physiologic temporal drift in PPR?**  
Reed R C<sup>1</sup>, Abou-Khalil B<sup>1</sup>, Rosenfeld W E<sup>1</sup>, Azar N J<sup>1</sup>, Osborn M R<sup>1</sup>, Schaefer P A<sup>1</sup>, Hosmane B<sup>1</sup>, Kasteleijn-Nolst-Trenite D G<sup>2</sup> (<sup>1</sup>USA, <sup>2</sup>Netherlands)
- p403 **Lamotrigine and cognitive function in children**  
Gniatkowska-Nowakowska A (Poland)
- p404 **Lamotrigine effective in myoclonic astatic epilepsy (Doose syndrome) as based on electronic documentation of treatment with Epivista®**  
Boor R, Doege C, von Spiczak S, Stephani U (Germany)
- p405 **The long-term effect of Levetiracetam in the treatment of idiopathic generalized epilepsies**  
Tsiropoulos I, Akanuma N, Tsatsou K, Bonakis A, Tsiptsios D, Koutroumanidis M (United Kingdom)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: non-epileptic paroxysmal events

Poster Area

Chair: Vigeveno F (Italy)

- |      |  |
|------|--|
| p406 | <b>Psychogenic seizures — diagnostic importance of video-EEG and ambulatory long term monitoring</b><br>Dias A I, Silva R L, Moreira A M, Calado E P, Leal A J (Portugal)                                  |
| p407 | <b>Nonepileptic paroxysmal events in patients with verified long turn epilepsy</b><br>Dubenko A, Litovchenko T A (Ukraine)   |
| p408 | <b>Pacemaker implantation after ictal asystoles: a case report</b><br>Kerling F, Kasper B, Stefan H (Germany)  |
| p409 | <b>Paroxysmal nonepileptic events in children: a video electroencephalographic monitoring records of 15 years</b><br>Lim B C, Kim S H, Kim H M, Hwang H, Chae J H, Kim K J, Hwang Y S (Korea, Republic of) |
| p410 | <b>Takotsubo syndrome (TKS) in epilepsy: a possible mechanism of SUDEP?</b><br>van Rijckevorsel K, Dupuis M, Evrard F (Belgium)  |



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30h

Poster Session

**Poster session: drug therapy XI**

**Poster Area**

Chair: Perucca E (Italy)

- p411 **Effects of carbamazepine withdrawal on serum levels of routine lab-tests in patients with epilepsy: a prospective randomised double-blind withdrawal study**  
Lossius M I, Taubøll E, Mowinckel P, Gjerstad L (Norway)
- p412 **Pregabalin vs placebo for the treatment of partial onset seizures in patients taking concomitant antiepileptic drugs: an analysis of combined clinical trials**  
Nimour M1, Giordano S2, Almas M2, Tomson T3 (1United Kingdom, 2United States, 3Sweden)
- p413 **Assessment of the impact of eslicarbazepine acetate on carbamazepine pharmacokinetics at steady-state: a pooled analysis of three placebo-controlled phase III studies**  
Perucca E1, Falcão A2, Maia J2, Nunes T2, Soares-da-Silva P2 (1Italy, 2Portugal)
- p414 **Lacosamide efficacy and safety in patients taking AEDs that act on non-sodium channel targets**  
Sake J-K1, Hebert D2, Doty P2, Zackheim J2, Eggert-Formella A2, Davies K2, Isojarvi J2 (1Belgium, 2United States)
- p415 **Pharmacokinetics of brivaracetam in subjects with severe renal impairment**  
Stockis A, Jacobs T, Leonard M, Sargentini-Maier M L (Belgium)
- p416 **A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in patients with partial-onset seizures**  
Fountain N B, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd G D (United States)
- p417 **Acute oxcarbazepine-induced hepatotoxicity in a patient susceptible to developing drug-induced liver injury**  
Sruk A, Planjar-Prvan M, Bielen A, Marušić M, Bielen I (Croatia)
- p418 **The effects of retigabine on the pharmacokinetics of concomitantly administered anti-epileptic drugs**  
Tompson D J1, VanLandingham K E2, on behalf of the RESTORE 1 and RESTORE 2 Study Investigators (1United Kingdom, 2United States)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30h

### Poster session: epilepsy syndromes in children and adults I

Poster Area

Chair: Jovic N (Serbia)

- p419 **Rasmussen's chronic progressive focal encephalitis in Uzbekistan**  
Matchanov O, Abdullaeva M, Sigatulina M (Uzbekistan)
- p420 **Prevalence of drug resistant epilepsy in children — one year prospective study in two Polish epilepsy centres**  
Mazurkiewicz-Beldzinska M, Steinborn B, Winczewska-Wiktor A, Matheisel A, Szmuda M (Poland)
- p421 **Thyroid function and lipid profile in children with epilepsy treated with oxcarbamazepine monotherapy: a prospective study**  
katsarou E, Attilakos A, Koemtzidou E, Foteinou A, Dracatos A, Kalimeraki I, Kyriakou D, Garoufi A (Greece)
- p422 **Rational therapeutical options in epilepsy treatment in children with metabolic disorders**  
Globa O, Platonova A, Kuzenkova L (Russian Federation)
- p423 **Risk factors, characteristics and prognosis of epilepsy in patients with cerebral palsy**  
Ignjatovic P M, Jovic N J (Serbia)
- p424 **Effect of pregnancy on seizure frequency in women with epilepsy**  
Boero G, La Neve A, Francavilla T, Plantamura M, Pontrelli G, Lamberti P, Logroscino G (Italy)
- p425 **Frontal lobe epilepsy: review of a series of cases in a tertiary level hospital in Spain**  
Guijarro M, Rodriguez-Orsorio X, Moreno E, Lopez-Gonzalez F J, Alberte-Woodward M, Corredera E, Pardo J, Peleteiro M (Spain)
- p426 **A clinical- and research-oriented electronic database for the management of patients with epilepsy: features and perspectives**  
Giorgi F S, La Spina A, Perini D, Pizzanelli C, Caserta A, Pelliccia V, Iudice A, Murri L (Italy)
- p427 **Ictal water drinking as the presenting epileptic phenomenon of temporal epilepsy in an 8 year old girl**  
Vorgia P, Anagnostatou N, Galanakis E, Bibaki I, Kalmanti M (Greece)



## POSTER SESSIONS

TUESDAY, 29<sup>TH</sup> JUNE 2010

13:30-14:30h

### Poster session: epilepsy syndromes in children and adults III

Poster Area

Chair: Kimiskidis V (Greece)

- p428 **Hashimoto's encephalopathy presenting as status epilepticus and subacute psychiatric disorder in a 15-year-old girl**  
Pustorino G, Polito A N, Circo S, Dell'Era A, Zizzo L, Turso L, Marzocco P L (Italy)
- p429 **RLate onset rasmussen's encephalitis: two cases in the fourth and seventh decades of life**  
Martin Barriga M L, Martín Moro M, Prieto J, Fernández García P, Guzmán de Villoria J, Fernández Carballal C, Salinero Paniagua E, Rábano A, Pareja J, Pilo B, Ezpeleta D (Spain)
- p430 **Landau-Kleffner syndrome: clinical and electroencephalographic follow-up**  
Martinovic Z (Serbia)
- p431 **Current management of West syndrome in Armenia**  
Sukhudyen B G (Armenia)
- p432 **Duplication (X)(p11.22-p11.23) associated with mental retardation, speech delay and EEG anomalies in males and females: description of a new syndrome**  
Broli M, Bisulli F, Magini P, Seri M, Cevolani D, Agati R, Bernardi B, Poda R, Oppi F, Gallassi R, Fiocchi I, Mastrangelo M, Tinuper P (Italy)
- p433 **Therapeutic approaches in children with Angelman syndrome**  
Budisteanu M, Arghir A, Chiriac S-M, Craiu D, Barca D, Magureanu S, Lungeanu A (Romania)
- p434 **Good response to polytherapy in a patient with 20 ring chromosome syndrome drug-resistant epilepsy**  
Gago A, Huertas N, Osejo V, Hernando-Requejo V (Spain)
- p435 **A population-based study on epilepsy with onset in the first year: incidence and syndrome classification**  
Lommi M, Heiskala H, Gaily E (Finland)
- p436 **Myoclonus following cardiopulmonary resuscitation**  
Doneva A, Ivanov E, Pili Kuzeva K, Donev V (Macedonia, the Former Yugoslav Republic of)







## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster Session: neurobiology and basic sciences V

### Poster Area

Chairs: Avanzini G (Italy), Onat F (Turkey)

- p437 **CHOP (GADD153) protects the hippocampus against seizure-induced neuronal death**  
Engel T<sup>1</sup>, Murphy B<sup>1,2</sup>, Lucas J J<sup>2</sup>, Henshall D<sup>1</sup>  
(<sup>1</sup>Ireland, <sup>2</sup>Spain)
- p438 **Neuroprotective effect and behavioral improvement by topiramate on global cerebral ischemia in young rat**  
EUN B-L, Choi H C, Shin H-K, Eun S-H, Chung H J  
(Korea, Republic of)
- p439 **Exogenous erythropoietin exerts opposite effects on cognitive deficits and anxiety in epileptic rats depending on the quality of living environment**  
Fares R P, Bonnet C, Georges B, Moulin C, Bezin L (France)
- p440 **Targeting the arachidonic acid cascade in the amygdala kindling model of temporal lobe epilepsy**  
Fischborn S V, Soerensen J, Potschka H (Germany)
- p441 **NR2B-containing N-methyl-D-aspartate (NMDA) receptors in a rat model of temporal lobe epilepsy (TLE)**  
Frasca A<sup>1</sup>, Aalbers M<sup>2</sup>, Colciaghi F<sup>1</sup>, Finardi A<sup>1</sup>, Hoogland G<sup>2</sup>, Battaglia G<sup>1</sup>, Vezzani A<sup>1</sup> (<sup>1</sup>Italy, <sup>2</sup>Netherlands)
- p442 **Co-existence of two types nonconvulsive discharges in absent epilepsy patients and genetic absence epilepsy WAG/Rij rats**  
Gabova A<sup>1</sup>, Kuznetsova G<sup>1</sup>, Samotaeva I<sup>1</sup>, Bosnyakova D<sup>1</sup>, Obukhov Y<sup>1</sup>, Gnezdiitski V<sup>1</sup>, Coenen A<sup>2</sup>, van Luijckelaar G<sup>2</sup>  
(<sup>1</sup>Russia, <sup>2</sup>Netherlands)
- p443 **Naringin protects kainic acid induced status epilepticus in rats: evidence for an antioxidant, anti-apoptotic, and neuroprotective intervention**  
Golechha M, Chaudhry U, Arya D S, Saluja D (India)
- p444 **Spreading depression as a potential mechanism of seizure termination: data from the audiogenic kindling model**  
Grinenko O, Novikova M, Sharova E, Vinogradova L  
(Russia)



## POSTER SESSIONS

### WEDNESDAY, 30<sup>TH</sup> JUNE 2010

- p445      **Apneas are associated with impaired resting metabolism and brainstem noradrenergic phenotype in rats with spontaneous recurrent seizures**  
Kouchi H, Fares R P, Bonnet C, Ryvlin P, Bezin L, Morales A (France)
- p446      **Impaired anxiety-trait and CA1 pyramidal cell excitability precede spontaneous recurrent seizures after induction of status epilepticus at weaning in rats: effect of environmental enrichment**  
Belmeguenai A, Bonnet C, Fares R, Bezin L (France)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: surgical treatment III

### Poster Area

Chair: Özbara Ç (Turkey)

- p447 **Antiepileptic drugs management and long-term seizure outcome in post surgical mesial temporal lobe epilepsy**  
Pimentel J, Peralta R, Campos A, Bentes C,  
Epilepsy Surgery Group (Portugal)
- p448 **Long-term developments in presurgical evaluation and surgical treatment of epilepsy at one tertiary center — part I: presurgical evaluation**  
Raabe A L, Elger C E, Schramm J, Becker A, Urbach H,  
Bien C G (Germany)
- p449 **Persistent epileptogenicity of irradiated hippocampus after gamma-knife radiosurgery: a SEEG study**  
Rheims S, Montavont A, Didelot A, Guenot M, Ryvlin P (France)
- p450 **Epilepsy surgery in a tertiary care hospital: a decade of experience**  
Rodriguez Osorio X, Guijarro Del Amo M, Arcos Algaba A,  
López González F J, Corredera García E, Pías Peleteiro J M, Prieto  
Gonzalez A, Peleteiro Fernández M, Pardo Fernández J (Spain)
- p451 **Reoperations in resective epilepsy surgery: data from the Swedish National Epilepsy Surgery Register 1990-2004**  
Rydenhag B, Flink R, Malmgren K (Sweden)
- p452 **Tools to define the epileptogenic zone in cryptogenic partial epilepsy non-invasively: correlations between FDG-PET, voxel-based MRI postprocessing, and scalp video-EEG recordings**  
Scholly J<sup>1</sup>, Staack A M<sup>1</sup>, Namer I J<sup>2</sup>, Kraus U<sup>1</sup>, Bilic S<sup>1</sup>,  
Strobl K<sup>1</sup>, Bast T<sup>1</sup>, Dylgjeri S<sup>2</sup>, Valenti M P<sup>2</sup>, Hirsch E<sup>2</sup>,  
Steinhoff B J<sup>1</sup> (<sup>1</sup>Germany, <sup>2</sup>France)
- p453 **Evaluation of operated patients with mesial temporal sclerosis**  
Sirin N G, Gurses C, Pulur G, Bebek N, Sencer S, Kulaksizoglu I B,  
Sencer A, Karasu A, Akca S, Tumac A, Baykan B, Imer M,  
Oktem-Tanor O, Bilgic B, Bayindir C, Gokyigit A, Canbolat A (Turkey)
- p454 **Vagus nerve stimulation and chronic migraine**  
Sporis D, Basic S, Chudy D, Colak Z, Romic D, Nevajda B (Croatia)



## POSTER SESSIONS

### WEDNESDAY, 30<sup>TH</sup> JUNE 2010

- p455      **Intracranial EEG monitoring with subdural grids in refractory epilepsy: implantation technique by linear craniotomy under neuronavigation ("letter box" technique), experience with 99 consecutive grids in 43 consecutive patients**  
van Rijckevorsel K, Vaz G, Grandin C, Raftopoulos C (Belgium)
- p456      **Innsbruck epilepsy surgery program (INES) 1999-2009: procedures and outcome**  
Walser G, Unterberger I, Dobesberger J, Larch J, Embacher N, Kuchukhidze G, Luef G, Gotwald T, Ortler M, Trinka E (Austria)
- p457      **Cortical responses to single-pulse electrical stimulation under general anesthesia**  
Kokkinos V, Valentin A, Selway R P, Alarcón G (United Kingdom)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: neuroimaging III

Poster Area

Chair: Duncan J (United Kingdom)

- p458 **MRI abnormalities associated with vigabatrin treatment - a longitudinal case study**  
Polster T, Axer S, Classen G, Hofmann-Peters A, Thiels C, Weise S, Woermann F G (Germany)
- p459 **Voxel-based optimised morphometry (VBM) in the identification of subtle focal cortical dysplasias (FCDs) in patients with refractory seizures**  
Radhakrishnan A, James J S, Kesavadas C, Thomas B, Radhakrishnan K (India)
- p460 **Towards investigating the causes of memory difficulties in temporal lobe epilepsy: A study using the novel alpha5 GABAA receptor PET ligand [11C]Ro15 4513**  
Riano Barros D A<sup>1</sup>, Heckemann R A<sup>1,2</sup>, Keihaninejad S<sup>1</sup>, McGinnity C J<sup>1</sup>, Gousias I S<sup>1</sup>, Duncan J S<sup>1</sup>, Koepp M J<sup>1</sup>, Brooks D J<sup>1</sup>, Hammers A<sup>1,2</sup> (<sup>1</sup>United Kingdom, <sup>2</sup>France)
- p461 **Electrical source imaging for presurgical focus localization in epilepsy patients with normal MRI**  
Seeck M, Brodbeck V, Spinelli L, Lascano A, Pollo C, Schaller K, Vargas M I, Wissmeyer M, Michel C M (Switzerland)
- p462 **Combined high-field MRI and histopathological study on specimens from temporal lobe epilepsy patients**  
Spreafico R, Zucca I, Milesi G, Tassi L, D'Incerti L, Villani F, Colombo N, Cattalini A, Marras C, Mastropietro A, Garbelli R (Italy)
- p463 **Group Independent Component Analysis (G-ICA) reveals differences in neurofunctional basis of semantic processing between healthy controls and epilepsy patients**  
Szaflarski J<sup>1</sup>, Kim K K<sup>1,2</sup>, Karunanayaka P<sup>1</sup>, Privitera M D<sup>1</sup>, Holland S K<sup>1</sup> (<sup>1</sup>USA, <sup>2</sup>Korea, Republic of)
- p464 **Metabolic evidence for episodic memory plasticity in the non-epileptic temporal lobe of patients with unilateral mesiotemporal epilepsy**  
Trotta N, Goldman S, Ligot N, Legros B, Baete K, Van Laere K, Van Bogaert P, De Tiège X (Belgium)



## POSTER SESSIONS

### WEDNESDAY, 30<sup>TH</sup> JUNE 2010

- p465      **Modifications in local Hemodynamic precedes epileptic spike: an animal model combining simultaneous ECoG and near infrared spectroscopy analysis**  
Wallois F, Osharina V, Ponchel E, Aarabi A, Grebe R (France)
- p466      **Hippocampal volume is reduced in children with other forms of convulsive status epilepticus compared to children with prolonged febrile seizures**  
Yoong M, Martinos M, Clark C, Chin R F, Scott R C (United Kingdom)
- p467      **Effect of epilepsy on intracranial volume**  
Keihaninejad S<sup>1</sup>, Vollmar C1, Duncan J S<sup>1</sup>, Koepp M J<sup>1</sup>, Hammers A<sup>1,2</sup> (<sup>1</sup>United Kingdom, <sup>2</sup>France)
- p468      **Diagnostic utility of immediate post-ictal MRI in acute seizure disorders**  
Kim D-H, Hong Y-H, Huh K (Korea, Republic of)



## POSTER SESSIONS

WEDNESDAY, 30TH JUNE 2010

13:30-14:30

### Poster session: genetics II

### Poster Area

Chair: Baulac M (France)

- p469 **Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease**  
Ilesca G<sup>1</sup>, Boutry-Kryza N<sup>1</sup>, de Toffol B<sup>1</sup>, Milh M<sup>1</sup>, Steschenko D<sup>1</sup>, Lemesle-Martin M<sup>1</sup>, Maillard L<sup>1</sup>, Foletti G<sup>2</sup>, Rudolf G<sup>1</sup>, Nielsen J E<sup>3</sup>, Rogvi-Hansen B A<sup>3</sup>, Erdal J<sup>3</sup>, Mancini J<sup>1</sup>, Thauvin-Robinet C<sup>1</sup>, Rrabet A M<sup>4</sup>, Ville D<sup>1</sup>, Szepietowski P<sup>1</sup>, Raffo E<sup>1</sup>, Hirsch E<sup>1</sup>, Ryvlin P<sup>1</sup>, Calender A<sup>1</sup>, Genton P<sup>1</sup> (1France, 2Switzerland, 3Denmark, 4Tunisia)
- p470 **Non paraneoplastic limbic encephalitis and familial myotonia: a common physiopathogenetic background?**  
Licchetta L, Bisulli F, Naldi I, Pittau F, Mostacci B, Broli M, Di Vito L, Stipa C, Tinuper P (Italy)
- p471 **Genome-wide analysis of structural genomic variations suggests novel candidate genes in early-onset absence epilepsy**  
Muhle H, Ostertag P, von Spiczak S, Tönnies H, Caliebe A, Siebert R, Stephani U, Sander T, Helbig I (Germany)
- p472 **The Val66Met BDNF gene polymorphism in Greek children with Rolandic epilepsy**  
Pavlou E, Fidani L, Gkampeta A, Karakasis C, Kalinderi K, Athanasiadou F (Greece)
- p473 **Pyridoxine dependent epilepsy: new strategies for diagnosis and therapy**  
Rusnáková Š, Ryzí R, Fajkusová L, Jansova E, Šultéssová P, Ošlejšková H (Czech Republic)
- p474 **A clinical and genetic study in a multiplex family with diverse epilepsy phenotypes: from FS and CAE to Panayiotopoulos syndrome**  
Sirén A<sup>1</sup>, Nuutila A<sup>1</sup>, Polvi A<sup>1</sup>, Anttonen A-K<sup>1</sup>, Hirvonen K<sup>1</sup>, Abboud S<sup>2</sup>, Pandolfo M<sup>2</sup>, Koivikko M<sup>1</sup>, Calafato S<sup>3</sup>, Palotie A<sup>1,3,4</sup>, Toliat M<sup>5</sup>, Lerche H<sup>5</sup>, Lehesjoki A-E<sup>1</sup> (1Finland, 2Belgium, 3United Kingdom, 4USA, 5Germany)
- p475 **Benign familial epilepsies with onset in the first year of life: a spectrum of potassium and sodium channelopathies**  
Specchio N, Striano P, Paravidino R, Capovilla G, Vigevano F, Zara F, and the Collaborative Group of LICE (Italy)
- p476 **Array-CGH identifies genomic rearrangements in patients with cryptogenic epilepsy**  
Striano P<sup>1</sup>, Coppola A<sup>1</sup>, Paravidino R<sup>1</sup>, Gimelli S<sup>2</sup>, Zara F<sup>1</sup>, and the Italian League Against Epilepsy study group (1Italy, 2Switzerland)



## POSTER SESSIONS

### WEDNESDAY, 30<sup>TH</sup> JUNE 2010

- p477      **Mutations in KCNQ2 are associated with severe neonatal epilepsy**  
Suls A<sup>1</sup>, Audenaert D<sup>1</sup>, Van Dyck T<sup>1</sup>, Weckhuysen S<sup>1,2</sup>, Baets J<sup>1</sup>,  
Hasaerts D<sup>1</sup>, Jansen A<sup>1</sup>, Lagae L<sup>1</sup>, Jordanova A<sup>1</sup>, De Jonghe P<sup>1</sup>  
(<sup>1</sup>Belgium, <sup>2</sup>Netherlands)
- p478      **Photosensitivity might be part of the Wolf-Hirschhorn syndrome!**  
Veredice C<sup>1</sup>, Cantonetti L<sup>1</sup>, Staccioli S<sup>1</sup>, Digilio M C<sup>1</sup>, Bisozzi E<sup>1</sup>,  
Lispi M L<sup>1</sup>, Lindhout D<sup>2</sup>, Kasteleijn-Nolst Trenité D<sup>2</sup>, Castelli E<sup>1</sup>  
(<sup>1</sup>Italy, <sup>2</sup>Netherlands)
- p479      **Epilepsy in adult patients with Down's syndrome**  
Vignoli A, Zambrelli E, Chiesa V, Savini M, La Briola F, Gardella E,  
Canevini M P (Italy)
- p480      **Another large family with infantile convulsions and choreo-athetosis (ICCA) with linkage to chromosome 16p12-q12**  
Weckhuysen S<sup>1,2</sup>, Suls A<sup>1</sup>, Deprez L<sup>1</sup>, Jansen A<sup>1</sup>, Lagae L<sup>1</sup>,  
De Jonghe P<sup>1</sup> (<sup>1</sup>Belgium, <sup>2</sup>Netherlands)
- p481      **MDR1 gene polymorphisms and drug-resistant epilepsy in a Portuguese population**  
Leal B, Chaves J, Carvalho C, Bettencourt A, Barros M, Lopes D,  
Silva A M, Lima J L, Costa P P, Silva B M (Portugal)
- p482      **A candidate gene association study of antiepileptic drug tolerability and efficacy**  
Depondt C, Godard P, Sens Espel R, Lopes Da Cruz A, Lienard P,  
Pandolfo M, and the EPIGEN Consortium (Belgium)
- p483      **Mutations in NIPA1 may predispose to idiopathic generalised epilepsy**  
Møller R S, Svenstrup K, Christensen J, Gilling M, Nielsen J E  
(Denmark)





## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: psychiatry

Poster Area

Chair: Brodie M (United Kingdom)

- p484 **Attention deficit hyperactivity disorder comorbidity with epilepsy in an university hospital pediatric clinic in China**  
Han Y, Qin J, Chen J, Ji X, Jiang Y, Lin Q (China)
- p485 **Electroencephalography in children with attention deficit hyperactive disorder and treatment results with central nervous system stimulants**  
Kim W S, Sim J Y (Korea, Republic of)
- p486 **Determinants of quality of life in people with epilepsy**  
Milovanovic M, Martinovic Z, Djokic R, Jovanovic M, Buder N, Simonovic P (Serbia)
- p487 **A case of continuous “sensed presence” related to spike activities**  
Okazaki M, Tsukada E, Ishikawa M, Kaneko Y (Japan)
- p488 **Use of short screening tools for anxiety and depression in a neurology outpatient setting**  
Rampling J, Agrawal N, Cock H R, Jackson J, Docker J, Mitchell A J, von Oertzen T J (United Kingdom)
- p489 **Psychiatric comorbidity in epilepsy**  
Rascheva M A, Ganeva G, Aleksiev P (Bulgaria)
- p490 **Epileptiform abnormalities on awake and sleep EEG in ADHD children without previous history of epilepsy**  
Socanski D, Herigstad A (Norway)
- p491 **Psychosocial determinants of maternal anxiety within the first year after diagnosis of epilepsy in child**  
Wisniewska B, Wendorff J, Ircha G, Zawodniak M (Poland)
- p492 **Study of emotional-volitional recovery dynamics in children with atypical frontal absence**  
Zaytsev D E, Eletskova L V, Titov N A, Lyutin D V (Russia)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy III

### Poster Area

Chair: Sills G (United Kingdom)

- p493 **Outcome of discontinuation of antiepileptic therapy in three years free-of-seizure patients**  
Angelopoulos P, Boziki M, Grivas G, Sitzoglou K (Greece)
- p494 **Neuropsychological impairment in mesial temporal lobe epilepsy: correlation with ictal features?**  
Santana I, Cunha C, Teotónio R, Bento C, Sales F (Portugal)
- p495 **Comparison of the efficacy and safety of zonisamide and carbamazepine as monotherapy in adults with partial epilepsy: design and current status of a phase III, double-blind, randomised, multicentre trial and long-term extension study**  
Baulac M<sup>1</sup>, van Maanen R<sup>2</sup> (1France, 2United Kingdom)
- p496 **A multi-center comparative trial of low and high dose zonisamide in children with newly diagnosed epilepsy as monotherapy**  
EUN S-H, Kim H D, Lee I K, Chung H J, Eun B-L, Lee J S, Kim J S, Kang H-C, Suh E S, Kim D W, Eom S, Moon H K (Korea, Republic of)
- p497 **Effects of retigabine on rates of seizure-free days and proportion of seizure-free patients in adults with refractory partial-onset seizures**  
Gil-Nagel A<sup>1</sup>, Burdette D<sup>2</sup>, Elger C<sup>3</sup>, VanLandingham K E<sup>2</sup>, Hall S<sup>2</sup>, on behalf of the RESTORE 1 and RESTORE 2 Study Investigators (1Spain, 2USA, 3Germany)
- p498 **Risk factors for recurrence of epileptic attacks after withdrawal of antiepileptic therapy**  
Vujisic S, Radulović L, Milović Ž, Milikić D, Peruničić S (Serbia and Montenegro)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy VI

Poster Area

Chair: Bialer M (Israel)

- p499 **Beta 1 Na<sup>+</sup> channel subunit loss impairs the effects of CBZ but not Lacosamide on repetitive firing via differential effects on persistent Na<sup>+</sup> currents**  
Uebachs M<sup>1</sup>, Opitz T<sup>1</sup>, Stoehr T<sup>1</sup>, Niespodziany I<sup>2</sup>, Wolff C<sup>2</sup>, Beck H<sup>1</sup> (1Germany, 2Belgium)
- p500 **Lacosamide as adjunctive therapy in patients with partial seizures: case study series**  
García-Morales I, Toledano Delgado R, Falip M, Campos-Blanco D, García-García M E, Gil-Nagel A (Spain)
- p501 **An investigation of the effect of eslicarbazepine acetate on cardiac repolarization: a pooled analysis of over-read electrocardiograms from three double-blind Phase III clinical studies**  
Gil-Nagel A<sup>1</sup>, Lopes-Lima J<sup>2</sup>, Nunes T<sup>2</sup>, Maia J<sup>2</sup>, Soares-da-Silva P<sup>2</sup> (1Spain, 2Portugal)
- p502 **Efficacy and tolerability of oral lacosamide as adjunctive therapy on paediatric patients with pharmacoresistant partial epilepsy**  
Gavatha M, Nikaina E, Paraskevoulakos E, Kotsalis C, Bazigou H, Rizou C, Papavasiliou A S (Greece)
- p503 **Rapamycin treatment improved epilepsy status in two patients with TSC and intractable epilepsy**  
Lapa E K, Attilakos A, Tsirouda M, Paschalidou M, Samiotaki M, Fretzagias A, Dinopoulos A (Greece)
- p504 **Seizure freedom and patient retention with adjunctive eslicarbazepine acetate therapy in adults with refractory partial seizures during three randomised, double-blind, placebo-controlled trials with 1-year, open-label extensions**  
Maia J<sup>1</sup>, Ben-Menachem E<sup>2</sup>, Elger C<sup>3</sup>, Gil-Nagel A<sup>4</sup>, Nunes T<sup>1</sup>, Soares-da-Silva P<sup>1</sup> (1Portugal, 2Sweden, 3Germany, 4Spain)
- p505 **Brivaracetam modulates Na<sup>+</sup> currents expressed in a neuroblastoma cell line: comparison with carbamazepine**  
Niespodziany I, Leclère N, Matagne A, Wolff C (Belgium)
- p506 **Comparative study of lacosamide with other sodium channel blocking antiepileptic drugs on sodium current slow inactivation**  
Niespodziany I, Leclère N, Vandenplas C, Foerch P, Wolff C (Belgium)
- p507 **Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from two randomized, double-blind, placebo-controlled trials**  
Werhahn\* K J<sup>1</sup>, Biton\* V<sup>2</sup>, Johnson M E<sup>2</sup>, Merschhemke M<sup>1</sup>, Lu S<sup>2</sup>,  
\*on behalf of the N01252 and N01253 Brivaracetam Study Groups  
(1Germany, 2USA)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: drug therapy IX

### Poster Area

Chair: Tomson T (Sweden)

- p508 **Frequency domain parameters of heart rate variability in patients with newly diagnosed epilepsy and lamotrigine monotherapy**  
Spasic M, Ljubisavljevic S, Lukic S (Serbia)
- p509 **Cardiac repolarization indices in epilepsy patients**  
Aslan K, Balal M, Şahin D Y, Peköz T, Demir T, Bozdemir H (Turkey)
- p510 **Case report: a rare case of sinus bradycardia under high dose of oral pulse methylprednisolone in an infant with tuberous sclerosis and hysarrhythmia**  
Wiemer-Kruel A, Dietel T, Arnold R, Stiller B, Bast T (Germany)
- p511 **Does lacosamide (Vimpat) prolong the PR interval of patients with a vagal nerve stimulator (VNS)?**  
Tidswell P, North L A, Dixon S (United Kingdom)
- p512 **Effects of lamotrigine on selected time domain parameters of heart rate variability in patients with newly diagnosed localization related epilepsy**  
Lukic S R, Spasic M, Ljubisavljevic S (Serbia)
- p513 **Evaluation of the new QMS® Topiramate immunoassay on the Olympus AU 640**  
Berry D, Clarke L A, Khan R (United Kingdom)
- p514 **Safety and tolerability of adjunctive brivaracetam in adults with uncontrolled epilepsy: randomized, double-blind, placebo-controlled trial**  
Kwan P<sup>1</sup>, Johnson M E<sup>2</sup>, Merschhemke M<sup>3</sup>, Lu S<sup>2</sup>, on behalf of the N01254 Brivaracetam Study Group (<sup>1</sup>China, <sup>2</sup>USA, <sup>3</sup>Germany)
- p515 **Zonisamide in adjunctive treatment of refractory epilepsy: monocentric retrospective study**  
Kuba R, Brazdil M, Tyrlikova I, Novotna I, Rektor I (Czech Republic)
- p516 **Cancer risk in people with epilepsy using valproate-sodium**  
Singh G<sup>1</sup>, Bell G<sup>2</sup>, Sander J W<sup>2,3</sup> (<sup>1</sup>India, <sup>2</sup>United Kingdom, <sup>3</sup>Netherlands)
- p517 **Pregabalin as the first add-on therapy of partial epileptic attacks and its influence upon depression, anxiety, cognitive functions, life quality and sleep disturbances in the Slovak Republic**  
Donath V, Lipovsky L (Slovakia)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

**Poster session: epilepsy syndromes in children and adults II**

**Poster Area**

Chair: Kimiskidis V (Greece)

- p518 **Serum prolactin levels following single temporal epileptic seizures**  
Rysz A (Poland)
- p519 **Clinical and diagnostic correlation of mesial temporal lobe epilepsy**  
Melikyan G R, Nahapetyan N Y, Khechumyan Z V, Kocharyan A G (Armenia)
- p520 **Long-term seizure outcome in adult patients with refractory epilepsy who were not candidates for surgery after presurgical evaluation**  
Elsharkawy A E, Ebner A (Germany)
- p521 **Causes of mortality in 1921 patients with chronic epilepsy during 12 years**  
Sokic D V, Jankovic S, Ristic A J, Bascarevic V, Vojvodic N M, Zovic L (Serbia)
- p522 **Lennox-Gastaut syndrome in adulthood: a cross-sectional study**  
Unterberger I, Bauer G, Walser G, Luef G, Larch J, Dobesberger J, Kuchukhidze G, Ndayisaba J P, Trinka E (Austria)
- p523 **In 29.3% of 65 patients the previous diagnosis of a therapy-resistant generalized epilepsy had to be revised - focal seizure onset could be proved by means of video-EEG and MRI**  
Kurth C, Steinhoff B J (Germany)
- p524 **Long-term mortality in people with epilepsy**  
Bell G S, Neligan A, Johnson A L, Goodridge D M, Shorvon S D, Sander J W (United Kingdom)
- p525 **Epilepsy and EEG abnormalities in 104 children with autism spectrum disorders**  
Monteiro J P, Rocha L, Duarte A, Ventosa L, Lourenço L, Fonseca M J (Portugal)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: epilepsy syndromes in children and adults IV

Poster Area

Chair: Jovic N (Serbia)

- p526 **Epileptic seizures with dissociative-like behaviour**  
Tomasek M, Krijtova H, Marusic P (Czech Republic)
- p527 **Electroencephalographic manifestations and their prognostic significance in idiopathic childhood occipital epilepsy of Gastaut (ICOE-G)**  
Tsiptsios D, Kokkinos V, Sanders S, Valeta T, Tsiropoulos I, Koutroumanidis M, Panayiotopoulos C P (United Kingdom)
- p528 **Prognostic significance of initial EEG in childhood absence epilepsy**  
Nam S-O, Oh J-M, Lee Y-J, Kim Y-M (Korea, Republic of)
- p529 **Absence syndromes in childhood and adolescence: clinical course and early response to treatment**  
Dragoumi P, Tzetzis O, I. Zafeiriou D, Paulou E, Vargiami E, Kontopoulos E (Greece)
- p530 **Ictal SPECT in myoclonic absence seizures**  
Ikeda H, Imai K, Ikeda H, Matsuda K, Nakamura F, Takahashi Y, Inoue Y (Japan)
- p531 **Somatic complaints in patients with idiopathic epilepsies of childhood onset**  
Rizou I<sup>1,2</sup>, Nikaina I<sup>1</sup>, Pat-El R<sup>2</sup>, Bazigou H<sup>1</sup>, Kotsalis C<sup>1</sup>, Paraskevoulakos E<sup>1</sup>, Papavasiliou A<sup>1</sup> (<sup>1</sup>Greece, <sup>2</sup>Netherlands)
- p532 **Monozygotic twins with juvenile myoclonic epilepsy — remarkable synchrony of biological clocks**  
Novak V, Kuncikova M, Maluskova A (Czech Republic)
- p533 **How frequent is fatigue in patients with epilepsy? A clinical study to measure its severity, impact and phenomenology**  
Tellez-Zenteno J F, Ronquillo L H, Moien-Afshari F, Britz J, Knox K (Canada)
- p534 **Prolonged cortical silent period (CSP) in patients with generalized or partial epilepsy**  
Hwang W S, Lee J Y, Kim H-J, Kim S-W, Hong S B, Joo E Y (Korea, Republic of)
- p535 **Seizures and neurological outcome in patients with congenital melanocytic naevi (CMN) and central nervous system (CNS) melanosis**  
Wijesekara D S, Chong W K, Jacques T S, Aylett S E (United Kingdom)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: social issues I

### Poster Area

Chair: Guekht A (Russia)

- p536 **Epilepsy nurse specialist in Switzerland: the development of a new role**  
Jaggi S, Mahrer R (Switzerland)
- p537 **Incidence of epilepsy in Eskisehir, Turkey after 15 years of age**  
Erdinc O O, Celikkas E, Metintas S, Fidan H S, Arikan I, Kalyoncu C, Ozdemir G (Turkey)
- p538 **Past and present public knowledge and attitudes toward epilepsy in Italy**  
Mecarelli O, Capovilla G, Romeo A, Rubboli G, Tinuper P, Beghi E (Italy)
- p539 **The knowledge of and attitudes toward epilepsy amongst university students**  
Mifsud J, Dempsey J (Malta)
- p540 **Enhancing quality, safety and efficiency of epilepsy care in Ireland using information and communications technology**  
O'Byrne P, Varley J, Dunleavy B, Delanty N, Normand C, Grimson J, Fitzsimons M (Ireland)
- p541 **Epilepsy care in a rural area of Togo**  
Oehl B<sup>1</sup>, Assigbley J<sup>2</sup>, Agbevide K A<sup>2</sup>, Taussig D<sup>3</sup>, Lanz M<sup>1</sup>, Heinzmann M B<sup>2</sup>, Schulze-Bonhage A<sup>1</sup> (<sup>1</sup>Germany, <sup>2</sup>Togo, <sup>3</sup>France)
- p542 **Treating epilepsy on board a train in India's underserved hinterlands: can this be a sustainable and successful model for epilepsy care delivery in India?**  
Singh M B, Padma M V, Bhatia R, Prasad K, Behari M (India)
- p543 **Epilepsy care in Ireland: a regional audit of general practice records**  
Varley J, Delanty N, O'Connor R, Normand C, Fitzsimons M (Ireland)



## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: social issues II

### Poster Area

Chair: Reetta Kälviäinen (Finland)

- p544 **Public awareness, attitudes and practice with respect to epilepsy in the Kumbo West health district, North West region, Cameroon**  
Dema F, Fonsah J Y, Angwafor S A, Wirngo M S, Acho A, Tabah E N, Yepnjio F N, Kuate C T, Bissek A-C Z-K, Obama M-T, Angwafo iii F F, Muna W F, Njamnshi A K (Cameroon)
- p545 **Assessment of needs of people with epilepsy, members of the association of parents with children with epilepsy in Bulgaria**  
Djalev L D, Sabeva V G, Markova G A (Bulgaria)
- p546 **Knowledge, attitudes and practice with respect to epilepsy among secondary school students in the Kumbo West Health District — Northwest region, Cameroon**  
Fonsah J Y, Angwafor S A, Dema F, Wirngo M S, Acho A, Tabah E N, Kuate C T, Yepnjio F N, Bissek A-C Z-K, Obama M-T, Angwafo iii F F, Muna W F, Njamnshi A K (Cameroon)
- p547 **A door-to-door survey to establish the prevalence, phenotype and treatment gap for epilepsy in a rural district of northern Tanzania: initial findings**  
Hunter E<sup>1</sup>, Chigudu S<sup>1</sup>, Kibiki J<sup>2</sup>, Jusabani A<sup>2</sup>, Aris E<sup>2</sup>, Walker R<sup>1</sup>  
(<sup>1</sup>United Kingdom, <sup>2</sup>Tanzania, United Republic of)
- p548 **Seizure impact on the quality of life of school-aged children in different cultural populations in Thrace region, Greece**  
Terzoudi A, Serdari A, Tsalkidis A, Tripsianis G, Vadikolias K, Samakouri M, Chatzimichael A, Livaditis M, Piperidou C (Greece)
- p549 **Differences of public knowledge, attitudes, and practice of epilepsy between people in metropolitan and urban area, Khon Kaen province**  
Tiamkao S, Srinagarind Epilepsy Research Group (Thailand)
- p550 **Is there a difference in maternal stress between mothers with epilepsy and mothers without epilepsy preliminary analysis? Gummery A, Bromley R L, Shallcross R, Briggs M and Baker GA (on behalf of the Liverpool and Manchester Neurodevelopmental Group)**  
Gummery A, Bromley R, Shallcross R, Briggs M, Baker G, The Liverpool and Manchester Neurodevelopmental Study (United Kingdom)
- p551 **Sexual dysfunction in adult patients with epilepsy**  
Henning O J, Nakken K O (Norway)





## POSTER SESSIONS

WEDNESDAY, 30<sup>TH</sup> JUNE 2010

13:30-14:30

### Poster session: social issues III

### Poster Area

Chair: Schulze-Bonhage A (Germany)

- |      |   |
|------|---|
| p552 | <b>Mortality in epilepsy: data of 23 patients</b><br>Jung R (Austria)   |
| p553 | <b>Diurnal pattern of focal seizures and health related quality of life of adults with epilepsy</b><br>Fawale M B, Ogunniyi A (Nigeria)   |
| p554 | <b>Can seizure recognition be improved? An eye-motion study</b><br>Fogarasi A, Szirtes G, Zsiak G, Lorincz A (Hungary)  |
| p555 | <b>Significance of EEG finding in assessing fitness to drive in seizure free epilepsy patients</b><br>Krijtova H, Tomasek M, Marusic P (Czech Republic)                                     |
| p556 | <b>Long-term follow up of non-surgical temporal lobe epilepsy patients with mesial temporal sclerosis</b><br>Kurita T, Sakurai K, Takeda Y, Koyama T (Japan)                                |
| p557 | <b>Audit of analgesic use postictally in epilepsy in adults with and without learning disability</b><br>Adadevoh C F, Nashef D L (United Kingdom)   |
| p558 | <b>The peculiarities of pregnancy and delivery in women with epilepsy and antiepileptic drug therapy in Lithuania</b><br>Valanciene I, Mameniskiene R, Jaskeviciene V, Budrys V (Lithuania) |
| p559 | <b>Risk communication in the preconception counselling visit</b><br>Winterbottom J B, Jacoby A, Baker G (United Kingdom)  |





## POSTER PRESENTATIONS

### Poster Session Information

The Poster Area is located on the upper level of the Capsis Convention Centre.

Posters will be on display from 09:00 to 18:00 Monday to Wednesday according to the timetable. The timetable below illustrates which topics are on each day.

Poster presenters are required to set up their posters between 08:00 and 09:00 on their assigned day. Posters must be removed between 18:00 and 19:00. The congress does not take responsibility for unclaimed posters.

Presenters are requested to be at their posters between 13:00 and 14:30.

Guided tours to poster sessions led by experts in each topic will take place between 13:30 and 14:30, according to the timetable outlined below. During guided tours presenters will have 5 minutes to illustrate the poster.

Abstracts for all posters are available on the congress website. You are invited to use the terminals in the Internet Centre which is located beside the Poster Area to view or print abstracts of interest.

### MONDAY 28TH JUNE 2010

Tour Guide	Session	Poster #
Marco de Curtis	Poster Session: neurobiology and basic sciences I	p103 · p114
Christophe Bernard	Poster Session: neurobiology and basic sciences II	p115 · p126
George Kostopoulos	Poster Session: neurobiology and basic sciences II	
Thanos Covanis	Poster session: cerebral dysplasias and epilepsy	p127 · p136
Peter Wolf	Poster session: surgical treatment I	p137 · p144
John Duncan	Poster session: neuroimaging I	p145 · p156
Simon Shorvon	Poster session: status epilepticus	p157 · p167
Giuliano Avanzini	Poster session: clinical neurophysiology I	p168 · p179
Martin Brodie	Poster session: clinical neurophysiology III	p180 · p191
Michalis Koutroumanidis	Poster session: epilepsy syndromes in development I	p192 · p202
Andreas Schulze-Bonhage	Poster session: neuropsychology I	p203 · p212
Alla Guekht	Poster session: acute symptomatic seizures	p213 · p225
Emilio Perucca	Poster session: drug therapy I	p226 · p234
Svein Johannessen	Poster session: drug therapy IV	p235 · p242
Torbjörn Tomson	Poster session: drug therapy VII	p243 · p249
Reetta Kälviäinen	Poster session: drug therapy VIII	p250 · p257
Eugen Trinka	Poster session: drug therapy X	p258 · p265



## POSTER PRESENTATIONS

### TUESDAY 29<sup>TH</sup> JUNE 2010

Tour Guide	Session	Poster #
Anna Maria Vezzani	Poster Session: neurobiology and basic sciences III	p266 · p276
Matthew Walker	Poster Session: neurobiology and basic sciences III	
Marco de Curtis	Poster Session: neurobiology and basic sciences IV	p277 · p287
Terence O'Brien	Poster Session: neurobiology and basic sciences IV	
Özhara Ç (Turkey)	Poster session: surgical treatment II	p288 · p295
John Duncan	Poster session: neuroimaging II	p296 · p307
Simon Shorvon	Poster session: alternative therapies and epilepsy in the elderly	p308 · p320
Giuliano Avanzini	Poster session: clinical neurophysiology II	p321 · p333
Eugen Trinka	Poster session: sleep and epilepsy	p334 · p343
Thanos Covanis	Poster session: epilepsy syndromes in development II	p344 · p353
Michel Baulac	Poster session: genetics I	p354 · p364
Martin Brodie	Poster session: neuropsychology II	p365 · p373
Torbjörn Tomson	Poster session: epileptic encephalopathies	p374 · p382
Michalis Koutroumanidis	Poster session: epileptic encephalopathies and neonatal seizures/syndromes	p383 · p390
Graeme Sills	Poster session: drug therapy II	p391 · p398
Svein Johannessen	Poster session: drug therapy V	p399 · p405
Federico Vigevano	Poster session: non-epileptic paroxysmal events	p406 · p410
Emilio Perucca	Poster session: drug therapy XI	p411 · p418
Nebojsa Jovic	Poster session: epilepsy syndromes in children and adults I	p419 · p427
Vasilios Kimiskidis	Poster session: epilepsy syndromes in children and adults III	p428 · p436

### WEDNESDAY 30<sup>TH</sup> JUNE 2010

Tour Guide	Session	Poster #
Giuliano Avanzini	Poster Session: neurobiology and basic sciences V	p437 · p446
Filiz Onat	Poster Session: neurobiology and basic sciences V	
Özhara Ç (Turkey)	Poster session: surgical treatment III	p447 · p457
John Duncan	Poster session: neuroimaging III	p458 · p468
Michel Baulac	Poster session: genetics II	p469 · p483
Martin Brodie	Poster session: psychiatry	p484 · p492
Graeme Sills	Poster session: drug therapy III	p493 · p498
Meir Bialer	Poster session: drug therapy VI	p499 · p507
Torbjörn Tomson	Poster session: drug therapy IX	p508 · p517
Vasilios Kimiskidis	Poster session: epilepsy syndromes in children and adults II	p518 · p525
Nebojsa Jovic	Poster session: epilepsy syndromes in children and adults IV	p526 · p535
Alla Guekht	Poster session: social issues I	p536 · p543
Reetta Kälviäinen	Poster session: social issues II	p544 · p551
Andreas Schulze-Bonhage	Poster session: social issues III	p552 · p559



## SPEAKER LIST

Name	Date	Start	Type	Hall	Chair/Speaker
Avanzini G (Italy)	27.06	09:00	Eurepa Course on Basic Science	Hall 8 (Lindos)	Speaker
Arzimanoglou A (France)	27.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Avoli M (Canada)	28.06	09:00	Chairs Symposium	Hall 1 (Jupiter)	Speaker
Auvin S (France)	28.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Arzimanoglou A (France)	28.06	18:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Akman O (Turkey)	29.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Arzimanoglou A (France)	29.06	14:30	Discussion Group	Hall 2 (Roses)	Chair
Avanzini G (Italy)	29.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Arzimanoglou A (France)	30.06	07:30	Teaching Session	Hall 2 (Roses)	Chair
Agirre-Arribi Z (United Kingdom)	30.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Alexopoulos A (USA)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Agathonikou A (Greece)	30.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Arzimanoglou A (France)	30.06	14:30	Discussion Group	Hall 1 (Jupiter)	Speaker
Battaglia G (Italy)	27.06	09:00	Eurepa Course on Basic Science	Hall 8 (Lindos)	Speaker
Blümcke I (Germany)	27.06	09:00	Eurepa Course on Basic Science	Hall 8 (Lindos)	Chair
Blümcke I (Germany)	27.06	09:00	Eurepa Course on Basic Science	Hall 8 (Lindos)	Speaker
Beghi E (Italy)	27.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Becker A (Germany)	28.06	07:30	Workshop	Hall 3 (Delphi)	Speaker
Bernard C (France)	28.06	07:30	Workshop	Hall 3 (Delphi)	Chair
Bernard C (France)	28.06	07:30	Workshop	Hall 3 (Delphi)	Speaker
Boon P (Belgium)	28.06	07:30	Satellite Symposium	Hall 1 (Jupiter)	Chair
Baulac M (France)	28.06	09:00	Chairs Symposium	Hall 1 (Jupiter)	Chair
Buzsaki G (USA)	28.06	09:00	Chairs Symposium	Hall 1 (Jupiter)	Speaker
Battino D (Italy)	28.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Ben-Zeev B (Israel)	28.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Bialer M (Israel)	28.06	11:30	Discussion Group	Hall 7 (Colossus)	Chair
Bien C (Germany)	28.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Bonelli S (United Kingdom)	28.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Boshuisen K (Netherlands)	28.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Bialer M (Israel)	28.06	14:30	Discussion Group	Hall 1 (Jupiter)	Speaker
Boon P (Belgium)	28.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Ben-Menachem E (Sweden)	28.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Baulac M (France)	28.06	18:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Bahi Buisson N (France)	29.06	07:30	Case Oriented Learning Session	Hall 2 (Roses)	Speaker
Baumgartner C (Austria)	29.06	07:30	Teaching Session	Hall 5 (Nefeli)	Speaker
Beniczky S (Denmark)	29.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Chair
Beniczky S (Denmark)	29.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Baulac M (France)	29.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Baumgartner C (Austria)	29.06	09:00	Main Session	Hall 1 (Jupiter)	Chair
Brodie M (United Kingdom)	29.06	09:00	Main Session	Hall 6 (Marika)	Chair
Bechtel N (Switzerland)	29.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Ben-Menachem E (Sweden)	29.06	11:30	Platform Session	Hall 4 (Nafsica)	Chair
Blümcke I (Germany)	29.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Bonnet C (France)	29.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Bahi Buisson N (France)	29.06	14:30	Discussion Group	Hall 2 (Roses)	Speaker
Bialer M (Israel)	29.06	14:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Brazdil M (Czech Republic)	29.06	14:30	Workshop	Hall 6 (Marika)	Speaker
Brodie M (United Kingdom)	29.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Beniczky S (Denmark)	30.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Braun K (Netherlands)	30.06	07:30	Teaching Session	Hall 2 (Roses)	Speaker
Brandt C (Germany)	30.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Blümcke I (Germany)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Beretta S (Italy)	30.06	14:30	Special Symposium	Hall 4 (Nafsica)	Speaker
Bien C (Germany)	30.06	14:30	Discussion Group	Hall 1 (Jupiter)	Speaker
Blümcke I (Germany)	30.06	14:30	Workshop	Hall 5 (Nefeli)	Speaker
Bouthillier A (Canada)	30.06	16:30	Workshop	Hall 3 (Delphi)	Speaker
Bialer M (Israel)	1.07	09:00	Special Symposium	Hall 1 (Jupiter)	Chair
Brodie M (United Kingdom)	1.07	09:00	Special Symposium	Hall 1 (Jupiter)	Speaker
Beghi E (Italy)	1.07	11:30	Discussion Group	Hall 4 (Nafsica)	Chair
Beghi E (Italy)	1.07	11:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Carreño M del Mar (Spain)	27.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Canevini M P (Italy)	28.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Chair
Canevini M P (Italy)	28.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Claus S (Netherlands)	28.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Centeno M (United Kingdom)	28.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Chowdhury F (United Kingdom)	28.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Covanis T (Greece)	28.06	14:30	Discussion Group	Hall 6 (Marika)	Speaker
Cramer J (USA)	28.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Cross H (United Kingdom)	29.06	07:30	Teaching Session	Hall 5 (Nefeli)	Speaker



## SPEAKER LIST

Name	Date	Start	Type	Hall	Chair/Speaker
Covanis T (Greece)	29.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Carmichael D (United Kingdom)	29.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Casciato S (Italy)	29.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Chipaux M (France)	29.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Ciomas C (France)	29.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Cuccaro M (USA)	29.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Cross H (United Kingdom)	29.06	14:30	Discussion Group	Hall 2 (Roses)	Speaker
Chiron C (France)	30.06	07:30	Teaching Session - Introduction to VIREPA	Hall 5 (Nefeli)	Chair
Chiron C (France)	30.06	07:30	Teaching Session - Introduction to VIREPA	Hall 5 (Nefeli)	Speaker
Capovilla G (Italy)	30.06	11:30	Platform Session	Hall 2 (Roses)	Chair
Callenbach P (Netherlands)	30.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Cojutti P G (Italy)	30.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Chauvel P (France)	30.06	14:30	Discussion Group	Hall 2 (Roses)	Speaker
Cross H (United Kingdom)	30.06	14:30	Discussion Group	Hall 1 (Jupiter)	Chair
Chauvel P (France)	30.06	16:30	Teaching Session	Hall 6 (Marika)	Speaker
Chiron C (France)	30.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Ceulemans B (Belgium)	30.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Covanis T (Greece)	30.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Chair
Chuang Y C (Taiwan, Republic of China)	1.07	09:00	Special Symposium	Hall 1 (Jupiter)	Speaker
Capovilla G (Italy)	1.07	11:30	Video Session	Hall 7 (Colossus)	Chair
Capovilla G (Italy)	1.07	11:30	Video Session	Hall 7 (Colossus)	Speaker
De Jonghe P (Belgium)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Speaker
Duncan J (United Kingdom)	27.06	09:00	Eurepa Course on Basic Science	Hall 8 (Lindos)	Speaker
Duncan J (United Kingdom)	27.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Chair
De Weerd A (Netherlands)	28.06	07:30	Teaching Session	Hall 2 (Roses)	Chair
De Weerd A (Netherlands)	28.06	07:30	Teaching Session	Hall 2 (Roses)	Speaker
Dimova P (Bulgaria)	28.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Dravet C (France)	28.06	11:30	Platform Session	Hall 3 (Delphi)	Chair
De Jonghe P (Belgium)	28.06	14:30	Discussion Group	Hall 4 (Nafsica)	Chair
De Kovel C (Netherlands)	28.06	14:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Deonna T (Switzerland)	29.06	07:30	Workshop	Hall 3 (Delphi)	Speaker
De Maria G (Italy)	29.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Duncan J (United Kingdom)	29.06	14:30	Discussion Group	Hall 7 (Colossus)	Chair
Duncan J (United Kingdom)	29.06	14:30	Discussion Group	Hall 7 (Colossus)	Speaker
De Curtis M (Italy)	30.06	09:00	Main Session	Hall 6 (Marika)	Chair
Dinopoulos A (Greece)	30.06	11:30	Platform Session	Hall 3 (Delphi)	Chair
Duffy B (United Kingdom)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Delalande O (France)	30.06	14:30	Discussion Group	Hall 1 (Jupiter)	Speaker
Dulac O (France)	30.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
De Jonghe P (Belgium)	30.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Dravet C (France)	30.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Chair
Dravet C (France)	30.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
de Curtis M (Italy)	1.07	11:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Eeg-Olofsson O (Sweden)	29.06	07:30	Workshop	Hall 3 (Delphi)	Speaker
Elger C (Germany)	29.06	14:30	Workshop	Hall 6 (Marika)	Chair
Elwes R (United Kingdom)	29.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Elger C (Germany)	30.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Engel J (USA)	30.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Ercegovic M (Serbia)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Evangelidou A (Greece)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Chair
Elger C (Germany)	30.06	16:30	Teaching Session	Hall 6 (Marika)	Speaker
Fountas K (Greece)	28.06	11:30	Platform Session	Hall 4 (Nafsica)	Chair
Feldwisch H (Germany)	28.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Ferrie C (United Kingdom)	28.06	14:30	Discussion Group	Hall 6 (Marika)	Chair
Friedman A (Israel)	28.06	14:30	Special Symposium	Hall 2 (Roses)	Speaker
French J (USA)	28.06	18:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Fogarasi A (Hungary)	29.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Friedman A (Israel)	29.06	11:30	Platform Session	Hall 6 (Marika)	Chair
French J (USA)	29.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Fried I (Israel)	29.06	14:30	Workshop	Hall 6 (Marika)	Speaker
Friedman A (Israel)	29.06	14:30	Discussion Group	Hall 5 (Nefeli)	Speaker
Francione S (Italy)	30.06	07:30	Case Oriented Learning Session	Hall 7 (Colossus)	Speaker
Ferreira H (Portugal)	30.06	14:30	Special Symposium	Hall 4 (Nafsica)	Speaker
Francione S (Italy)	30.06	16:30	Workshop	Hall 3 (Delphi)	Chair
Fohlen M (France)	1.07	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Francione S (Italy)	1.07	07:30	Workshop	Hall 2 (Roses)	Speaker
French J (USA)	1.07	07:30	Teaching Session - Introduction to VIREPA	Hall 6 (Marika)	Chair
French J (USA)	1.07	07:30	Teaching Session - Introduction to VIREPA	Hall 6 (Marika)	Speaker
Ferlazzo E (Italy)	1.07	11:30	Video Session	Hall 7 (Colossus)	Speaker



## SPEAKER LIST

Name	Date	Start	Type	Hall	Chair/Speaker
Ferrie C (United Kingdom)	1.07	11:30	Discussion Group	Hall 3 (Delphi)	Speaker
Fusco L (Italy)	1.07	11:30	Discussion Group	Hall 3 (Delphi)	Speaker
Guerrini R (Italy)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Speaker
Guekht A (Russia)	28.06	07:30	Case Oriented Learning Session	Hall 6 (Marika)	Chair
Guekht A (Russia)	28.06	07:30	Case Oriented Learning Session	Hall 6 (Marika)	Speaker
Gröppel G (Austria)	28.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Grosso S (Italy)	28.06	14:30	Discussion Group	Hall 6 (Marika)	Speaker
Gil-Nagel A (Spain)	28.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Glauser T (USA)	28.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Chair
Glauser T (USA)	28.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Galanopoulou A (USA)	29.06	07:30	Workshop	Hall 7 (Colossus)	Speaker
Gallmetzer P (Austria)	29.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Granata T (Italy)	29.06	07:30	Workshop	Hall 7 (Colossus)	Speaker
Giannakodimos S (Greece)	29.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Gotsis E (Greece)	29.06	11:30	Platform Session	Hall 5 (Nefeli)	Chair
Guekht A (Russia)	29.06	11:30	Platform Session	Hall 7 (Colossus)	Chair
Guerrini R (Italy)	30.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Gnatkovsky V (Italy)	30.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Graf W (Germany)	30.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Granbichler C (Austria)	30.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Guaranha M (Brazil)	30.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Gardella E (Italy)	30.06	14:30	Discussion Group	Hall 7 (Colossus)	Speaker
Genton P (France)	30.06	16:30	Workshop	Hall 4 (Nafsica)	Speaker
Giannakodimos S (Greece)	30.06	16:30	Workshop	Hall 4 (Nafsica)	Speaker
Guerrini R (Italy)	30.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Guerrini R (Italy)	1.07	07:30	Teaching Session	Hall 3 (Delphi)	Speaker
Garganis K (Greece)	1.07	11:30	Video Session	Hall 7 (Colossus)	Speaker
Genton P (France)	1.07	11:30	Discussion Group	Hall 3 (Delphi)	Speaker
Guerrini R (Italy)	1.07	11:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Hermier M (France)	28.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Hammers A (United Kingdom)	28.06	11:30	Platform Session	Hall 5 (Nefeli)	Chair
Helbig I (Germany)	28.06	14:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Holmes G (USA)	29.06	07:30	Workshop	Hall 3 (Delphi)	Speaker
Halford J (USA)	29.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Holmberg B (Sweden)	29.06	14:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Hammers A (United Kingdom)	30.06	07:30	Teaching Session	Hall 3 (Delphi)	Speaker
Huppertz H J (Switzerland)	30.06	07:30	Teaching Session	Hall 3 (Delphi)	Speaker
Halasz P (Hungary)	30.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Haan G J (Netherlands)	30.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Hesdorffer D (USA)	30.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Hughes E (United Kingdom)	30.06	11:30	Platform Session	Hall 2 (Roses)	Chair
Helmstaedter C (Germany)	30.06	14:30	Workshop	Hall 5 (Nefeli)	Speaker
Helmstaedter C (Germany)	30.06	14:30	Workshop	Hall 5 (Nefeli)	Chair
Hirsch E (France)	30.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Holthausen H (Germany)	30.06	14:30	Discussion Group	Hall 7 (Colossus)	Speaker
Huppertz H J (Switzerland)	30.06	14:30	Discussion Group	Hall 2 (Roses)	Speaker
Hirsch E (France)	1.07	07:30	Workshop	Hall 2 (Roses)	Speaker
Ishii A (Japan)	28.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Ito M (Japan)	30.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Johannessen S (Norway)	28.06	14:30	Discussion Group	Hall 1 (Jupiter)	Chair
Johannessen S (Norway)	28.06	14:30	Discussion Group	Hall 1 (Jupiter)	Speaker
Ioannides A (Cyprus)	29.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Jacobs J (Germany)	29.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Jason T (Czech Republic)	29.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Jiruska P (United Kingdom)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Jahodova A (Czech Republic)	30.06	14:30	Special Symposium	Hall 4 (Nafsica)	Speaker
Johannessen S (Norway)	30.06	14:30	Special Symposium	Hall 4 (Nafsica)	Chair
Jovic N (Serbia)	30.06	16:30	Workshop	Hall 4 (Nafsica)	Chair
Kahane P (France)	27.06	09:00	Eurepa Course on Basic Science	Hall 8 (Lindos)	Speaker
Koeleman B (Netherlands)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Speaker
Kelemen A (Hungary)	28.06	07:30	Teaching Session	Hall 2 (Roses)	Speaker
Kimiskidis V (Greece)	28.06	07:30	Teaching Session	Hall 5 (Nefeli)	Speaker
Kostopoulos G (Greece)	28.06	09:00	Chairs Symposium	Hall 1 (Jupiter)	Chair
Kapsalaki E (Greece)	28.06	11:30	Platform Session	Hall 5 (Nefeli)	Chair
Karlovassitou A (Greece)	28.06	11:30	Platform Session	Hall 6 (Marika)	Chair
Kasteleijn-Nolst Trenité D (Netherlands)	28.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Keihaninejad S (United Kingdom)	28.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Kennedy F (United Kingdom)	28.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Kjaer D (Denmark)	28.06	11:30	Platform Session	Hall 6 (Marika)	Speaker



## SPEAKER LIST

Name	Date	Start	Type	Hall	Chair/Speaker
Kostiuk K (Ukraine)	28.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Kravljanac R (Serbia)	28.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Koepp M J (United Kingdom)	28.06	14:30	Special Symposium	Hall 2 (Roses)	Speaker
Kraemer G (Switzerland)	28.06	14:30	Discussion Group	Hall 1 (Jupiter)	Speaker
Kahane P (France)	29.06	07:30	Teaching Session	Hall 5 (Nefeli)	Chair
Krsek P (Czech Republic)	29.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Kalviainen R (Finland)	29.06	11:30	Platform Session	Hall 3 (Delphi)	Chair
Karakis I (USA)	29.06	11:30	Platform Session	Hall 7 (Colossus)	Speaker
Kelly K (United Kingdom)	29.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Koepp M (United Kingdom)	29.06	11:30	Platform Session	Hall 5 (Nefeli)	Chair
Kramer U (Israel)	29.06	11:30	Platform Session	Hall 2 (Roses)	Chair
Kirschstein T (Germany)	29.06	14:30	Discussion Group	Hall 5 (Nefeli)	Speaker
Koehling R (Germany)	29.06	14:30	Discussion Group	Hall 5 (Nefeli)	Chair
Kostopoulos G (Greece)	29.06	14:30	Discussion Group	Hall 3 (Delphi)	Chair
Klitgaard H (Belgium)	29.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Kahane P (France)	30.06	07:30	Case Oriented Learning Session	Hall 7 (Colossus)	Speaker
Kimiskidis V (Greece)	30.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Koutourmanidis M (United Kingdom)	30.06	09:00	Main Session	Hall 1 (Jupiter)	Chair
Kahane P (France)	30.06	16:30	Workshop	Hall 3 (Delphi)	Speaker
Kaufman K (USA)	30.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Kimiskidis V (Greece)	30.06	11:30	Platform Session	Hall 3 (Delphi)	Chair
Koutourmanidis M (United Kingdom)	30.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Kovac S (United Kingdom)	30.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Kraemer G (Switzerland)	30.06	11:30	Platform Session	Hall 6 (Marika)	Chair
Kasteleijn-Nolst Trenité D (Netherlands)	30.06	14:30	Discussion Group	Hall 6 (Marika)	Chair
Kasteleijn-Nolst Trenité D (Netherlands)	30.06	14:30	Discussion Group	Hall 6 (Marika)	Speaker
Kostopoulos G (Greece)	30.06	14:30	Special Symposium	Hall 4 (Nafsica)	Chair
Kuhn H (Sweden)	30.06	14:30	Workshop	Hall 5 (Nefeli)	Speaker
Kokaia M (Sweden)	30.06	16:30	Workshop	Hall 7 (Colossus)	Speaker
Kellemen A (Hungary)	1.07	07:30	Case Oriented Learning Session	Hall 5 (Nefeli)	Speaker
Koehling R (Germany)	1.07	11:30	Discussion Group	Hall 6 (Marika)	Speaker
Lerche H (Germany)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Chair
Livingston J (United Kingdom)	28.06	14:30	Discussion Group	Hall 6 (Marika)	Speaker
Loescher W (Germany)	28.06	14:30	Special Symposium	Hall 2 (Roses)	Speaker
Larsson P G (Norway)	29.06	07:30	Workshop	Hall 3 (Delphi)	Chair
Lerche H (Germany)	29.06	07:30	Teaching Session - Introduction to VIREPA	Hall 6 (Marika)	Chair
Lerche H (Germany)	29.06	07:30	Teaching Session - Introduction to VIREPA	Hall 6 (Marika)	Speaker
Lux A (United Kingdom)	29.06	07:30	Workshop	Hall 7 (Colossus)	Speaker
Lemieux L (United Kingdom)	29.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Levi H (Israel)	29.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Lewis S (United Kingdom)	29.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Librizzi L (Italy)	29.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Loescher W (Germany)	29.06	14:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Lachaux J (France)	29.06	14:30	Workshop	Hall 6 (Marika)	Speaker
Larner A (United Kingdom)	29.06	14:30	Special Symposium	Hall 1 (Jupiter)	Speaker
Larsson P G (Norway)	30.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Lebrun A (France)	30.06	14:30	Special Symposium	Hall 4 (Nafsica)	Speaker
LeGuern E (France)	1.07	07:30	Teaching Session	Hall 3 (Delphi)	Speaker
Lindhout D (Netherlands)	1.07	07:30	Teaching Session	Hall 3 (Delphi)	Chair
Marini C (Italy)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Speaker
Malmgren K (Sweden)	28.06	11:30	Platform Session	Hall 4 (Nafsica)	Chair
Marini C (Italy)	28.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Montavont A (France)	28.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Morrow J (United Kingdom)	28.06	11:30	Platform Session	Hall 6 (Marika)	Chair
Marusic P (Czech Republic)	28.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Macheras P (Greece)	28.06	14:30	Discussion Group	Hall 1 (Jupiter)	Speaker
Moshe S L (USA)	29.06	07:30	Workshop	Hall 7 (Colossus)	Chair
Morrow J (United Kingdom)	29.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Macedo J (Brazil)	29.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Mahrer-Imhof R (Switzerland)	29.06	11:30	Platform Session	Hall 7 (Colossus)	Speaker
Mentesidou E (Sweden)	29.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Mira J (Spain)	29.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Marusic P (Czech Republic)	30.06	07:30	Teaching Session - Introduction to VIREPA	Hall 5 (Nefeli)	Speaker
Manreza M (Brazil)	30.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Magloczky Z (Hungary)	30.06	16:30	Workshop	Hall 7 (Colossus)	Speaker
Manni R (Italy)	30.06	16:30	Teaching Session	Hall 6 (Marika)	Speaker
Martins Da Silva A (Portugal)	30.06	16:30	Teaching Session	Hall 6 (Marika)	Chair
Moshe S L (USA)	1.07	11:30	Discussion Group	Hall 3 (Delphi)	Speaker
Nabbout R (France)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Speaker





## SPEAKER LIST

Name	Date	Start	Type	Hall	Chair/Speaker
Neufeld M (Israel)	28.06	07:30	Case Oriented Learning Session	Hall 6 (Marika)	Speaker
Nobili L (Italy)	28.06	07:30	Teaching Session	Hall 2 (Roses)	Speaker
Navarro V (France)	28.06	09:00	Chairs Symposium	Hall 1 (Jupiter)	Speaker
Nobili L (Italy)	28.06	09:00	Chairs Symposium	Hall 1 (Jupiter)	Speaker
Navarro V (France)	28.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Noebels J (USA)	29.06	07:30	Workshop	Hall 7 (Colossus)	Speaker
Nehlig A (France)	29.06	14:30	Special Symposium	Hall 1 (Jupiter)	Chair
Nilsson D (Sweden)	29.06	14:30	Discussion Group	Hall 7 (Colossus)	Speaker
Noebels J (USA)	29.06	14:30	Special Symposium	Hall 1 (Jupiter)	Chair
Nikanorova M (Denmark)	30.06	16:30	Workshop	Hall 4 (Nafsica)	Chair
Nashef L (United Kingdom)	1.07	11:30	Discussion Group	Hall 6 (Marika)	Speaker
Özbara Ç (Turkey)	27.06	09:00	Eurepa Course on Basic Science	Hall 8 (Lindos)	Chair
Özbara Ç (Turkey)	27.06	14:30	Video Session	Hall 3 (Delphi)	Chair
Özbara Ç (Turkey)	27.06	14:30	Video Session	Hall 3 (Delphi)	Speaker
Otte W (Netherlands)	29.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Onat F (Turkey)	29.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Özbara Ç (Turkey)	30.06	07:30	Case Oriented Learning Session	Hall 7 (Colossus)	Chair
Onat F (Turkey)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Chair
Özbara Ç (Turkey)	30.06	14:30	Discussion Group	Hall 7 (Colossus)	Speaker
Özbara Ç (Turkey)	1.07	07:30	Case Oriented Learning Session	Hall 5 (Nefeli)	Speaker
Plouin P (France)	27.06	14:30	Video Session	Hall 3 (Delphi)	Chair
Plouin P (France)	27.06	14:30	Video Session	Hall 3 (Delphi)	Speaker
Plouin P (France)	28.06	07:30	Teaching Session - Introduction to VIREPA	Hall 7 (Colossus)	Speaker
Papavasiliou A (Greece)	28.06	11:30	Platform Session	Hall 2 (Roses)	Chair
Perucca P (Italy)	28.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Petrelli C (Italy)	28.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Pitkanen A (Finland)	28.06	11:30	Discussion Group	Hall 7 (Colossus)	Chair
Perucca E (Italy)	28.06	18:30	Satellite Symposium	Hall 1 (Jupiter)	Chair
Plouin P (France)	29.06	07:30	Case Oriented Learning Session	Hall 2 (Roses)	Chair
Perucca E (Italy)	29.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Pirmohamed M (United Kingdom)	29.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Pandis D (Greece)	29.06	11:30	Platform Session	Hall 6 (Marika)	Chair
Piperidou C (Greece)	29.06	11:30	Platform Session	Hall 4 (Nafsica)	Chair
Polychronopoulos P (Greece)	29.06	11:30	Platform Session	Hall 7 (Colossus)	Speaker
Perucca E (Italy)	29.06	14:30	Discussion Group	Hall 4 (Nafsica)	Chair
Pitkanen A (Finland)	30.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Pasnicu A (France)	30.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Patsalos P (United Kingdom)	30.06	11:30	Platform Session	Hall 4 (Nafsica)	Chair
Polychronopoulos P (Greece)	30.06	11:30	Platform Session	Hall 4 (Nafsica)	Chair
Potschka H (Germany)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Pugnaghi M (Italy)	30.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Pujar S (United Kingdom)	30.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Parrá J (Spain)	30.06	14:30	Discussion Group	Hall 6 (Marika)	Speaker
Pauli E (Germany)	30.06	14:30	Workshop	Hall 5 (Nefeli)	Speaker
Perucca E (Italy)	1.07	07:30	Teaching Session - Introduction to VIREPA	Hall 6 (Marika)	Chair
Perucca E (Italy)	1.07	07:30	Teaching Session - Introduction to VIREPA	Hall 6 (Marika)	Speaker
Plouin P (France)	1.07	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Chair
Polster T (Germany)	1.07	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Pressler R (United Kingdom)	1.07	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Rubboli G (Italy)	28.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Richardson M (United Kingdom)	28.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Rösche J (Germany)	28.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Ryvlin P (France)	28.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Riikonen R (Finland)	29.06	07:30	Workshop	Hall 7 (Colossus)	Chair
Rosenow F (Germany)	29.06	07:30	Teaching Session	Hall 5 (Nefeli)	Speaker
Ryvlin P (France)	29.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Ryvlin P (France)	29.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Ryvlin P (France)	30.06	07:30	Teaching Session	Hall 2 (Roses)	Speaker
Rajna P (Hungary)	30.06	11:30	Platform Session	Hall 6 (Marika)	Chair
Rakitin A (Estonia)	30.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Ristic A (Serbia)	30.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Rubboli G (Italy)	30.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Ramp S (Germany)	30.06	14:30	Discussion Group	Hall 2 (Roses)	Speaker
Ryvlin P (France)	30.06	16:30	Workshop	Hall 3 (Delphi)	Speaker
Repressa A (France)	1.07	09:00	Special Symposium	Hall 1 (Jupiter)	Speaker
Ryvlin P (France)	1.07	11:30	Discussion Group	Hall 6 (Marika)	Speaker
Schorge S (United Kingdom)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Speaker
Serratos J (Spain)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Chair
Serratos J (Spain)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Speaker




## SPEAKER LIST

Name	Date	Start	Type	Hall	Chair/Speaker
Striano P (Italy)	27.06	09:00	Eurepa Course on Basic Science	Hall 7 (Colossus)	Speaker
Selway R (United Kingdom)	28.06	07:30	Teaching Session	Hall 5 (Nefeli)	Speaker
Simonato M (Italy)	28.06	07:30	Workshop	Hall 3 (Delphi)	Speaker
Stefan H (Germany)	28.06	07:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Salonen R (Finland)	28.06	11:30	Discussion Group	Hall 7 (Colossus)	Speaker
Serratos J (Spain)	28.06	11:30	Platform Session	Hall 2 (Roses)	Chair
Shallcross R (United Kingdom)	28.06	11:30	Platform Session	Hall 6 (Marika)	Speaker
Staack A (Germany)	28.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Schelter B (Germany)	28.06	14:30	Discussion Group	Hall 3 (Delphi)	Chair
Steensbjerre Moller R (Denmark)	28.06	14:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Silvestri R (Italy)	29.06	07:30	Workshop	Hall 3 (Delphi)	Speaker
Schulze-Bonhage A (Germany)	29.06	09:00	Main Session	Hall 1 (Jupiter)	Chair
Shukralla A (United Kingdom)	29.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Sierra-Marcos A (Spain)	29.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Steinhoff B (Germany)	29.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Stroebele A (Germany)	29.06	11:30	Platform Session	Hall 7 (Colossus)	Speaker
Sills G (United Kingdom)	29.06	14:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Storm J (Norway)	29.06	14:30	Discussion Group	Hall 5 (Nefeli)	Speaker
Schmitt D (Germany)	29.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Stefan H (Germany)	30.06	07:30	Case Oriented Learning Session	Hall 7 (Colossus)	Speaker
Strobl K (Germany)	30.06	07:30	Teaching Session	Hall 2 (Roses)	Speaker
Shiller Y (Israel)	30.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Shorvon S (United Kingdom)	30.06	09:00	Main Session	Hall 6 (Marika)	Speaker
Sonmez M (Turkey)	30.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Sterjev Z (Macedonia, the Former Yugoslav Republic of)	30.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Shazadi K (United Kingdom)	30.06	14:30	Special Symposium	Hall 4 (Nafsica)	Speaker
Shorvon S (United Kingdom)	30.06	14:30	Discussion Group	Hall 3 (Delphi)	Chair
Siniatchkin M (Germany)	30.06	14:30	Discussion Group	Hall 6 (Marika)	Speaker
Stefan H (Germany)	30.06	14:30	Discussion Group	Hall 2 (Roses)	Chair
Stephani U (Germany)	30.06	14:30	Discussion Group	Hall 6 (Marika)	Speaker
Sperk G (Austria)	30.06	16:30	Workshop	Hall 7 (Colossus)	Chair
Sperk G (Austria)	30.06	16:30	Workshop	Hall 7 (Colossus)	Speaker
Stephani U (Germany)	30.06	16:30	Workshop	Hall 4 (Nafsica)	Speaker
Seeck M (Switzerland)	1.07	07:30	Workshop	Hall 2 (Roses)	Chair
Sisodiya S (United Kingdom)	1.07	07:30	Teaching Session	Hall 3 (Delphi)	Speaker
Steinhoff B (Germany)	1.07	07:30	Workshop	Hall 2 (Roses)	Speaker
Sander J W (United Kingdom)	1.07	11:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Stefan H (Germany)	1.07	11:30	Discussion Group	Hall 6 (Marika)	Chair
Tassi L (Italy)	27.06	09:00	Eurepa Course on Basic Science	Hall 8 (Lindos)	Speaker
Trinka E (Austria)	28.06	07:30	Case Oriented Learning Session	Hall 6 (Marika)	Speaker
Tatishvili N (Georgia)	28.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Tosetti P (Belgium)	28.06	11:30	Discussion Group	Hall 7 (Colossus)	Speaker
Trinka E (Austria)	28.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Tassi L (Italy)	29.06	07:30	Teaching Session	Hall 5 (Nefeli)	Speaker
Tomson T (Sweden)	29.06	09:00	Main Session	Hall 6 (Marika)	Chair
Theofanidis D (Greece)	29.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Thijs R (Netherlands)	29.06	11:30	Platform Session	Hall 3 (Delphi)	Speaker
Taglialetela M (Italy)	29.06	14:30	Discussion Group	Hall 5 (Nefeli)	Speaker
Tanila H (Finland)	29.06	14:30	Special Symposium	Hall 1 (Jupiter)	Speaker
Tomson T (Sweden)	29.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Chair
Tomson T (Sweden)	29.06	16:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Tassi L (Italy)	30.06	07:30	Teaching Session	Hall 2 (Roses)	Speaker
Trinka E (Austria)	30.06	07:30	Teaching Session	Hall 3 (Delphi)	Chair
Tanaka T (Japan)	30.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Tassinari C A (Italy)	30.06	14:30	Discussion Group	Hall 7 (Colossus)	Chair
Tassinari C A (Italy)	30.06	14:30	Discussion Group	Hall 7 (Colossus)	Speaker
Trinka E (Austria)	30.06	16:30	Workshop	Hall 3 (Delphi)	Chair
Tomson T (Sweden)	1.07	09:00	Special Symposium	Hall 1 (Jupiter)	Chair
Thomas P (France)	1.07	11:30	Video Session	Hall 7 (Colossus)	Chair
Thomas P (France)	1.07	11:30	Video Session	Hall 7 (Colossus)	Speaker
Timuper P (Italy)	1.07	11:30	Discussion Group	Hall 6 (Marika)	Chair
Tomson T (Sweden)	1.07	11:30	Discussion Group	Hall 6 (Marika)	Speaker
Van Bogaert P (Belgium)	28.06	07:30	Satellite Symposium	Hall 1 (Jupiter)	Speaker
Van Emde Boas W (Netherlands)	28.06	07:30	Teaching Session - Introduction to VIREPA	Hall 7 (Colossus)	Chair
Van Emde Boas W (Netherlands)	28.06	07:30	Teaching Session - Introduction to VIREPA	Hall 7 (Colossus)	Speaker
Velis D (Netherlands)	28.06	07:30	Teaching Session	Hall 5 (Nefeli)	Chair
Velis D (Netherlands)	28.06	07:30	Teaching Session	Hall 5 (Nefeli)	Speaker
Vezzani A M (Italy)	28.06	07:30	Workshop	Hall 3 (Delphi)	Speaker



## SPEAKER LIST

Name	Date	Start	Type	Hall	Chair/Speaker
Valeta T (Greece)	28.06	14:30	Discussion Group	Hall 6 (Marika)	Speaker
Vezzani A M (Italy)	28.06	14:30	Special Symposium	Hall 2 (Roses)	Speaker
Vigevano F (Italy)	29.06	07:30	Case Oriented Learning Session	Hall 2 (Roses)	Speaker
Vigevano F (Italy)	29.06	11:30	Platform Session	Hall 7 (Colossus)	Chair
Vlooswijk M (Netherlands)	29.06	11:30	Platform Session	Hall 5 (Nefeli)	Speaker
Van Luijtelaar G (Netherlands)	29.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Vincent A (United Kingdom)	29.06	14:30	Discussion Group	Hall 2 (Roses)	Speaker
Vulliemoz S (Switzerland)	29.06	14:30	Discussion Group	Hall 7 (Colossus)	Speaker
Van Nieuwenhuizen O (Netherlands)	30.06	07:30	Teaching Session	Hall 2 (Roses)	Chair
Velis D (Netherlands)	30.06	07:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Chair
van Luijtelaar G (Netherlands)	30.06	14:30	How to do? Seizure Monitoring in the EMU Setting	Hall 4 (Nafsica)	Speaker
Van Nieuwenhuizen O (Netherlands)	30.06	14:30	Discussion Group	Hall 2 (Roses)	Speaker
Van Emde Boas W (Netherlands)	1.07	07:30	Discussion Group	Hall 1 (Jupiter)	Speaker
Van Emde Boas W (Netherlands)	1.07	07:30	Case Oriented Learning Session	Hall 5 (Nefeli)	Chair
Van Nieuwenhuizen O (Netherlands)	1.07	07:30	Case Oriented Learning Session	Hall 5 (Nefeli)	Speaker
Vigevano F (Italy)	1.07	07:30	Workshop	Hall 2 (Roses)	Speaker
Williams E (United Kingdom)	1.07	11:30	Discussion Group	Hall 3 (Delphi)	Chair
Wu X (Germany)	28.06	11:30	Discussion Group	Hall 7 (Colossus)	Speaker
Wendling F (France)	28.06	11:30	Platform Session	Hall 2 (Roses)	Speaker
Wolf P (Denmark)	28.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Wolf N (Netherlands)	28.06	14:30	Special Symposium	Hall 2 (Roses)	Chair
Witt J A (Germany)	29.06	07:30	Case Oriented Learning Session	Hall 2 (Roses)	Speaker
Wyckhuys T (Belgium)	29.06	11:30	Platform Session	Hall 7 (Colossus)	Speaker
Wolf N (Netherlands)	29.06	14:30	Platform Session	Hall 5 (Nefeli)	Speaker
Wellmer J (Germany)	29.06	14:30	Discussion Group	Hall 2 (Roses)	Speaker
Wolf P (Denmark)	30.06	07:30	Teaching Session	Hall 3 (Delphi)	Speaker
Walker M (United Kingdom)	30.06	09:00	Main Session	Hall 1 (Jupiter)	Speaker
Walker M (United Kingdom)	30.06	14:30	Discussion Group	Hall 3 (Delphi)	Speaker
Wong-Kissel L (USA)	30.06	14:30	Special Symposium	Hall 4 (Nafsica)	Speaker
Walker M (United Kingdom)	30.06	16:30	Workshop	Hall 7 (Colossus)	Speaker
Yacubian E (Brazil)	29.06	11:30	Platform Session	Hall 4 (Nafsica)	Speaker
Yoshioka S (Japan)	29.06	11:30	Platform Session	Hall 7 (Colossus)	Speaker
Yogarajah M (United Kingdom)	29.06	14:30	Discussion Group	Hall 7 (Colossus)	Speaker
Youroukos S (Greece)	29.06	14:30	Discussion Group	Hall 2 (Roses)	Chair
Yogarajah M (United Kingdom)	30.06	07:30	Teaching Session	Hall 3 (Delphi)	Speaker
Zafeiriou D I (Greece)	28.06	11:30	Platform Session	Hall 3 (Delphi)	Chair
Zara F (Italy)	28.06	14:30	Discussion Group	Hall 4 (Nafsica)	Speaker
Zara F (Italy)	29.06	07:30	Teaching Session - Introduction to VIREPA	Hall 6 (Marika)	Speaker





## EXHIBITORS LIST


### EXHIBITION OPENING HOURS


Monday 28<sup>th</sup> June 2010      09:00 - 17:00  
Tuesday 29<sup>th</sup> June 2010    09:00 - 17:00  
Wednesday 30<sup>th</sup> June 2010   09:00 - 17:00  
Thursday 1<sup>st</sup> July 2010      09:00 - 12:00

Exhibitor	Stand no.
Ad-Tech Medical	10
Biocodex	12
CareFusion	14
Compumedics Germany	15
Cyberonics	3
Dixi Medical	11
EB Neuro SpA	17
Eisai Europe Ltd.	5
Electrical Geodesics, Inc.	13
Elekta	1
EURAP	19
Grass Technologies	8
International League Against Epilepsy	7
International League Against Epilepsy – Centenary Exhibition	Gallery Foyer
Janssen-Cilag	23
John Libbey Eurotext	18
Micromed	9
Natus Medical Incorporated	20
NeuroTech	2
Pfizer	4
PMT Corporation	24
Special Products Limited	9a
UCB Pharma SA	6
Wiley-Blackwell	16
Wisepress Online Bookshop	21/22




EXHIBITION FLOOR PLAN



[illegible]

[illegible]



[illegible]

**EU ABBREVIATED PRESCRIBING INFORMATION Name of the medicinal product:** VIMPAT® (lacosamide). **Pharmaceutical form:** Film-coated tablets containing 50mg, 100mg, 150 mg, or 200mg lacosamide, syrup containing 15 mg/ml lacosamide, and solution for infusion containing 10 mg/ml lacosamide. **Therapeutic indications:** VIMPAT® is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. VIMPAT® solution for infusion is an alternative for patients when oral administration is temporarily not feasible. **Posology and method of administration:** VIMPAT® must be taken twice a day. The recommended starting dose is 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week. Depending on response and tolerability, the maintenance dose can be further increased by 50 mg twice a day every week, to a maximum recommended daily dose of 400 mg (200 mg twice a day). VIMPAT® may be taken with or without food. If VIMPAT® has to be discontinued, it is recommended this be done gradually (e.g. taper the daily dose by 200 mg/week). A maximum dose of 250 mg/day is recommended for patients with severe renal impairment and in patients with end-stage renal disease. For patients requiring haemodialysis a supplement of up to 50% of the divided daily dose directly after the end of haemodialysis is recommended. **Contraindications:** Hypersensitivity to the active substance or any of the excipients; known second- or third-degree atrioventricular (AV) block; VIMPAT® film-coated tablets only: Hypersensitivity to peanuts or soya. **Special warnings and precautions for use:** Treatment with VIMPAT® has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine. Prolongations in PR interval with VIMPAT® have been observed in clinical studies. VIMPAT® should be used with caution in patients with known conduction problems or severe cardiac disease such as a history of myocardial infarction or heart failure. Caution should especially be exerted when treating elderly patients as they may be at an increased risk of cardiac disorders or when VIMPAT® is used in combination with products known to be associated with PR prolongation. Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for VIMPAT®. Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. VIMPAT® syrup contains sodium propylhydroxybenzoate [E217] and sodium methylhydroxybenzoate [E219], which may cause allergic reactions (possibly delayed). It contains 3.7 g sorbitol (E420) per dose (200 mg lacosamide), corresponding to a caloric value of 9.7 kcal. Patients with rare hereditary problems of fructose intolerance should not take this medicine. The syrup contains aspartame [E951], a source of phenylalanine, which may be harmful for people with phenylketonuria. VIMPAT® syrup and solution for infusion contain sodium. To be taken into consideration for patients on a controlled sodium diet. **Effects on ability to drive and use machines:** VIMPAT® may have minor to moderate influence on the ability to drive and use machines. VIMPAT® treatment has been associated with dizziness or blurred vision. Accordingly, patients should be advised not to drive a car or to operate other potentially hazardous machinery until they are familiar with the effects of VIMPAT® on their ability to perform such activities. **Interaction with other medicinal products and other forms of interaction:** VIMPAT® should be used with caution in patients treated with medicinal products known to be associated with PR prolongation (e.g. carbamazepine, lamotrigine, pregabalin) and in patients treated with class I antiarrhythmic drugs. However, subgroup analysis did not identify an increased magnitude of PR prolongation in patients with concomitant administration of carbamazepine or lamotrigine in clinical trials. Strong enzyme inducers such as rifampicin or St John's wort (*Hypericum*

*perforatum*) may moderately reduce the systemic exposure of VIMPAT®. Therefore, starting or ending treatment with these enzyme inducers should be done with caution. With antiepileptic drugs: In interaction trials lacosamide did not significantly affect the plasma concentrations of carbamazepine and valproic acid. Lacosamide plasma concentrations were not affected by carbamazepine and by valproic acid. A population PK analysis estimated that concomitant treatment with other anti-epileptic drugs known to be enzyme inducers (carbamazepine, phenytoin, phenobarbital, in various doses) decreased the overall systemic exposure of lacosamide by 25%. With oral contraceptives: In an interaction trial there was no clinically relevant interaction between lacosamide and the oral contraceptives ethinylestradiol and levonorgestrel. Progesterone concentrations were not affected when the medicinal products were co-administered. With other medicinal products and substances: Interaction trials showed that lacosamide had no effect on the pharmacokinetics of digoxin. There was no clinically relevant interaction between lacosamide and metformin. Omeprazole 40 mg q.d. increased the AUC of lacosamide by 19%. The effect probably lacks clinical relevance. Lacosamide did not affect the single-dose pharmacokinetics of omeprazole. No data on the interaction of lacosamide with alcohol are available. Lacosamide has a low protein binding of less than 15%. Therefore, clinically relevant interactions with other drugs through competition for protein binding sites are considered unlikely. **Pregnancy:** There are no adequate data from the use of VIMPAT® in pregnant women. The potential risk for humans is unknown. VIMPAT® should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). If women decide to become pregnant, the use of this product should be carefully re-evaluated. **Lactation:** It is unknown whether VIMPAT® is excreted in human breast milk. For precautionary measures, breastfeeding should be discontinued during treatment with VIMPAT®. **Undesirable effects:** The most common adverse reactions (>10%) are dizziness, headache, diplopia, and nausea. They were usually mild to moderate in intensity. Some were dose-related and could be alleviated by reducing the dose. Incidence and severity of CNS and gastrointestinal (GI) adverse reactions usually decreased over time. Other common adverse reactions (1-10%) are depression, balance disorder, coordination abnormal, memory impairment, cognitive disorder, somnolence, tremor, nystagmus, vision blurred, vertigo, vomiting, constipation, flatulence, pruritus, gait disturbance, asthenia, fatigue, fall, and skin laceration. The use of VIMPAT® is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation (e.g. atrioventricular block, syncope, bradycardia) may occur. Refer to the Summary of Product Characteristics for other adverse reactions. **Overdose:** There is limited clinical experience with VIMPAT® overdose in humans. Clinical symptoms (dizziness and nausea) following doses of 1200 mg/day were mainly related to the central nervous system and the gastrointestinal system and resolved with dose adjustments. The highest reported overdose in the clinical development program for VIMPAT® was 12 g taken in conjunction with toxic doses of multiple other antiepileptic drugs. The subject was initially comatose and then fully recovered without permanent sequelae. There is no specific antidote for overdose with VIMPAT®. Treatment of VIMPAT® overdose should include general supportive measures and may include haemodialysis if necessary. **Date of revision:** February 2009. Refer to the full prescribing information in your country before prescribing. **Marketing authorisation holder:** UCB Pharma, S.A. Allée de la Recherche 60 B-1070 Bruxelles Belgium. **Marketing authorisation number(s):** EU/1/08/470/001-016. **Date of first authorisation:** 29 August 2008. **Legal classification:** Medicinal product subject to medical prescription. **GPSRC CNS 027 S 0309 ICM.** © 2008 - 2009 UCB Pharma, S.A. All rights reserved. **Date of preparation:** April 2010. **GVE 051. References:** 1. UCB Data on file. 2. Cross, S.A. et al. *Drugs* 2009; **69** (4): 449-459. 3. VIMPAT® Summary of Product Characteristics, February 2009. 4. Beyreuther BK et al. *CNS Drug Rev* 2007; **13** (1): 21-42. 5. Errington AC et al. *Mol Pharmacol* 2008; **73**: 157-169.

[www.vimpat.eu](http://www.vimpat.eu)



**VIMPAT®**  
lacosamide

Confidence, when monotherapy is not enough

Life with epilepsy can be much more  
than just a gap between seizures

Add VIMPAT® with confidence when monotherapy is not enough

- ◆ Improved seizure control, regardless of current or prior AED therapy<sup>1</sup>
- ◆ High long term retention rate – Efficacy is maintained<sup>1,2</sup>
- ◆ Easy to use – with a low potential for PK drug-drug interactions<sup>3</sup>
- ◆ A novel mode of action<sup>3,5\*</sup>

Licensed for adjunctive therapy in epilepsy patients with partial-onset seizures  
≥16 years old.

\* The precise mechanism by which VIMPAT® (lacosamide) exerts its anti-epileptic  
effect in humans remains to be fully elucidated.

Please consult Abbreviated prescribing information and references placed overleaf

  
**VIMPAT®**  
lacosamide

CP29C CHS: LCM-SC707033\_0410



Confidence, when monotherapy is not enough